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Abstract 
 
 
 
 
Dried Blood Spot (DBS) sampling is a microsampling technique used throughout the 
World for neonatal screening.  The work set out in this thesis shows the development 
and implementation of DBS in the area of preclinical and clinical pharmaceutical drug 
development, specifically in support of Toxicokinetics and Pharmacokinetics.  The 
advantages of the technique are explored along with the issues faced.  The papers 
discussed in this commentary, include in papers 1 and 2, the concept of supporting 
both Toxicokinetics and Pharmacokinetics studies and the validation of bioanalytical 
assays utilising DBS.  Commentary paper 3 further explores the practicalities of DBS in 
the Clinical environment and commentary paper 4 the transferability of DBS 
technology between laboratories.  Commentary paper 5 uses Incurred Sample 
Reanalysis data to answer questions around specific DBS issues and commentary paper 
6 looks at indicating papers for Dried Plasma Spots.  Commentary papers 7 and 8 
explore the use of consortia to investigate hematocrit and homogeneity when using 
DBS and finally commentary paper 9 explores the training required to ensure quality 
DBS samples.   The impact and contributions to this field of research are demonstrated 
through discussion and critical examination of selected examples of the author’s peer-
reviewed publications in this area.    Developments of scientific practices, where the 
author has contributed intellectual, leadership and practical insight to achieve 
significant improvements in the generation of knowledge, are highlighted throughout 
the commentary.   
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Glossary, Abbreviations and Definitions 
 
[Bold in the text] 
 
Term Definition 
3Rs Replacement, Reduction and Refinement 
of animals 
Developed over 50 years ago as a 
framework for humane animal research 
ADME The investigation of the Adsorption, 
Distribution, Metabolism and Elimination 
of a drug 
AUC Area Under Curve 
Bioanalytical/bioanalysis Bioanalysis is the quantitative 
measurement of a drug and/or their 
metabolites in a biological matrix typically 
blood, plasma, serum, urine or tissue  
 
Blanks A sample of a biological matrix to which 
no analyte(s) have been added.  For 
internally standardized methods this 
would contain the internal standard(s).   
Blood cell association (BCA) The partition of drug between the blood 
cells and plasma content of blood.  
Measured by spiking into whole blood, 
centrifuging and quantifying analyte 
concentration in blood cells and plasma 
Calibration curve Comparison of a set of standard samples 
of known concentration against samples 
with unknown concentrations to 
determine their concentration  
Cmax Maximum concentration reached within a 
profile 
vi 
 
Contract Research Organizations (CRO) Organisations that provide research 
services on a contract basis 
Cross validation Validation of an assay across multiple 
laboratories using QCs or pooled samples 
Direct analysis Analytical techniques that eliminate 
manual extraction steps required for 
sample preparation prior to sample 
analysis 
Dried Blood Spots (DBS) The use of solid support to collect blood 
samples 
Dried Plasma Spots (DPS) The use of solid support to collect plasma 
samples 
GSK GlaxoSmithKline Research and 
Development Ltd. 
Haemodynamic effects Dynamics of blood flow 
Hematocrit (hct) The proportion, by volume, of the blood 
that consists of red blood cells and is 
expressed as a percentage.  For example, 
a hematocrit of 50% means that there are 
50 mL of red blood cells in 100 ml of 
blood 
 
 
 
 
Hemolysis Red blood cells in plasma 
HPLC High Performance Liquid Chromatography 
Homogeneity A mixture that has the same proportions 
of its components throughout a given 
sample 
Incurred Sample Reanalysis (ISR) A repeated measurement of analyte 
concentration from study samples to 
demonstrate reproducibility 
In vitro In body 
In vivo Out of body (in glass) 
vii 
 
LC-MS/MS Liquid Chromatography interfaced to a 
Mass Spectrometer (often shortened to 
this even when MS fragmentation is 
carried out i.e. LC-MS/MS or LC-MSn) 
Lipemic Lipids (fats) in the matrix 
LLQ (s) Lower Limit of Quantification; lowest 
concentration at which the analyte can be 
detected with predefined bias and 
precision 
Metabolite Product of metabolism 
(biotransformation of parent drug, or of 
another metabolite) 
Microsampling Defined as <50 µL of sample 
MS Mass Spectrometry 
No Adverse Effect Level (NOAEL) The highest experimental point that is 
without adverse effect 
Pharmacokinetics Study of the time course of drug 
absorption, distribution, metabolism, and 
excretion – described through 
mathematical models 
Pharmacodynamics Study of the biochemical and physiologic 
effects of drugs in humans 
Post Column Infusion Checks for suppression effects.  
Compound of interest is infused into the 
MS and extracted total blanks are 
injected.  A change in the baseline shows 
suppression or enhancement 
Quality controls A sample with a known quantity of 
analyte that is used to monitor the 
performance of a bioanalytical method 
and to assess the integrity and validity of 
the results of the unknown samples 
viii 
 
analyzed in an individual run 
Total blank A blank which does not contain the 
drug(s) or internal standard(s) 
Toxicokinetics The study of PK at high doses using 
toxicology studies where absorption and 
clearance mechanisms may be saturated 
Toxicodynamics Study of the biochemical and physiologic 
effects of drugs in animals 
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Scope of the Commentary 
 
This commentary focuses on the use of Dried Blood Spots (DBS) in support of 
Toxicokinetic (TK) and Pharmacokinetic (PK), studies exploring the learnings’ and 
expertise gained by the author and subsequently shared with the industry.  The 
publications give strong evidence of the significant role in which the author took in 
implementing DBS and Microsampling and provide a critical commentary on both the 
successes and issues associated with the technique.   
 
The papers selected herein span the conceptual idea of using DBS in support of both 
preclinical/clinical analysis and gives a framework for the experiments required to 
scientifically demonstrate the validity of the Bioanalytical data.  In depth 
investigations into clinical practicalities, both from a patient and nurse’s perspective, 
are explored and further validation of the technique including cross validation, 
Incurred Sample Reproducibility (ISR), sampling sites and comparisons with wet 
samples are considered.  Taking the DBS principle and applying to plasma resulted in 
Dried Plasma Spots (DPS) and the novel use of indicating papers for simple sample 
identification.  Experiences of unifying the industry through consortia to give an 
industry perspective on key issues (hematocrit (hct) and homogeneity) are considered.  
Finally, practicalities of multi-site clinical studies and how to successfully implement 
DBS in later stage development are discussed. 
 
The impact of the author’s contributions to the development of DBS and 
microsampling approaches, describes the positive impact on aligning the community 
from pharma, academia and manufacturers together in order to offer solutions and 
new ideas to make microsampling a reality and standard platform.   
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1: Introduction 
 
The pharmaceutical industry is obliged to use animals to ensure medicines are fit for 
human use (Regulation, 1986 (Revised 2013)), but the industry has always been 
interested and encouraged to look for opportunities to minimize the use of animals in 
the drug discovery and development process (Cox, 1990, Michael F.W. Festing et al., 
1998).  The author’s interest in DBS began in 2005 on finding a poster exploring DBS as 
a sample collection technique in support of metabolite identification (Bateman, 2005).  
Further research into the subject revealed its potential benefits from a Reduction and 
Refinement (2 of the 3Rs), clinical and financial perspective compared against 
conventional sampling and work began to investigate how to introduce the technique 
and its utility in supporting TK and PK studies. 
 
The thesis will focus on the background information and principles associated with DBS 
in support of bioanalytical methods for TK and PK studies.  In particular validation of 
quantitative methods utilizing DBS will be addressed along with advantages and 
disadvantages of the technique in support of the development of medicines.  The basis 
of the commentary will be the published works of this author, demonstrating the novel 
application of DBS in the drug development process and providing evidence for the 
significant and sustained contribution that this author has made to microsampling over 
many years.  Finally, the impact of the work to the wider community will be discussed. 
1.1: Toxicokinetics, Pharmacokinetics and Bioanalysis 
 
By quantifying the concentration of drug in the systemic circulation of humans, PK 
models can be built which describe the effect the body has on the drug (e.g. 
Adsorption, Distribution, Metabolism and Elimination (ADME)).  The mathematical 
model of the relationship between PK and pharmacodynamics (PK/PD) can be built to 
help understand the efficacy, or lack of, observed in clinical trials and preclinical animal 
models.  Thus a PK assessment is vital to drug development.  Blood, plasma or serum 
are commonly selected to measure drug concentrations, although the systemic 
circulation is usually not the target of drug action.  However, the systemic circulation is 
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easily accessible for sampling purposes and there is a fundamental assumption that 
unbound drug levels in the circulation reflect those in the target tissue (Emmons and 
Rowland, 2010).   
Prior to administration to humans, toxicology studies are undertaken to identify 
potential hazards to humans.  A TK assessment is vital to this risk assessment.  
Knowledge of the relationship between TK and toxicodynamics (TK/TD) can be 
extremely useful, especially in, for example, cardiovascular studies where TK/TD 
models can be built to understand haemodynamic effects.  However, the biggest use 
of a TK assessment is to determine a safety margin with respect to 
concentration/exposure rather than dose between animal systemic exposure at the No 
Adverse Effect Level (NOAEL) and human systemic exposure. 
 
To quantify circulating drug concentrations accurately and precisely in humans and 
animals requires validated bioanalytical methodology which assesses a range of 
parameters (chapter 1.8).  At the relatively high doses used in toxicity studies, assay 
sensitivity is generally not an issue, but at the relatively low therapeutic doses 
employed in the clinic, the assay must be sufficiently sensitive to permit an accurate 
estimation of systemic exposure.  Bioanalysis is a heavily regulated area as patient 
safety is at risk if circulating concentrations are not accurately measured. 
 
Blood is the obvious choice to measure circulating concentrations, but it has always 
been perceived as a difficult matrix to analyse from a storing and shipping perspective.  
Typically 50:50 blood:water (to lyse the cells) has historically been used when freezing 
the blood (more recently it has been proven that whole blood can be used, refer to 
chapter 2.4.4), which requires an accurate volumetric measurement to obtain the 
correct ratio.  In practice this is not possible in Drug Development with far larger 
studies spanning across many continents and many people that would need training to 
carry out the procedure.  Generally, in Development, plasma has historically been used 
to support TK and PK, as it is fairly simple to harvest (centrifuge whole blood at 
approximately 3000 g) ship, freeze and store.  Also, blood is colored and interferes 
with assays with a colorimetric endpoint, whereas plasma is compatible with such 
techniques.  The main issue with plasma is that approximately 50% (depends on 
affinity for plasma versus cellular compartments) of the blood sample is wasted when 
16 
 
deriving plasma (Emmons and Rowland, 2010), which means larger sample volumes 
are required to support developing medicines.  A review of methods in 2005/2006 
(Fang et al., 2006, Kubo et al., 2005, Trivedi et al., 2005) typically shows aliquot 
volumes of 100 µL – 500 µL, which would equate to up to 2mL of sample required per 
time point.  
 
This wastage and the following examples summarised below and discussed further in 
this chapter are why the author and industry have explored techniques such as DBS in 
order to reduce and drive down the sample volumes required to develop new 
medicines (Spooner, 2010): 
 
 increasing pressure from society to promote the ethical use of animals in 
research embodied as the 3Rs of animals. DBS sampling can lead to notable 
reductions and refinement in animal use, particularly rodents;  
 the recent requirements of pharmaceutical companies by regulators to file 
their first applications to market new drugs for children, as well as adults 
where appropriate, has led to the search for techniques to handle the small 
blood samples to support paediatric drug studies and the juvenile rodent 
toxicology studies used to support their safety;  
 the need to provide appropriate medicines for, and conduct clinical studies in 
developing nations and emerging markets, where clinics do not always have 
the equipment and infrastructure for deriving, storing and shipping of plasma 
samples (e.g., the availability of centrifuges and freezers and/or dry ice for 
shipping).  
 
1.2: Dried Blood Spots 
 
DBS sampling is a microsampling technique, which is a relatively simple technique for 
collecting small volumes of blood, and offers a way of removing the need to freeze 
blood samples and move away from wasteful plasma harvesting.  Blood is collected via 
a skin prick (from a finger or heel) or venous cannula.  The blood is collected often by a 
glass capillary or into a tube and then pipetted onto a substrate, typically a cellulose or 
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polymer based paper (figure 1).  The samples are allowed to dry for a minimum of 2 
hours and, where suitable analyte stability has been demonstrated, can be stored and 
shipped at ambient temperature and analysed by a host of different analytical 
techniques.   
For the application of TK and PK Bioanalysis, typically 3 x 15 µL samples are taken at 
each time point; this allows for an original analysis, ISR (Timmerman et al., 2009) and 
any repeats. 
The first report of DBS dates back to the analysis of glucose in 1913 (Schmidt, 1986) 
and utilized filter papers.  Other early adopters (1925-1950) reported interesting 
benefits when using DBS for syphilis testing.  Notable advantages included reduced 
sample volumes, inexpensive as using filter papers, enhanced stability and reduced 
chance of spoiling the sample (Zimmermann, 1939, Anderson et al., 1961, Harris and 
Olansky, 1951, Chapman, 1924).  The most known, and often mistakenly considered as 
the first publication, using DBS was published by Guthrie in 1961 (Guthrie, 1961) for 
the detection of phenylketonuria in newborns.  Guthrie coupled DBS with an agar 
diffusion microbial assay and also collected urine on paper for analysis.  This was the 
start of mass screening of infants across the world and today the modern test is still 
referred to as the Guthrie Test and checks for up to 54 conditions utilizing multiple 
analytical procedures.  Prior to the author’s first publication, there were few 
publications focusing on the technique for TK (Tawa et al., 1998, Posyniak et al., 2002) 
and PK (Beaudette and Bateman, 2004).  As these papers didn’t explore the potential 
benefits that DBS offered (3Rs, paediatrics and home sampling) they did not excite the 
community and have the impact they deserved. 
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Figure 1. Example of DBS card's 
 
1.3: Advantages of DBS for TK and PK analysis 
 
DBS offers advantages over conventional ‘wet’ plasma, which historically has been the 
main matrix used in TK and PK bioanalysis.  Advantages for TK are summarized below 
and The NC3Rs website (NC3Rs) and ICH SA3 guidelines (ICH, 2014) cover in detail 
expectations and advantages: 
 
Reduction: The largest influence on the number of animals in toxicity studies is TK 
profiling (Sparrow et al., 2011). Conventional plasma samples require >250 µL of blood 
(yielding approximately 125 µL of plasma) compared with <50 µL for DBS per TK time 
point.  Due to the large volume required for plasma samples, TK satellite samples 
(rodents only) are used so as not to impact the main study animals (e.g. Hematology 
data can change due to the blood loss).  Also regulations govern the amount of blood 
that can be drawn from an animal per day (Diehl et al., 2001).  Taking conventional TK 
samples along with multiple blood draws to support such studies as hematology from 
the main study animal would exceed the maximum limit and therefore is not a viable 
option.   The ability to microsample has the potential to drastically reduce rodent use.  
Even the simplest of studies (7-day dose range finder study) uses 12 TK satellite 
animals, which would not be required if microsampling were employed.  
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Higher quality data: The removal of TK satellite animals means that the data for both 
toxicity and exposure is derived from the same animal.  This makes interpretation 
much simpler as a direct comparison in the same animal can be made.  Reduced 
sample volumes also allows for serial sampling rather than composite.  The generation 
of concentration profiles from an individual animal rather than across multiple animals 
generally leads to less variability as inter-animal differences are removed (Sparrow et 
al., 2011, Wickremsinhe and Perkins, 2015). 
 
 Refinement: Ability for simplified sampling sites (Stokes et al., 2011) and removal of 
animal warming.  Taking large blood volumes from animals is only possible if the 
animals are first warmed which makes the blood less viscous.  Options for animal 
warming include the use of hot box’s or water baths with the animals warmed for 
approximately 10 minutes. These benefits result in causing less stress to the animal 
which is an obvious advantage but also reduces the likelihood of adverse events.  
 
Economic: Removal of satellites reduces the amount of compound dosed and also the 
cost of animals and housing.  A typical 28-day rodent study would save approximately 
335g of drug substance (24 fewer animals, weighing 250g for 28 days at 
2000mg/kg/day) and result in a saving of approximately £1000 in animal and 
husbandry costs. 
 
1.4: Advantages for PK are 
 
Access to paediatric populations: Many of today’s medicines could have major 
positive impacts on the welfare of paediatrics. Studies have shown that over 50% of 
the medicines used for children might not have been tested for use in this specific age 
group (EU).  Regulators have recognized this need and now encourage companies to 
test medicines in infants as a first intent.  Regulators allow extended patents to 
medicines that comply (EU) .  Paediatric studies do pose many challenges, including 
limited blood volumes and acquiring parent’s consent to allow sampling.   DBS 
sampling offers the opportunity to overcome these issues due to the small blood 
volumes withdrawn and the ability to utilize different sampling techniques.  Both 
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finger and heel pricks can be used to obtain DBS samples (limited number of sticks 
allowed) and these are seen as less intrusive and more acceptable to parents, which 
aids recruitment.   
 
Access to remote areas and home sampling:  DBS requires less processing than 
plasma samples; less invasive sampling, no requirement to centrifuge, ambient storage 
(removal of -20oC and -80oC storage) and ambient temperature shipments (removal of 
dry ice requirements) where analyte stability has been demonstrated.  All these factors 
combined, allow studies to be conducted in previously unconsidered applications. 
Examples are sampling in remote locations, home sampling and the cost savings 
associated (Martial et al., 2016). 
 
1.5: Advantages associated with both TK and PK 
 
Simplified workflow: Figure 2 demonstrates preclinical workflow advantages but also 
applies to clinical support.  DBS removes the centrifugation, decanting, capping and 
freezing/defrosting steps.  
  
Figure 2. Process flow showing difference between conventional and DBS sampling 
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Stability: It has been proven that a DBS sample is generally more stable than a liquid 
sample (Bowen et al., 2010, D'Arienzo et al., 2010).  Enzymes are rendered inactive in a 
DBS sample and are unable to degrade the compound.  Generally, if the compound of 
interest is stable over the drying period, it will be stable on the card for many months 
and possibly even years.  However, the sample must be protected from high humidity 
(Denniff et al., 2013, Denniff and Spooner, 2010b) as the sample must remain in a dry 
state. 
 
Storage and shipping: Storage and shipping is at ambient temperature for DBS 
compared with liquid samples, which are generally stored at -200C or -800C and 
shipped on dry ice.  This has major financial advantages, with a dry ice shipment 
costing in excess of £500 and banks of freezers being costly to run.  There is also an 
environmental advantage through power saving (generating dry ice and freezers).  In 
the US DBS cards are transported using the conventional postal service as DBS cards 
are considered as nonhazardous if double contained (Service, 2013). 
 
1.6: Issues associated with DBS for TK and PK analysis 
 
Many advantages of DBS have been explored previously but there are issues 
associated with DBS which the author has explored and reported.  Also not all 
advantages can be fully realised.  Shipping companies require minimum box sizes and 
to make full advantage of reduced shipping costs, other options would need to be 
developed e.g. the use of Fedex.  Also using conventional postal services would never 
be an option, as supply needs to be guaranteed due to ethical and financial reasons.  
Also within GSK in Good Laboratory Practice (GLP) Toxicology studies, TK satellite 
animals have not been removed in part due to skepticism and reluctance to change.  
There is a growing body of evidence in supporting microsampling (Mitchard et al., 
2017, Poitout-Belissent et al., 2016, Caron et al., 2015, Chapman et al., 2014, Niu et al., 
2016, Prior et al., 2015) but there is still more need for companies to join together to 
share data covering a diverse chemical space and build a convincing factorial scientific 
justification that using microsamples to support TK from the main study animals will 
not impact any other measurement.   With satellite animals still being used in GLP 
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studies at GSK the option of reducing the size of animal facilities is also currently not a 
potential advantage. 
 
Hematocrit:  Hct values vary between healthy humans (table 1) with the greatest 
variance observed with infants below 1 month of age.  Also drugs can change hct 
based on mechanism of action (e.g., increased production of RBC’s), or secondary 
effects (e.g. dehydration) or disease state/illness (e.g. bone marrow toxicity).  In 
preclinical species hct is generally better controlled but can be affected by drugs and 
disease states. 
 
Age/Sex Hematocrit (%) 
0-2 years 28-67 
2-12 years 34-45 
12-18 years female 36-46 
12-18 years male 37-49 
Adult female 36-44 
Adult male 41-50 
Table 1. Human hematocrit values across sex and age (Denniff and Spooner, 2010a) 
 
Varying hct impacts the size of the DBS sample.  As the hct increases the viscosity of 
the blood rises, causing the blood to spread less across the substrate (figure 3).  This 
results in a linear, inverse relationship between spot area and hct (De Kesel et al., 
2013).  Higher hct values give rise to smaller, more concentrated spots.  This is an issue 
when taking a small central sample punch and can drastically impact PK and cause 
misleading outcomes.  A small central punch takes away the necessity for animal 
technicians and clinical staff to accurately spot a fixed blood volume, and places the 
burden on the analytical lab who are better placed to deal with accurate 
measurements.  The simplest way to overcome varying hct between subjects is to 
accurately dispense a fixed volume of blood and punch out the entire spot.  This relies 
on an accurate volume of blood to be spotted, which in reality is not possible with 
current technology, as calibrated pipettes or capillaries are required which require 
trained personnel to operate.  Novel solutions are being investigated and developed 
which will be discussed later in the thesis (chapter 2.7.4).   
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Recovery - To further complicate the hematocrit issue it has been reported (De Vries 
et al., 2013) that, in some cases, as hematocrit increases the recovery decreases, 
which can mask the increase in concentration due to a smaller more concentrated spot 
with higher hct.  Also reduced recoveries in aged spots can be observed (De Vries et 
al., 2013) upon extended storage, which in turn can seriously limit the viability of long 
term storage for some analytes. 
 
 
 
Figure 3. Change in spot size with changing hematocrit 
 
Homogeneity: The distribution of analytes across the card should ideally be constant.  
Chromatography on the substrate can impact the homogenous nature of the sample, 
with some analytes having greater affinity for the substrate than the blood and vice 
versa (O'Mara et al., 2011).  This can be likened to affinity chromatography with the 
paper substrate acting as the solid phase and the blood as the liquid phase (Fanali et 
al., 2013).  Analyte, paper substrate and hct all impact the homogeneity of the sample.  
Some papers have less impact and blood with a larger hct (70%) tends to produce 
more homogeneous samples when spotted.  There are two ways to overcome this, 
either spot an accurate volume of blood (which poses its own issue) and punch the 
entire sample or always punch from exactly the same place for each assay.  Both are 
dependent on the accuracy of the user and cannot be guaranteed.  Some paper 
manufacturers are attempting to create new substrates that guarantee a homogenous 
sample that would overcome the issue, but with so many variables, this may not be 
possible. 
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Regulatory:  Microsampling is encouraged by all regulatory authorities (Beharry, 2010, 
ICH, 2014), including the U.S. Food and Drug Administration (FDA) and accept that 
blood is a recognized matrix to support PK and TK analysis (guideline, 1994).  In such a 
highly regulated area, agencies must be confident that the data reported is a true 
reflection of the circulating concentration and public health is critical.  As DBS is 
relatively new, in this setting, the agencies are cautious and require a large body of 
evidence to allow DBS as the first intent.  Agencies for clinical studies have been 
requesting both conventional and DBS data to be presented (Evans et al., 2015, Xu et 
al., 2013).  However, this has a very large economic burden on the industry and 
ultimately doubles the cost of the Bioanalytical phase.  This is not acceptable to project 
teams and is causing major concern with companies not wishing to spend the 
resources and regulators not allowing DBS to be the only method to obtain circulating 
concentrations.  A stalemate is in place with no group making any progress. 
 
Sensitivity:  Taking a 3mm center punch from a DBS sample yields a 2.1 µL sample, 
which can pose issues when attempting to achieve pg/mL assay sensitivities.  Mass 
spectrometers are, however, becoming progressively more sensitive.  If data issued by 
the manufactures can be believed (it is not published), on average each new 
generation machine should give between 5 - 10 fold increase in sensitivity.  From the 
introduction of Mass Spectrometry (MS) into the bioanalytical work stream, currently 
we have access to the 7th generation MS.  With the 1st generation machines pg/mL 
assays required large samples volumes, typically 1 mL.    Using microsamples today 
should allow equivalent Lower Limits of Quantitation (LLQ) and in some cases this is 
the case.  However, there is a tradeoff between analyte sensitivity and background (as 
analyte signal increases so does the background) so often any gain is swamped by a 
gain in the background noise.  
 
Bioanalytical resource:  When DBS was first introduced into the bioanalytical 
laboratory it was harder to develop assays and no automation was available.  Multiple 
paper types and solvents needed to be evaluated up front before any in vivo work 
could take place.  As the technique became more embedded the impact on resource 
reduced.  The implementation of dedicated automation, including direct analysis tools 
and generic workflows, increased efficiencies and this became less of an issue. 
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There are advantages and disadvantages associated with DBS and some of the 
disadvantages were only discovered as the technique was further investigated.  The 
advantages to animals, paediatric studies and home sampling are obviously key to the 
continued interest in DBS and microsampling.  
 
 
1.7: Early DBS work prior to publication (Evans, 2010) 
 
When the author presented the concept of DBS to the bioanalysis group, the first 
comment was “this technique has been around for years, why would we use it?”  After 
discussing the potential benefits and gaining interest amongst the group, the author 
started to investigate the DBS application to support TK.  To convince any bioanalyst of 
any new technique, an analytical validation is required.  A validation was carried out on 
a compound in early development, concentrating on precision and accuracy, on card 
stability and robustness to spotting volume (described in section 1.8).  The technique 
proved to be simple and resulted in a precise and accurate method (e.g. precision and 
accuracies less than 15%).  This data then allowed extra resource to be given within 
bioanalysis and 10 compounds were validated across multiple scientists to ensure the 
technique was robust across multiple people.  Simple chemical properties are shown in 
table 2 to demonstrate that a diverse range of molecules were chosen.  Analysts on 
questioning found the technique easy to use and the assays were fit for purpose. 
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Compound cLogP Polar 
Surface 
Area 
Å 
Assay LLQ 
(ng/mL Rat 
Plasma) 
Blood 
Spot 
Recovery 
(%) 
Blood Spot Assay 
Range 
(ng/mL) 
1 3.02 76.07 20 98.4 2.5-1000 
2 5.29 102.49 0.1 91.7 0.1-100 
3 5.06 71.53 1000 103.0 0.1-100 
4 2.82 46.53 2500 (human) 93.0 2.5-250 
5 3.86 73.56 2 93.4 2-1000 
6 2.79 84.56 - 88.3 2-1000 
7 3.98 71.09 5 92.4 1-1000 
8 4.29 79.29 2 90.0 10-1000 
9 5.32 75.13 2 47.3 1-1000 
10 3.75 97.12 - 94.7 10-10000 
Table 2. Chemical properties of 10 compounds for development work 
 
These validations confirmed that, from a bioanalytical standpoint, samples from DBS 
supported validations that were fit for purpose.  The next question was the in vivo 
comparison of conventional wet blood (50:50 blood:water) versus DBS.  Does DBS give 
the same concentration from in vivo samples when compared against blood:water? 
To answer this question, 12 ongoing DMPK rat studies were chosen and excess blood 
was used to generate DBS samples alongside conventional wet blood samples.  The 
bioanalytical approach was to use fit for purpose assays, employing a generic HPLC 
gradient, comparing peak area ratios and the same assays used to support both 
sample types.   
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Figure 4. Example from the 12 compounds - Blood:water & DBS comparison 
 
All 12 compounds showed no significant difference (<5% in all AUC) between the two 
sample types (figure 4).  This data allowed the creation of a partnership between 
Bioanalysis, Toxicology and the Animal Scientists, as it was vital to gain acceptance of 
the new approach across these disciplines.  The team was made up of individuals open 
to critical assessment of DBS and a strategy was developed to validate DBS across the 
TK platform worldwide.  Unlike Discovery studies, which utilize blood, historically 
plasma was used to support TK, and therefore this had to be taken into account.  10 
non GLP, 7 day, rat TK studies formed the pilot, with 3 samples being generated 
(plasma, DBS and 50:50 blood:water).  Assays were generated for each compound, 
independent of matrix type and also in vitro blood cell association (BCA) data was 
generated, to assess if DBS and blood data could be directly compared with plasma 
using the BCA correction value.  Alongside this investigation, the animal scientists were 
looking at new blood sampling techniques to be able to minimize any blood wastage.  
This included different bleeding sites and also collection methods. 
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Figure 5. Comparison of plasma against blood  
 
The results showed no notable differences were observed that would impact the 
interpretation of TK between DBS and blood.  The in vivo plasma concentrations 
(figure 5) always had the same profile compared with the blood but were offset, which 
was expected (different compounds often partition more readily to blood cells or 
plasma).  What wasn’t expected is that the in vitro BCA value did not always correct 
and overlay the data, however no pattern to these discrepancies could be identified.  
This could be due to the magnitude, how the blood was collected, age or even 
temperature of the blood being used for the test (Abu-Rabie and Spooner, 2010).  The 
result was that DBS was considered to be a viable sampling technique but plasma and 
blood could not simply be interchanged.  Once a compound entered Development the 
matrix was chosen and that matrix would be used throughout the development of the 
drug in the pre-clinical and clinical stage (Emmons and Rowland, 2010). 
 
DBS sampling was endorsed as the preferred technique for all non GLP TK studies for 
the development of small molecule oral drugs.   
During these developments, the author forged strong links with the paper 
manufacturers, initially Whatman, who were subsequently purchased by GE 
Healthcare.  Time was spent focusing on the format of the card for this DBS application 
and a 4 spot card (figure 6) was designed and implemented, allowing for 3 samples to 
be taken, (sufficient for original analysis, pharmacokinetic repeats and ISR analysis) 
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and a spare spot if an error occurred.  Room was incorporated for a label and spot 
rings were included to direct the sampler to where to place the blood.  Also small 
boxes above the spots were added to allow the sampler to indicate if there was 
anything wrong when conducting the process (a cross could be placed in the box 
indicating not to use that sample).  A rigid card design was chosen for easy handling 
and this card became the industrial standard format for all manufacturers.  The size of 
the card was equivalent to a credit card, which was also compatible with a 
commercially available automated puncher (BSD Biosampler punch).  This punch was 
an off-the-shelf product but working with the manufacturer, a camera was included 
which could detect the center of the spot so as to take a central punch sample. 
 
This method development and validation stage took approximately 3 years and this 
work led to the first pivotal paper (chapter 2.1) and subsequent publication strategy. 
 
Figure 6. Schematic of a DBS card for TK and PK support at GSK 
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1.8: Bioanalysis – Validation of LC/MS/MS assays 
 
The aim for any bioanalytical assay is to demonstrate that the measured concentration 
accurately and precisely reflects the concentration of the circulating drug/metabolite 
at the time of sample collection (Summerfield et al., 2016).  This measurement could 
be in a different country from where the sample was taken and sometimes years after 
the sampling occasion.  Methods are validated in accordance to regulations (Shah et 
al., 2000) to ensure data quality.  Quantitation is performed by spiking relevant control 
matrix, with known concentrations of the analyte(s) in question.  This is used to 
construct a calibration curve from which the concentration of analyte(s) in control and 
unknown samples can be determined.  Quality controls (QC), blanks and total blank 
samples are typically included to monitor the performance of an analytical method 
during an analytical run.   
 
A Bioanalytical method consists of sample preparation, detection and validation. 
 
Sample preparation and detection 
 
Biological samples are complex in nature, containing not only the analyte(s) to be 
quantified but also endogenous materials.  Sample preparation techniques aim to 
remove the unwanted materials and ultimately produce a cleaner sample to aid 
robustness, limit variability and on occasions concentrate the sample (Anjana Vaghela, 
2016).  The three most common techniques are protein precipitation, solid phase 
extraction (SPE) and liquid-liquid extraction (LLE).  All methods can be used as a sample 
clean up for DBS (Oliveira et al., 2014, Liu et al., 2010) but for most methods at GSK, 
the simple addition of methanol (containing I.S.) to the DBS sample has allowed 
suitable assays to be developed, validated and supported both TK and PK studies.  This 
makes sample preparation for DBS extremely fast and simple. 
 
The introduction of LC-MS/MS into Bioanalysis (Jemal, 2000) in the early nineties 
revolutionised bioanalysis, allowing greater sensitivity and selectivity, shorter run 
times and allowing simpler extraction techniques.  Mass spectrometers have become 
increasingly sensitive, and readily available, which allows bioanalytical assays to be 
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developed that are compatible with the small blood volumes typically used with DBS 
sampling. 
 
Validation 
 
Often the phase of the molecule in product development dictates the extent of 
validation that is required.  An early discovery assay will have no validation, whereas 
an assay supporting late phase development asset requires a full validation.  That said 
an assay is never fully tested and only real samples often actually unearth issues that 
cannot be mitigated through validation e.g. drug-drug interactions.  Table 3 details the 
requirements for a full DBS validation at GSK, and was built around the experimental 
work and learnings’ made by the author and colleagues.  This is not an inclusive list 
and does not include basic validation procedures e.g. linearity, precision and accuracy. 
 
Test Description Acceptance 
Se
le
ct
iv
it
y 
Demonstrate selectivity by analyzing a minimum of 
six independent sources of the drug-free biological 
matrix, e.g., individual lots as total blanks.  
Any observed 
interference (as defined 
by peak height) should 
be no greater than 20% 
of the analyte response 
at the LLQ and no 
greater than 5% of the 
internal standard 
response 
C
ar
ry
 
O
ve
r 
Assess carry-over by injecting blank sample(s) after a 
high concentration standard or validation sample.  
≤ 20% of LLQ response 
R
ec
o
ve
ry
 
Assessed at three concentrations (low, medium & 
high) at three different levels of hematocrit (e.g., 
25%, 45% (typical control matrix) and 65%) for a 
total of nine samples. Compare the response (peak 
area or peak area ratio) of QCs spiked with analyte 
prior to extraction (6 replicates per concentration) 
with the response of blank matrix spiked at the same 
concentrations post extraction, which represent 
100% recovery (6 replicates per concentration).  
The recovery of an 
analyte should be 
precise (CV ≤ 15%) at 
each of the 
concentrations. If the 
spread of mean recovery 
values across the three 
concentrations exceeds 
25%, then an 
investigation should be 
conducted and 
documented 
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M
at
ri
x 
ef
fe
ct
s Compare the response of matrix blank samples 
spiked after extraction with analyte at three 
concentrations (low, mid and high) with those of 
matrix free samples at the same concentrations.  At 
least six sources of matrix 
 
The extent of the matrix 
effects between the 
separate sources of 
matrix should be precise 
(CV 15%) at each 
concentration. 
A
ss
ay
 r
o
b
u
st
n
es
s 
to
 p
ip
et
ti
n
g 
er
ro
r 
Performed when taking a fixed diameter sub-punch 
at three different volumes corresponding to the 
volume specified in the method and to 5 µL 
increments above and below the target (i.e., the 
method states to spot 15 µL; then evaluate the 
robustness of the method with 10 µL, 15 µL and 20 
µL spots). 
 
Spot the DMS cards with the appropriate volumes in 
replicates of six at two concentrations (low & high). 
The diameter of the disc removed from the spot 
must be the same as listed in the method.  
The within-run precision 
(CV) and bias (%) at all 
concentrations should be 
15% 
Im
p
ac
t 
o
f 
h
em
at
o
cr
it
 
To assess any potential impact of hematocrit on the 
resulting measured quantitative concentrations, test 
validation samples (in replicates of six) at two 
concentrations (low & high) in whole blood, at 
hematocrit levels bracketing the anticipated 
hematocrit range, are analyzed. For normal subjects, 
this corresponds to 25% and 65%.  These samples 
should be analyzed using a calibration curve and QC 
samples with a hematocrit level of 45%. If the 
anticipated hematocrit range of subjects is expected 
to be shifted outside of normal, based on population 
or disease state, the investigated hematocrit levels 
for validation and calibrants can be adjusted as 
appropriate 
The results of QC 
samples at each 
concentration with 
hematocrit levels (e.g., 
25% and 65%) should be 
within 15% of that for 
the QC samples with the 
standard hematocrit 
level, e.g., 45%.  
 
A
n
al
yt
ic
al
 s
to
ck
 s
ta
b
ili
ty
 
Determine the storage stability of the analyte(s) in 
analytical stock solutions for 6 hours at ambient 
temperature, plus appropriate long term storage 
conditions (e.g., freezer or refrigerator storage). If 
working solutions are stored, then test their stability 
at two concentrations (typically low and high). 
 
At the appropriate time interval, compare the stored 
solution to be tested with a fresh solution which has 
been accurately prepared at an equal concentration. 
Dilute the solutions (each in replicates of six) to a 
concentration within the linear response range of 
the instrument, using an appropriate diluent 
containing internal standard. 
The difference between 
the analyte: internal 
standard mean peak 
area ratios of the stored 
and fresh solutions 
should be ≤5% for 
stability to be 
demonstrated 
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Sh
o
rt
 t
e
rm
 s
ta
b
ili
ty
 
The conditions evaluated should include room 
(ambient), -20˚C, and 40˚C temperatures and should 
be evaluated at the maximum anticipated storage 
time under those conditions.  Experiments should 
include validation samples or other suitably 
prepared samples (in replicate of six), at two 
concentrations (low & high), maintained at typical 
ambient conditions, -20˚C, and 40˚C for a minimum 
of 48 hours, to evaluate a "worst" case for sample 
stability (Bowen et al., 2011).  
The average result of 
the short term storage 
samples at each 
concentration should be 
within 15% of the 
nominal concentration 
(or of the Time 0 
response in the case of 
whole blood stability). 
W
h
o
le
 b
lo
o
d
 s
ta
b
ili
ty
 Test fresh whole blood (≤48 hours from collection) 
up to 37°C for 2 hours. Use for this stability 
experiment where possible, with the same anti-
coagulant.  
At each concentration to be tested, directly extract 
six replicate aliquots (using internal standard) 
immediately after spiking into blood at 37C, and 
again after typically 2 hours’ incubation at 37C and 
if required at ambient and on wet-ice.  
At each concentration 
and temperature tested, 
the difference in mean 
(analyte: internal 
standard) peak area 
ratio between fresh and 
stored whole blood 
must be ≤15%. 
Lo
n
g 
te
rm
 s
ta
b
ili
ty
 
Determine long term storage stability at ambient 
temperature of analyte(s) in the appropriate 
biological matrix, to cover the longest time interval 
between collection of individual samples and the 
date of their last analysis, including analytical and PK 
repeats, and incurred sample reanalysis. 
 
This determination may be made through ongoing 
assessment of results for study QCs, validation 
samples, or other appropriate samples that are 
prepared at or before the time of sample receipt, 
stored with the study samples under identical 
storage conditions, and analyzed against freshly 
prepared calibration standards. Assess stability using 
six replicates per concentration, measured against a 
freshly prepared calibration line. Include freshly 
prepared QCs in the same run, in order to verify the 
integrity of the calibration standards. 
Within 15% of the 
nominal concentration 
R
e-
in
je
ct
ab
ili
ty
 
o
f 
ex
tr
ac
ts
 This may be evaluated by re-injecting an entire 
validation run at 24 hours, 48 hours, or other 
appropriate time interval after completion of its 
initial run. 
 
Acceptance criteria as 
any validation run.   
IS
R
 
Take a minimum of 10% of study samples and re-
extract in a unique run.  Not required for all studies. 
At least 66.7% (2/3) of 
the repeat results should 
be within ±20% of the 
mean (of original and 
repeat result). 
Table 3. Validation requirements for DBS assays 
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These specific papers were selected as they provide an in depth understanding and 
demonstrate the author’s contribution to the advancement of DBS in this area of 
research. 
 
Each of the papers is summarised and discussed in section 2.  Citation numbers were 
collected on the 11th of May 2017 from Scopus. 
 
See Appendix for supporting letters from lead authors and detail of the contributions 
made by this author to each of these published works.  
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2.1: Commentary paper 1 
 
Matt Barfield, Neil Spooner, Rakesh Lad, Simon Parry, and Susan Fowles (2008). 
Application of dried blood spots combined with HPLC-MS/MS for the 
quantification of acetaminophen in toxicokinetic studies. Journal of Chromatography 
B, 870 (2008) 32–37. 
Citations- 190 
 
 
 
 
 
 
        
2.1.1: Objectives 
 
The novel use of DBS in support of a toxicokinetic study was described in this study 
with the following objectives: 
 
1) To investigate the use of DBS as a means to significantly reduce sample 
volumes in TK studies 
2) To conduct a full bioanalytical LC/MS/MS quantitative assay validation to 
recognized standards for conventional samples with additional experiments 
proposed for DBS samples 
3) To compare TK parameters derived from conventional wet samples (50:50 
blood:water) and DBS   
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Table 4. Paper 1: Origin of citations 
Figure 7. Paper 1: Number of citations per year 
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Commentary paper 1 was the first to report the application of DBS for the analysis of 
samples obtained in a TK study, considering the advantages offered.  Bioanalytical 
validations designed to meet these objectives by applying DBS are commonplace today 
across the industry.  However, at the time this work was published in 2008 there was 
minimal information concerning preclinical validation employing DBS or other types of 
microsampling in support of TK.  Publications prior to this focused on screening of in-
born errors of metabolism (Guthrie, 1961), Therapeutic drug monitoring and 
pharmacokinetics (Beaudette and Bateman, 2004).  Interestingly there was minimal 
work published around preclinical TK (Posyniak et al., 2002, Tawa et al., 1998).  No 
work concentrated on the benefits that DBS or microsampling could offer in reducing 
and refining the use of animals and the many advantages that the technique could 
afford. 
2.1.2: Experimental design 
 
This paper described the validation of a DBS dog blood method for acetaminophen 
using 15µL of blood per sample. Dog and acetaminophen were chosen as there was an 
ongoing study which was utilized and saved running a dedicated study and using 
animals unnecessarily.   A 3mm punch was taken and extracted with 100 µL of 
methanol containing internal standard ([2H4]-acetaminophen).  Analysis was 
performed by means of LC-MS/MS using a reverse phase C18 chromatographic system 
and selected reaction monitoring. 
 
Performance of the assay was assessed by demonstrating that validation parameters 
met predefined standards as discussed in section 1.8.  Parameters investigated 
included linearity, selectivity, sensitivity, accuracy/precision, stability and matrix 
suppression.   
 
To assess the application of DBS in support of toxicokinetic studies, a single daily oral 
gavage suspension of acetaminophen was dosed to one male and one female dog for 7 
days at a target dose of 50 mg/Kg.  Blood samples (1mL) were collected on days 1 and 
7 at 0.5, 1, 2, 4, 8, 12 and 24 hours.  For DBS samples, 15 µL of whole blood was 
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spotted onto DBS cards using a pipette and for blood samples, 50:50 blood:water 
samples were prepared by diluting 15 µL of blood with an equal volume of water. 
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Figure 8. Schematic of study design for paper 1
Study Design: 
 Validation of a quantitative DBS 
method in dog blood 
 Comparison of DBS to conventional 
wet samples (50:50 blood:water) 
Experimental: 
 Validation 
 Linearity, selectivity and sensitivity 
 Precision and accuracy 
 Matrix suppression effects 
 Stability 
 Wet versus dry comparison 
 Study 
 Oral dose of 50 mg/kg, sampling on day 1 and 7, both DBS 
 and 50:50 blood:water collected 
Conclusions: 
 Successfully validated a quantitative method utilising DBS 
  
 Method proved to be selective 
 Linear range 0.1 – 50 µg/mL 
 Intra-day precision and bias less than 12% 
 Storage stability for at least 10 days 
 
 DBS physiologically comparable with conventional wet samples 
 
  
 
Comparison of DBS with 50:50 blood:water 
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2.1.3: Validation and toxicokinetic data output and impact 
 
This study showed that a quantitative assay could be validated using DBS and used to 
support a TK study.   
 
Using a 2.1 µL sample (3mm punch), a lower limit of quantitation of 0.1 µg/mL was 
achieved and linearity demonstrated up to 50 µg/mL.   Precision and accuracy met 
acceptance criteria with a maximum accuracy and intra-day precision of 14.5% and 
10.4%.  Stability was acceptable, covering spotting and drying times in whole blood 
and 9 days of room temperature stability was generated to cover the length that cards 
would be stored for this study. The successful validation proved that robust assays 
could be developed using small sample volumes collected using DBS and at the time 
there was no other means to reduce blood volumes to these levels.  This work at the 
time was considered radical and game changing. 
 
The most important and pivotal output was the comparison between conventional wet 
sampling (50:50 blood:water) and that of dry (DBS).  Comparison of AUC and Cmax 
from both techniques showed a less than 1.4 fold difference (Parry, 2014) and in TK 
terms this confirmed that DBS sampling was comparable with conventional. 
 
This manuscript marked the start of the DBS microsampling revolution and focused 
bioanalysts, toxicologists and animal scientists to challenge the amount of sample 
required for each study (for TK purposes) and moved the industry forward in realising 
enhanced 3R benefits. 
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2.1.4: Technical considerations and reflections 
 
This paper was designed to demonstrate that DBS (as a microsampling technique) had 
the potential to support preclinical studies and set about defining the advantages of a 
dried blood sample versus conventional samples.  Acetaminophen was chosen as it 
was a marketed compound that was being used to support an investigative 
programme internally.    
 
This paper focused the industry on microsampling and the 3Rs and the benefits that 
can be afforded by reducing the volume of samples collected. 
 
As this was a novel application for DBS supporting TK and the community (Bioanalysis, 
Toxicology and regulators) as a whole (internal and external) was reserved, the 
publication was set out to present the data that was expected from the groups and to 
raise interest.  Demonstrating that a full validation including precision, accuracy and 
stability could be achieved and obtaining an equivalent LLQ to previously published 
work using much larger volumes of liquid plasma was designed to raise interest within 
the bioanalytical and regulatory community.  As the assay validation answered many 
of the questions potentially raised by the bioanalysts and regulators, the in-vivo data 
was designed to raise interest across the toxicology arena and also further enhance 
the technique to the bioanalysts and regulators.   
 
This paper also opened up the discussion around which is the correct matrix to 
measure and really questioned why plasma was deemed appropriate when blood is 
actually what circulates. 
A dry sample does offer different challenges.  A good example is how to dilute samples 
when they are outside of the validated assay range.  With a plasma method, control 
matrix is added to the sample but obviously a new approach was needed for DBS.  The 
solution was to spot control matrix onto the relevant DBS card, allow to dry, punch and 
extract.  
The main issue that was not considered at the time of the publication was the physical 
properties of blood.  As an organization the matrix of choice in drug development had 
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always been plasma, and at that time, such experiments as the impact of hemolysis 
and lipemic plasma were not considered important; today these experiments are 
common place.  Future investigations by GSK (Denniff and Spooner, 2010a) raised the 
concerns of varying hct and the impact on DBS.  As discussed in 1.6 this is undoubtedly 
the largest concern facing DBS but was not understood at the time this work was 
conducted.  Preclinically, hct is not as large an issue as with humans, as inbred animal 
strains have much smaller hct ranges.  The greatest risk of varying hct is if the drug 
under evaluation causes the hct value to change or when evaluating disease states.  
Other factors not considered in this publication were homogeneity and recovery, both 
an issue with preclinical and clinical species and explored in 1.6. 
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2.2: Commentary paper 2 
 
Neil Spooner, Rakesh Lad, and Matt Barfield (2009). Dried Blood Spots as a Sample 
Collection Technique for the Determination of Pharmacokinetics in Clinical Studies: 
Considerations for the Validation of a Quantitative Bioanalytical Method. 
Anal. Chem. 2009, 81, 1557–1563. 
Citations – 277 
 
 
 
Figure 9. Paper 2: Number of citations per year 
 
 
 
 
 
2.2.1: Objectives 
             Table 5. Paper 2: Origin of citations 
           
The novel use of DBS in support of a pharmacokinetics study was described in this 
study with the following objectives: 
 
1) To explore validation experiments pertinent to the acceptability of DBS assays 
2) To conduct a validation for Acetaminophen in human blood utilizing DBS 
3) To support a DBS clinical study    
 
This paper described the utility of DBS in the clinic and set out how to scientifically 
validate an assay, considering the characteristics of a dry sample.  The industry had 
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many years of experience dealing with plasma samples in the clinical environment but 
the use of DBS in a quantitative manner was new to the industry.    
 
The validation was designed to make the collection of the sample as straight forward 
for the site as possible.  The author worked closely with the clinic to understand the 
pressures that face clinical staff and explore ways of building experiments into the 
validation that could help alleviate issues when sampling.  One consequence of these 
interactions was to investigate the impact of the volume spotted.  This was designed to 
ensure that when the sample was taken the volume did not need to be exactly 15 µL 
but instead a tolerance was built into the method. 
 
2.2.2: Experimental design 
 
This paper described the validation of a DBS human blood method for Acetaminophen 
using 15 µL of blood per sample.  A 3mm punch was extracted using 100 µL of 
methanol containing internal standard ([2H4]-acetaminophen).  Analysis was 
performed by means of LC-MS/MS using a reverse phase C18 chromatographic system 
and selected reaction monitoring. 
 
Performance of the assay was assessed by demonstrating validation parameters met 
predefined standards as discussed in 1.8. Typical parameters investigated included 
linearity, selectivity, sensitivity, accuracy/precision, stability and matrix suppression.  
Also experiments to confirm the validity of the DBS were investigated, including 
stability of the analyte /metabolites in whole blood and as a DBS, volume spotted, 
spotting device and temperature of the blood spotted. 
 
To assess the application of utilising DBS in support of clinical studies, a two period, 
single dose oral administration of acetaminophen at 0.5 and 1g was accessed.  Blood 
samples were collected at 0.5, 1, 1.5, 3, and 5 hour, post-dose.   
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Figure 10. Schematic of study design for paper 2 
Study Design: 
 Access relevant scientific experiments 
to validate a clinical DBS method 
 Validation of a quantitative DBS 
method in human blood 
 Support a clinical study utilizing DBS 
Experimental: 
 Typical validation experiments 
 Linearity, selectivity and sensitivity 
 Precision and accuracy 
 Matrix suppression effects 
 Stability 
 Bespoke to DBS validation experiments 
 Stability of the analyte /metabolites in whole blood 
 Stability of the analyte /metabolites on card 
 Volume spotted 
 Spotting device 
 Temperature of the blood spotted 
 Pilot study: Acetaminophen oral dose of 0.5 and 1g on two 
occasions  
Conclusions: 
 Successfully validated a quantitative method utilising DBS 
 Method proved to be selective with <5% suppression 
 Linear range 25 – 5000 ng/mL 
 Intra-day precision and bias less than 11.2% 
 Storage stability for at least 113 days 
 Experiments pertinent to DBS 
 Whole blood stability 
 No difference observed in spotting device (pipette:capillary) 
 No impact of the temperature of blood spotted (0oC, room 
 temperature or 37oC) 
 No impact of spotting volume (10-20 µL) 
 Pilot study supported with expected results  
 
  
 
 
 
 
PK Profile for one subject, dose of 500 mg and 1g  
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2.2.3: Validation and data output and impact 
 
This paper demonstrated the use of DBS to support clinical PK and also explored 
validation experiments pertinent to a dry sample; a quantitative assay could be 
validated using DBS and used to support a clinical PK study.  The ability to drive down 
sample volumes from typically >0.5 mL to 45 µL was so important to support paediatric 
investigations, reduce shipping costs and open up otherwise closed opportunities e.g. 
remote areas and home sampling. 
 
Using a 3 mm punch, a lower limit of quantitation of 25 ng/mL was achieved and 
linearity demonstrated up to 5000 ng/mL.   Precision and accuracy met acceptance 
criteria with a maximum accuracy and intra-day precision of -8.4% and 11.2%.  Stability 
data was shown to cover spotting and drying times in whole blood and 113 days of 
room temperature stability was generated to cover the length that cards would be 
stored for this study. Investigations unique to a dry sample were explored and for this 
assay spotting volume (10-20 µL), temperature of the spotted blood (0oC, room 
temperature and 37oC) and spotting device (pipette and capillary) all had negligible 
impact (<15%). 
 
The ability to support a clinical study was demonstrated and feedback from clinical 
staff, patients and analysts was extremely favourable, especially with its simplicity.   
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2.2.4: Technical considerations and reflections 
 
This paper was pivotal to influencing the industry and showed DBS as a way of 
supporting PK and the potential to support paediatric studies and home sampling. It 
also provided an insight on the background investigations, and the thought process on 
how to deal with a dry sample from a clinical and bioanalyst’s perspective.  A dry 
sample is considerably different from a wet sample and experiments needed to be 
designed to prove the validity of the assay to support PK. 
 
At the time GSK did not look at whole blood stability even though with plasma there is 
a short period (<1hour) when the sample is whole blood before being processed to 
plasma.  With DBS, the blood sample is potentially still wet for approximately 2 hours 
(proven by constant weighing of the cards) and therefore the analyte(s) need to be 
proven to be stable for this period.  As a result of this work it was actually 
demonstrated that GSK and the industry were lacking in their wet validation work and 
now whole blood stability is carried out for all new compounds regardless of matrix 
and technique. 
 
Unique experiments detailed in this paper included stability, designed around a dry 
matrix.  It was important to show that capillary sampling (to enable a less invasive 
sampling method for paediatrics and home sampling) was equivalent to a pipette.  
However, this experiment only showed the accuracies of the device and not the actual 
process of taking a finger prick using a capillary and comparing with an IV sample 
spotted using a pipette.  This issue was investigated in commentary paper 3 as the 
technique was further developed. 
 
The idea of including the spotting volume experiment to remove the need for accurate 
spotting volumes worked well, but this would still not highlight the hct impact or 
homogeneous nature of the sample.  This investigation would require further 
development which is covered in commentary paper 7 and 8. 
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2.3: Commentary paper 3 
 
 
Neil Spooner, Y Ramakrishnan, M Barfield, O Dewit & S Miller (2010). Use of DBS 
sample collection to determine circulating drug concentrations in clinical trials: 
practicalities and considerations. 
Bioanalysis (2010) 2(8), 1515–1522. 
Citations – 30 
 
 
       
2.3.1: Objectives 
 
The use of DBS in support of a pharmacokinetics study was described in this study with 
the following objectives: 
 
1) Practicalities of utilizing DBS in a clinical setting 
2) Considerations of using finger pricks to obtain samples 
3) Comparison of wet versus dry sampling and impact of collection site on 
concentration data 
 
This paper set out to understand from both a clinical staff’s perspective and a patient’s 
view point the practicalities of using DBS to obtain PK samples in a clinical setting.  It 
was critical to have a way of assessing the entire procedure in an unbiased way, which 
was achieved by employing a questionnaire to staff and patients.  This was pivotal in 
progressing the use of DBS in the clinical environment. 
 
A secondary objective was to compare concentrations in DBS samples, derived from 
finger pricks and venous cannula against conventional sampling. 
0
1
2
3
4
5
6
7
8
9
2010 2012 2014 2016 2018
N
u
m
b
e
r 
o
f 
ci
ta
ti
o
n
s
Year
Overview of origin of citations 
 
Bioanalysis 
Mass Spectrometry 
Analytical Chemistry 
AAPS 
Colloids and Surfaces 
Analytical Methods 
DBS – Applications & Techniques 
British Journal, Clinical Pharmacology 
Figure 11. Paper 3: Number of citations per year Table 6. Paper 3: Origin of citations 
49 
 
2.3.2: Experimental design 
 
Acetominophen was chosen as the work could easily be published and was 
administered orally at 500mg (first period) and 1g (second period) to 11 healthy 
subjects (male = 8, female = 3).  Blood was sampled at 30, 60, 90, 180 and 300 minutes 
post dose.  Finger prick samples (15 µL, n=3) were obtained by means of a single use 
lancing device, glass capillary collection and then spotted directly onto FTA filter paper.    
Blood from the cannula (6mL collected into EDTA tube) was split into two portions, 
one for spotting (15 µL, n=3) using a repeater pipette and the other to dilute 1:1 v/v 
with water for conventional analysis.  Blood spots were allowed to dry for 2 hours 
under ambient conditions and then stored and shipped in desiccated bags.  Wet 
samples were shipped and stored frozen until analysis. 
 
For DBS analysis a 3 mm diameter central disc was extracted with methanol and 
blood:water samples (50 µL) were extracted by means of protein precipitation both 
followed by LC/MS/MS. 
 
16 study staff completed a questionnaire relating to collecting samples and 11 patients 
answered questions relating to tolerability of sampling. 
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Figure 12. Schematic of study design for paper 3
Experimental: 
 Oral administration of Paracetamol to 11 patients at 500mg 
and 1g 
 DBS samples and 50:50 blood:water samples taken at 30, 60, 
90, 180 and 300 min 
 Samping from both finger pricks and venus cannula  
 Finger pricks for DBS and venus used for both DBS and 
 50:50 blood:water  
Conclusions: 
 Finger pricking well tolerated by patients 
 Staff found the use of DBS to be acceptable 
 A small difference was seen when switching between 50:50 
blood:water and DBS 
 Differences were observed when comparing cannula sampling to 
finger prick, especially with low concentrations and early post-
dose time points 
 
 
 
  
Study Design: 
 Practicalities of DBS in a clinical setting 
 Finger prick acceptance 
 Wet vs dry samples and comparison of 
sampling sites 
                                           Number of subjects responding 
Overall pain/discomfort  None  Mild  Moderate    Severe   Extreme  
Finger-prick    5  15  1  0  0  0  
Cannula    2  11  8  0  0  0  
 
Number responding 
Staff rating of sample collection step   Extremely easy  Easy   Neither  Difficult  Extremely difficult  
Taking blood by finger-prick     3   9   3   0   0   
Taking blood by cannula     7   6   2   0   0   
Blood spotting onto card     2   14   0   0   0   
 
Survey data – Pain scores 
Survey data – Staffs view of ease of DBS 
51 
 
 
2.3.3: Data output and impact 
 
This paper showed the viability of DBS for both staff and patients in a clinical setting.  
For the continued development of DBS to support pharmacokinetics this was essential 
because the techniques employed needed to be accepted by the impacted groups. 
 
Patients tended to prefer finger prick sampling (19 out of 21 occasions).  Also at least 
two finger pricks per sample and six time points per study day were deemed 
acceptable.  Staff who had received no more than 3 hours of familiarisation found 
taking samples via finger pricks and spotting onto cards to be generally easy. 
 
The secondary outcome of the investigation was not as favorable but in the case of 
sampling site not surprising.  When comparing measurement methods, only 
concentrations below 8000 ng/mL could be considered interchangeable.  Comparison 
of sampling site showed concentrations at early time points and low concentrations to 
be significantly different (up to 4 fold higher using finger pricks).  This observation has 
been well documented (Chiou, 1989) and forms the basis of modern requirements to 
perform bridging studies when switching sampling sites (Evans et al., 2015). 
 
Differences between blood concentrations when comparing sampling sites (arterial 
and venous) are considered to be dependent on when the drug was dosed.   Early time 
points show higher concentrations in arterial samples due to diffusion into the 
extravascular space via capillary membranes.  Later time points show higher venous 
concentrations due to distribution of the drug into tissues which allows diffusion via 
capillary walls into the venous system.  Expected concentrations for finger prick blood 
should be between arterial and venous blood concentrations. 
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2.3.4: Technical considerations and reflections 
 
It was important to get an honest representation from the perspectives of both the 
clinical staff and patients.  The feedback was extremely positive and important, 
especially around patient acceptance for finger pricks, which was encouraging for 
paediatrics.   
 
Looking back at this work one of the largest assumptions was that the experiences of 
clinical staff in this study would be similar across other clinics.  With this study the 
author spent time training face to face and was on hand during sampling occasions to 
help if any questions arose.  Also this was a dedicated first time into patient clinic with 
well trained staff and well versed with the importance of accurate measurements.  In 
reality across multi-sites clinical centers, training has to be remote. The training relies 
on individuals reading, watching videos and taking time to digest and understand the 
instructions. The author created a training video detailing the entire process.  In reality 
clinics are a busy and often chaotic environment with time constraints.  Often bank 
nurses are used for just a few hours and training can be missed.  The majority of 
clinical staff will have seen DBS in the form of the Guthrie test where accuracy is not 
important and this does cause issues.  Sometimes clinical staff feel that they don’t 
require training and can ignore the materials provided, which can lead to unusable 
samples.  This is obviously a serious cause for concern with all samples needing to be 
viable.  This is further developed in commentary paper 9 where a solution to this issue 
is proposed. 
 
However, the quality of the sample is not just limited to DBS and any accurate 
volumetric measurement needs to be carefully considered when moving to clinical 
centers.  Experience has shown that even when taking 50:50 blood water samples, 
clinics have been known to ignore the provided accurate pipette and guess the 
measurements, utilizing plastic pastettes.  It is the importance of the accurate 
measurement which can be missed and lost in the complexities of the studies. 
Techniques need to be as simple, logical and straightforward to be successful.  
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The fact that cannula samples did not match finger pricks means that careful 
consideration is required at an early stage for each compound.  If switching between 
matrix type and/or sampling site the impact needs to assessed (by bridging studies) 
and ideally avoided if possible (Evans et al., 2015, Xu et al., 2013).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
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2.4: Commentary paper 4 
         
       
Phillip E Turpin, Josephine EC Burnett, Lee Goodwin, Amanda Foster and Matthew 
Barfield (2010). Application of the DBS methodology to a toxicokinetic study in rats                                                                                                                                                                                                                                                                                                                                                                                                                                                               
and transferability of analysis between bioanalytical laboratories.  
Bioanalysis (2010) 2(8), 1489–1499  
Citations – 17 
 
 
 
2.4.1: Objectives 
 
With a trend for large pharmaceutical companies to reduce the size of internal 
Bioanalytical functions and to outsource large proportions of work to Contract 
Research Organizations (CRO), it is essential that analytical assays are transferable 
between laboratories.  This paper had the following objectives: 
                 
1) To support a Pioglitazone TK study utilizing DBS with analysis across two 
laboratories  
2) To compare wet sampling (50:50 blood:water) with dry sampling (DBS) 
 
At the time of authorship, transferring assays between labs was still not that common, 
whereas in today’s world it is routine.  Confidence is needed that any laboratory using 
the same or similar assay will provide equivalent data.  Any change in PK or TK results 
must not be attributed to the Bioanalysis and any risk minimised by cross validation.  
Cross validation is usually carried out by a transfer of pooled samples or quality 
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controls and analysed at both sites.  In today’s world it is not uncommon to have three 
Bioanalytical centres for a single assay. 
 
2.4.2: Experimental design 
 
This paper described the validation of two different DBS methods across two 
laboratories to support a Pioglitazone study.  In the originator laboratory a DBS 
method and a 50:50 blood:water method were developed and in the receiver 
laboratory only a DBS method was developed.  The DBS method, in both instances, 
used 15µL of blood per DBS sample.  A 3mm punch was extracted using 200µL of 
methanol containing internal standard ([2H4]-Pioglitazone) in the originator laboratory 
whereas the receiver laboratory used 100 µL.  For the 50:50 blood:water samples, 20 
µL of blood was extracted.  Analysis was performed by LC-MS/MS using a reverse 
phase C18 chromatographic system (originator laboratory employed a gradient and 
receiver laboratory an isocratic) and selected reaction monitoring. 
 
Performance of the DBS assay was assessed by demonstrating validation parameters 
met predefined standards as discussed in 1.8.  Typical parameters were investigated 
and also bespoke tests included, specific to DBS e.g. effect of aliquot volume to 
remove the need to be very accurate when spotting.                         
For the 50:50 blood:water analysis an abbreviated validation was conducted and 
limited to intra-assay precision and accuracy, response, selectivity, room temperature 
stability, three freeze thaw cycles and processed extract. 
 
For the investigation 12 rats received an oral (gavage) dose of 30mg/kg.  The following 
time points were taken: 
Rats 1-3; 0, 1, 2, 3.5, 5 and 7 hour (50:50 blood:water and DBS); 
Rats 4-6; 0.5, 1.5, 2.75, 4.25, 6 and 24 hour (50:50 blood:water and DBS); 
Rats 7-12; 0, 0.5, 1, 1.5, 2, 2.75, 3.5, 4.25, 5, 6, 7 and 24 hour (DBS only); 
Rats 1-6 were used to generate composite profiles due to a larger blood volume being 
taken to accommodate the liquid blood samples.  Rats 7-12 were used to generate 
serial profiles.  All samples were taken from the lateral cordial vein.  DBS samples (15 
µL x 3) were obtained via a glass capillary.  
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Experimental: 
 Validation of different methods for pioglitazone 
 Originator lab – DBS (full validation) and liquid blood 
 (abbreviated validation) 
 Receiver lab – DBS (full validation) 
 Bespoke DBS validation experiments 
 Volume spotted 
 30mg/kg oral dose to 12 rats 
 Serial and composite sampling  
 
 
  
 
Conclusions: 
 Successfully validated two quantitative methods utilising DBS 
across two independent laboratories 
 Method proved to be selective with <3.5% suppression 
 Linear range 5 – 2500 ng/mL 
 Intra- and inter-day precision and bias acceptable 
 Recovery >75% 
 Reinjectability: minimum of 3 days and DBS room temperature 
 stability up to 4 months 
 Variation of blood spot volume acceptable: 15-25 µL and 10-
 20 µL 
 Ability to dilute samples 
 Abbreviated blood validation met all requirements 
 Transferability of DBS analysis between laboratories showed 
excellent correlation (99% of results within 20%) 
 Liquid blood and DBS samples gave excellent correlation 
                      
  
Study Design: 
 Evaluate transferability of DBS assays 
between laboratories 
 Evaluate ability to switch between 
liquid and dry samples for Pioglitazone 
 
 
 
 
 
 
 
 
 
Correlation between PK data across two laboratories 
Blood concentration DBS profiles across two laboratories 
Figure 14. Schematic of study design for paper 4 
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2.4.3: Validation and data output and impact 
 
This paper demonstrated that different assays for Pioglitazone could be validated and 
then used to support analysis of equivalent DBS samples across two independent 
laboratories.  This employed different analytical instrumentation, personnel, extraction 
and approach to the methodology.  In reality this is common place with CROs 
redeveloping assays transferred from customers to fit their workflows and 
instrumentation.  In the case of Pioglitazone, transferring between wet and dry 
samples was a viable option that is extremely important to aid projects and utilise 
paediatric studies in later phase studies. This was also the first time that the CRO had 
performed method development, a validation and sample analysis to support a DBS 
study. 
 
A lower limit of quantitation of 5 ng/mL was achieved and linearity demonstrated up 
to 2500 ng/mL.   Selectivity was proven and recovery proven to be >75%.  Precision 
and accuracy met acceptance criteria of +/-15% and 20% at the LLQ.  DBS stability was 
demonstrated at room temperature for up to 4 months, demonstrating one of the 
large benefits of the technique.  Processed extract stability was also demonstrated for 
a minimum of three days.  Accurate sample spotting volume was shown to not be 
critical with variances of size tested between 15-25 µL and 10-20 µL.   
 
It was also shown that a 50:50 blood:water assay could be validated and this was used 
to compare DBS and wet samples.  The correlation between the two was excellent                                                 
allowing future changes of wet and dry samples moving forward. 
 
However, the greater impact was the demonstration of the transferability of DBS 
analysis between laboratories with an excellent correlation (99% of results within 
20%). 
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2.4.4: Technical considerations and reflections 
 
The ability to support validations and sample analysis using different assays in different                                 
laboratories is essential.  Acceptance criteria is 66.7% of the data sets (originator and 
receiver) should be within 20%.  The results showed 99% correlation which in the 
author’s experience, is very unusual and was very encouraging especially as this was a 
new and novel approach.  Further to this the CRO had never been involved with the 
analysis of DBS showing that the technique was simple and robust.   Cross validations 
do fail, and investigations into the reasons can be complex and time consuming.  In 
some cases, the root cause cannot be identified.  The majority of solutions when a 
cross validation fails has been to replicate the originators methodology and to not 
allow the freedom to alter the method.  This can sometimes be challenging, with 
different equipment being utilized. 
 
The comparison between blood:water (50:50) and DBS showed that for Pioglitazone 
the two could be inter-changeable.  However, it is important to keep the sampling site 
consistent as described in commentary paper 3.  This work was in the rat and at the 
time different sampling sites were investigated to minimize blood loss and make use of 
DBS.  The work with DBS focused GSK to introduce a consistent approach to rat 
sampling across all sites (independent of sample collection technique) and encourage 
the industry to follow suit by presenting data and engaging the NC3Rs committee to 
publicise.   
 
The greatest concern was actually ensuring that the blood:water (50:50) procedure 
was carried out correctly.  In the past comparisons have failed due to the accuracy of                       
the 50:50 measurement.  One unexpected outcome from this work was to dispel the 
assumption that when dealing with blood as a liquid it had to be mixed (50:50) with 
water when freezing.  This was a belief going back before the author joined the 
industry.  This approach works well in discovery but is hard to ensure accurate volumes 
are dispensed as the complexities of studies progress.  Work at the time showed that 
for some compounds, whole blood could be sub aliquoted after being frozen.   This 
offered the benefit of reducing complexities and ensured high quality data when 
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dealing with blood.  For all blood work now in development at GSK, whole blood is 
preferred over blood:water (50:50) if proven to be viable. 
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2.5: Commentary paper 5 
 
 Matthew Barfield, Sheelan Ahmad & Maria Busz  (2011). GlaxoSmithKline’s 
experience of incurred sample reanalysis for dried blood spot samples.  
Bioanalysis (2011) 3(9), 1025–1030  
Citations – 10 
 
 
      Ta 
 
2.5.1: Objectives 
                              
To critic the Incurred Sample Reproducibility (ISR) data generated during routine 
analysis within GSK and add to the growing evidence supporting the use of DBS within 
the industry for TK and PK analysis.  The objectives were: 
 
1) Review and compare all ISR studies conducted within GSK utilizing both DBS 
and blood 
2) Explore reasons of concern 
 Differences between DBS sampling techniques 
 Card contamination 
 Explore any differences between liquid and DBS ISR    
 
ISR is a regulatory requirement for TK and PK studies, originating from 1992 (Shah et 
al., 2000) and more recent regulations the 2008 AAPS/FDA (Fast et al., 2009).  ISR 
involves the reanalysis of study samples to further validate the assay and has the 
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potential to highlight issues with metabolites or more commonly within-study user 
error e.g. incomplete mixing or sample ordering issues. 
 
Whilst building confidence with DBS, routinely both DBS and liquid blood were used to 
support studies and this included ISR which allowed the opportunity to compare and 
contrast the two techniques.                 
2.5.2: Experimental design 
 
The design was split into three areas of investigation in order to address concerns and 
possible issues with DBS when supporting TK and PK.  Data were evaluated from 42 
studies containing both liquid blood and DBS ISR. 
 
1. Differences between DBS sampling techniques 
Unlike liquid blood which is collected into a tube and that is the sample, DBS 
has two possible approaches to sample collection.  Either collecting the blood 
into a tube (wasteful of blood), mixing and then pipetting onto the DBS card, or 
using a capillary and taking the blood directly from the subject to the card.  In 
the latter case it could be considered that each spot is a unique sample as 3 
capillaries are required and each sample is separated by a small amount of 
time.  To assess, studies containing both DBS cards spotted from a tube and 
capillary were evaluated. 
2. Effect of card contamination 
DBS cards are more prone to contamination as they are relatively large and                               
exposed to the environment (2 hour air drying time) than a simple blood tube 
with a cap.  ISR data was scrutinized for impact of contamination. 
3. Differences between liquid ISR and DBS ISR 
As with experiment 1, liquid ISR should actually give better ISR data due to a 
homogenous sample in a tube compared with potentially three discrete DBS 
samples from three capillaries.  ISR data was explored to see if there was a 
marked difference or not. 
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Study Design: 
 Full data review of ISR studies for DBS 
and liquid blood studies  
 Different sampling techniques 
 Card contamination 
 Differences between liquid and DBS 
ISR 
    
  
Experimental: 
ISR Protocol 
 Run samples (DBS and 50:50 blood:water), review data and 
approve results 
 After approval but as close to original analysis, re-extract 
10% of the approved samples for ISR determination 
 Acceptance criteria: >66.7% of incurred results need to be 
within +/- 20% of the mean result.  This is the minimal 
requirement, also need to be aware of trends in data e.g. 
positive of negative bias 
 Test multiple card types e.g. FTA DMPK A, FTA DMPK B and 
Alstrohm 226 
 
Conclusions: 
 Out of 42 DBS ISR investigations, two did not meet acceptance 
criteria 
 One was due to contamination.  A portion of the study was 
 repeated taking extra precautions and ISR was successful 
 One could not be explained.  This has been observed with 
 conventional ISR when the cause cannot be identified 
 
 No differences were observed with DBS sampling techniques 
 DBS and liquid blood ISR compared well with one exception.  The 
ISR for one liquid blood study failed and the reason could not be 
explained.  It wasn’t due to stability even though a negative bias 
of 40% was seen 
   
 
  
 Access relevant scientific experiments 
to validate a clinical DBS method 
 Validation of a quantitative DBS 
method in human blood 
 Support a clinical study utilizing DBS 
 
 
 
ISR results for DBS study 
Figure 17 Schematic of study design for paper 5 
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2.5.3: Data output and impact 
 
This data built on the confidence that DBS was a reliable means of collecting, storing 
and shipping samples for TK and PK analysis.   
 
42 studies containing ISR for both DBS and liquid blood were reviewed with two not 
meeting the acceptance criteria.  One concern around DBS was contamination and this 
was observed with one of the failures.  Contamination of a large proportion of the 
cards was observed to the extent that fur was visible on some cards.  With the addition 
of extra precautions to minimize contamination for this study a portion of the study 
was rerun which was successful, including the ISR.  Precautions                                                                                  
included using different laboratories to sample, spot and dry and different personnel 
to dose and spot.  However, this is not a routine practice and typical precautions are 
generally employed and no issues are observed. 
The second failure was never resolved even though an investigation did take place.  
The ISR results were generally 40% higher than the original analysis.  Contamination 
was ruled out as this would have been less consistent.   The author has observed other 
situations using conventional methods of sample collection where ISR has failed and 
even after extensive investigation the cause has never been determined. 
  
No difference was observed from DBS sampling from a tube or individual capillaries 
and the argument of capillary sampling being 3 individual samples was found to be 
unfounded.   
 
Liquid blood ISR and DBS ISR showed excellent correlation apart from one instance 
when liquid ISR failed showing a negative bias of more than 40%.  Originally this was 
thought to be an issue of stability but stability testing disproved this theory.  The cause 
was once again never answered.   
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2.5.4: Technical considerations and reflections 
 
When ISR first became a regulatory requirement, it was felt as a tick box, and an 
experiment that would never fail or add quality.  Now with 1000s of ISR experiments 
performed at GSK it has proven a valuable tool to give confidence of the validity and 
robustness of a bioanalytical assay.  It is now used as one of the decision factors when 
considering contracting the method.  However, when the reason for a failure is 
unknown and extensive investigation leads to no conclusions, it does pose serious 
questions to the data.  There is always the question of which data set is correct and if 
any is actually valid.   
 
From a recent review of over 1000 ISR studies (all sample types) from 2007 to 2017, 3 
% of the studies reviewed have had ISR issues.  From these 3 % of studies, only 4 
studies have resulted in non-reportable data.  The majority of failures can actually be 
associated with user error or stability when there is too greater time difference 
between original and re-analysis.  User error is usually associated with insufficient 
mixing of the sample.  From the author’s experience these errors are associated with 
conventional plasma samples where samples are frozen and then thawed and this 
builds greater opportunities for non-homogenous samples and stability issues.  As 
discussed previously DBS should show greater stability (D'Arienzo et al., 2010, Heinig 
et al., 2010, Bowen et al., 2010) and the freeze thaw process is negated.  Scientifically 
DBS samples should offer greater ISR acceptance as long as recovery from the DBS 
card is consistent. 
 
With capillary bleeds becoming more common place with increased use of 
microsampling, this data review has been invaluable in confirming that for one-time 
point, 3 capillaries taken one after the other does not impact the data.  This has 
allowed for new and exciting developments in microsampling which are explored in 
chapter 3.   
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2.6: Commentary paper 6 
 
Matthew Barfield and Robert Wheller (2011). Use of Dried Plasma Spots in the 
Determination of Pharmacokinetics in Clinical Studies: Validation of a Quantitative 
Bioanalytical Method. 
Anal. Chem. 2011, 83, 118–124 
Citations – 48 
 
 
     T 
 
2.6.1: Objectives 
 
The novel use of DPS in support of a pharmacokinetics study was described in this 
study with the following objectives: 
 
1) To explore validation experiments pertinent to assess the acceptability of DPS 
assays 
2) To conduct a validation for Paroxetine in human blood utilizing DPS 
3) To evaluate DPS in support of a clinical study    
4) To investigate the potential to interchange between wet and dry plasma 
samples 
5) To investigate the use of indicating papers to simplify the visual identification 
of plasma spots 
 
Since historically the matrix of choice for TK and PK was plasma, the ability to switch 
from liquid plasma to dry plasma could afford some advantages demonstrated with 
DBS.  A dry sample is simpler and cheaper to ship and store (requiring no freezers or 
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dry ice shipments) than a wet plasma sample.  It also lends itself to the rapidly 
upcoming techniques focusing on card samples and removing the need to punch 
samples making the extractions more efficient and less time consuming e.g. CAMAG 
(Abu-Rabie and Spooner, 2009, Abu-Rabie and Spooner, 2011, Fingerhut et al., 2014) 
and DART (Crawford et al., 2011, Wagner et al., 2016, Wang et al., 2013).     
 
The author used the strong relationships that were built with the paper manufacturers 
during the early work on DBS to have a new indicating paper developed.  When plasma 
is spotted onto paper the sample is visible, however upon drying the plasma spot is 
almost invisible to the naked eye.  Working with GE Healthcare (formerly Whatman) a 
new paper was developed that was purple in colour and then when plasma was 
spotted and dried the sample was easily identifiable (plasma turns the paper pink).  
This was unique and never attempted before for plasma even though others had 
experimented with non-commercial options (Christianson et al., 2010). 
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2.6.2: Experimental design 
 
The paper included three sample types, liquid plasma, DPS on Ahlstrom 226 (plain 
cellulose paper), and DPS on indicating FTA DMPK (cellulose paper impregnated with 
chemicals that lyse blood cells and has colour changing properties).  This design 
allowed the comparison of liquid versus dry and conventional papers compared with 
an indicating paper.  The paper described the validation of the three paroxetine 
methods.  For DPS, 20 µL of plasma was used per sample and a 6mm punch was 
extracted using 100µL of 70:30 methanol-water (v/v) containing internal standard 
([2H6]- Paroxetine).  For liquid plasma a 50 µL aliquot was used per sample and 
extracted using 100µL of acetonitrile containing internal standard ([2H6]- Paroxetine).  
Analysis was performed by means of LC-MS/MS using a reversed phase C18 
chromatographic system and selected reaction monitoring to provide a highly selective 
method. 
 
Performance of the assays were assessed by demonstrating validation parameters met 
predefined standards as discussed in chapter 1.8.   
Typical parameters investigated included linearity, selectivity, sensitivity, accuracy, 
precision, stability and matrix suppression, ability to dilute.  Also experiments to 
confirm the validity of the DBS were also investigated including volume spotted. 
 
To assess the application of utilising DPS in support of clinical studies, a two period, 
single dose oral administration of paroxetine at 37.5 mg was accessed.  Venous blood 
samples were collected at 0, 2, 4, 6, 8, 10, 12, 15, 18, 24, 32, 48, 72, 120, and 168 
hours.  This was not a dedicated study and old remaining samples were pooled from 
an existing study to generate profiles for testing. 
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Experimental: 
 Validation experiments 
 Linearity, selectivity and sensitivity 
 Precision and accuracy 
 Matrix suppression effects 
 Stability 
 Ability to dilute 
 37.5 mg oral dose  
 Serial sampling but pooled profile for analysis 
 
Conclusions: 
 Successfully validated a quantitative method utilising DPS 
  
 Method proved to be selective 
 Linear range 0.2 - 200 ng/mL 
 Storage stability for at least 35 days on paper  
 No impact of spotting volume (15-25 µL) 
 
 Liquid plasma validation successful as was abbreviated indicating 
paper validation 
 Excellent comparison between liquid plasma and DPS 
 Advantages of indicating papers demonstrated i.e. Plasma spot 
easily identifiable even when dry and extracted sample also 
coloured to aid manual procedures 
  
 
 Pilot study supported with expected results  
 
  
Study Design: 
 Access relevant scientific experiments to 
validate a clinical DPS method 
 Validation of quantitative DPS methods and 
liquid plasma method in human plasma 
 Support a clinical study utilizing DPS 
 Assess the use of indicating papers 
 Assess the ability to change sampling 
 
 
 
 
 
 
 
 
 
Figure 19. Schematic of study design for paper 6 
A) and B) Extracted sample indicating/non indicating  
C) Indicating papers D) non indicating 
PK profiles comparing wet plasma and DPS 
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2.6.3: Validation and data output and impact 
 
This paper demonstrated the use of DPS to support clinical PK.  As virtually all late 
stage clinical assets utilize plasma, the data was important to show the ease of 
transition between a wet and dry sample.  This was designed to allow the benefits of a 
dry sample to be utilised until DBS transitioned into late stage clinical.  The 
investigation of a new development grade of indicating paper showed no detrimental 
impact (proven by post column infusion) to the data generated but had significant 
advantages.  The ability to easily identify the plasma spot is essential and not easily 
possible with conventional papers.  Simple recognition also allows automation to be 
developed and used to reduce the manual extractions carried out at the bioanalytical 
laboratory.  An unexpected advantage was the colouring of the extracted sample 
making it easier to track extracted samples through the bioanalytical phase. 
 
Using a 20 µL sample and a 6mm punch, a lower limit of quantitation of 0.2 ng/mL was 
achieved and linearity demonstrated up to 200 ng/mL for both DPS and wet plasma.  
Assay spotting volume was also investigated for a 15, 20 and 25 µL spot and the 
accuracy differences between the three volumes was less than 9.2%.  Essential 
evidence to allow for inaccuracies in spotting volume and ensuring a representative 
sample can be achieved. 
 
Comparing DPS with liquid plasma in a pooled PK profile showed interconversion of 
the two techniques to be possible with PK parameters (AUC, Tmax and Cmax) being 
calculated to within 10% across the two techniques. 
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2.6.4: Technical considerations and reflections 
 
The ability to switch from a plasma sample to a dry sample between studies at the 
time was an interesting idea.  It takes approximately 20 years to develop a drug which 
equates to 20 years to have all suitable assets supported by DBS.  DPS was seen as a 
way of transitioning and gave certain benefits offered by a dry sample.  It was not 
considered as a substitute for DBS, due to the wastage of sample (creating plasma) and 
specialist equipment required (centrifuges). 
 
 One major advantage is the removal of the hct effect compared with DBS, which is the 
main issue associated with the technique.  Hct would only be an issue if the plasma 
sample was hemolysed, which is an issue with any plasma sample, be it wet or dry.  
Although hct may not be an issue, investigations into the properties of plasma would 
be required.  Varying levels of lipid, albumin and glycoproteins may have a similar 
impact as varying hct levels for DBS. 
 
The regulatory acceptance of DPS would be a concern with the continued drive to 
support all studies with both conventional sampling and dry sample (Emmons and 
Rowland, 2010, Evans et al., 2015).  The cost associated with this is unacceptable on a 
long term basis. 
 
From this investigation the use of indicating papers would be strongly advised.  The 
papers are more expensive (20%) and it is adding another chemical into the sample, 
but the advantages in the author’s opinion are considerable.  The ability to visually see 
the sample throughout the process is essential and this is true for manual and 
automatic processing.   The indicating paper would also lend itself well to other 
matrices, such as saliva and sweat.  These matrices are becoming more important in 
areas such as home sampling and forensics (Meesters and Hooff, 2013). 
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2.7: Commentary paper 7 and 8 
 
Papers 7 and 8 have been combined as both papers are fundamentally based on a 
consortium approach. 
 
Paper 7:  Ronald de Vries, Matthew Barfield, Nico van de Merbel, Bernhard Schmid, 
Christoph Siethoff, Jordi Ortiz, Elwin Verheij, Ben van Baar, Zoe Cobb, Steve White & 
Philip Timmerman. The effect of hematocrit on bioanalysis of DBS: results from the EBF 
DBS-microsampling consortium. 
Bioanalysis (2013) 5(17), 2147–2160  
Citations – 54 
 
 
         
 
Paper 8:  Zoe Cobb, Ronald de Vries, Neil Spooner, Stephen Williams, Ludovicus 
Staelens, Mira Doig, Rebecca Broadhurst, Matthew Barfield, Nico van de Merbel, 
Bernhard Schmid, Christoph Siethoff, Jordi Ortiz, Elwin Verheij, Ben van Baar, Steve 
White & Philip Timmerman.  In-depth study of homogeneity in DBS using two different 
techniques: results from the EBF DBS-microsampling consortium." 
Bioanalysis (2013) 5(17), 2161–2169 
Citations - 30 
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2.7.1: Objectives 
 
Paper 7: To use a consortium approach to explore the impact of hct on DBS: 
 
1) To explore relationship between hct and the following: 
 Response 
 Spot homogeneity 
 Spot size 
 Extraction recovery 
 Card type 
2) To explore relationship between age of wet blood and the result 
3) To explore relationship between age of blood spot and the result 
  
These objectives were pivotal to the continued success of DBS.  The advantage of using 
a consortium was to give a view from the industry rather than just one company’s 
perspective.  Also the diverse portfolio across six companies gave access to a vast array 
of different compounds covering a broad chemical space and different experience and 
knowledge to design a robust protocol. 
The author was a key player in instigating the European Bioanalytical Forum 
consortium and bringing likeminded companies to a general consensus.   
 
Paper 8:  To bring the learnings’ from two EBF DBS-microsampling consortium Working 
Groups, focusing on homogeneity of DBS samples.  Two methods to investigate 
homogeneity were chosen: 
 
1) Nonradiolabeled approach 
2) Radiolabeled approach 
 
So as not to have too many work streams the consortium initially had four areas of 
focus.   
1. Effect of hct (Paper 7) 
2. Addition of I.S. (Van Baar et al., 2013)  
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3. Stability of blood and cards (Timmerman et al., 2013) 
4. Mechanism for dilution of samples (Timmerman et al., 2013)  
The teams investigating hct and stability both included experiments to investigate 
homogeneity and it was these data that made up the content of this paper.  
 
2.7.2: Experimental design 
 
Paper 7:  This paper described experiments to best answer the impact of a changing 
hct.  Generally hct in preclinical species is constant, however in human patient 
populations differences can be large e.g. neonates at birth 31-67% (Denniff and 
Spooner, 2010a) 
Twelve compounds were selected with a broad spectrum of chemical properties e.g. 
log P and pKa. 
 
Multiple papers were tested selecting from the main manufacturers.  Ahlstrohm 226 
TM, BondElut DMS TM, GE DMPK-A TM, and GE DMPK-B TM and the following hct tested 
for each experiment. 
Spot size and analyte response on Ahlstrohm paper using fresh blood (less than 48 
hours old): 20, 30, 35, 40, 45, 50, 60, and 70%.  Aged blood (was spotted onto all cards 
and tested at 20, 45 and 70% hct).  25 µL was spotted and a 3-3.3 mm punch was 
sampled. 
Recovery and Spot homogeneity: 20, 45 and 70% on all papers in fresh blood, with 
aged blood tested at 45% hct.  For recovery, 5 µL was spotted and a 6 mm punch was 
sampled.  For spot homogeneity 25 µL was spotted and two 1 mm punches were 
sampled, one from the centre and the other from the perimeter. 
 
 All results were expressed as peak area ratios. 
 
Hct preparation:  It was important to have a consistent way of preparing the samples 
across all 12 sites to allow for a fair test.  The hct of fresh blood was first tested in 
duplicate and then the volume of plasma to be added or taken away calculated to 
obtain the required hct level.  To decrease the hct plasma was added.  To increase the 
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hct the blood was centrifuged, the required plasma removed and then the resulting 
blood roller mixed to obtain a homogenous sample and the hct levels checked in 
duplicate. 
 
Paper 8:  The experimental design for the nonradiolabeled investigation has already 
been described in paper 7. 
The radiolabeled approach used 14C-lacosamide and 14C-deoxy-D-glucose and the work 
was carried out across two companies (limited due to availability of equipment).  Fresh 
blood (heparin and EDTA) was spiked at 2200 and 1400 ng/mL with one site focusing 
on lacosamide mouse blood and the second site, deoxyglucose in human and rat 
blood. 
 
The same DBS papers were tested as paper 7 and both 15 and 30 µL volumes were 
spotted on day 1.  For lacosamide, samples were also spotted on days 2, 3, 4, 5, 8, 10 
and 15.  Spots were allowed to dry for 2 hours and the radioactivity across the spots 
measured with a scanner.   
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Experimental: 
 Varying hct tested for fresh and aged blood tested at the following 
levels 
 20, 30, 35, 40, 45, 50, 60, and 70% (not all levels tested for  each 
 variable) 
 Hct levels prepared by either removal of plasma (>hct) or 
addition of plasma (<hct) 
 Hct experiments included: 
 Spot size and analyte response - 25 µL spot / 3-3.3 mm punch 
 Recovery / Spot homogeneity - 5 µL spot / 6 mm punch 
 Spot homogeneity - 25 µL spot / two 1 mm punches (one center 
 punch and second from the perimeter) 
  All results were expressed as peak area ratios with internal 
standard correction 
Conclusions: 
 Absolute response is impacted by hct 
 Higher hct gives a higher viscosity resulting in a smaller spot and 
higher concentration from a partially punched spot 
 Hct impacts recovery and homogeneity and is compound 
dependent 
 Aged blood can lower the recovery 
 During validation the risks associated with changing hematocrit 
should be accessed 
 
  
Study Design: 
 6 companies testing 12 compounds of 
varying chemical space 
 Identical experiments following the 
same protocol 
 4 card types tested with varying hct 
values spanning the minimum and 
maximum values possible across 
patient populations (20-70%) 
 
 
 
 
Figure 22. Schematic of study design for paper 7 
Spot size measurements with varying HCT  
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Study Design: 
 Two methods assessed to study 
homogeneity: 
Non radiolabeled approach 
Radiolabeled approach 
Experimental: 
 Non radiolabeled – covered in paper 7 
 
 Radiolabeled approach 
 14C-lacosamide and 14C-deoxy-D-glucose tested 
 DMPK-A, DMPK-B, DMPK-C, Ahlstrom 226 & Bond Elut 
 Concentrations tested – 2200 and 1400 ng/mL 
 Spotting volumes – 15 and 30 µL 
  
  
 
 
 
 
 
Radioactivity across DBS on Bond Elute 
Conclusions: 
 Radiolabeled and nonradiolabeled investigations into 
homogeneity provide complimentary data 
 
 Homogeneity of DBS is impacted by 
 Compound 
 Card type 
 Hct levels 
  
 Data produced by both methods supports results reported in the 
literature 
 
 Homogeneity must be investigated during validation to ensure 
accuracy of the measurement  
 
  
Figure  23. Schematic of study design for paper 8 
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2.7.3: Data output and impact 
 
Paper 7:  The data confirmed the literature data going back to the first paper published 
on hct (Denniff and Spooner, 2010a). 
 
As the hct levels increase, viscosity of the blood increases causing the blood to flow 
less freely across the card.  This results in a smaller more concentrated spot and when 
taking a partial punch, larger concentrations of analyte are observed. 
 
Hct can impact the extract recovery of the analyte from DBS samples.  The age of the 
spot can reduce the extract recovery and this can sometimes be associated with hct.  
Spot homogeneity is also impacted by hct and is compound dependant. 
 
Varying hct can cause increased variability exceeding the acceptance criteria for 
regulated bioanalysis.  The impact should be greatest with the widest spread of hct 
values e.g. neonates, but results show that even normal hct variances in healthy 
humans could push the assay variances beyond acceptance criteria. 
 
Careful validation is required to fully understand the impact of hct for each assay and 
negate the impact of hct and the negative impacts that it plays on DBS. 
 
Paper 8:  Radiolabeled and nonradiolabeled investigations into homogeneity provide 
complimentary data and also agree with previously published work (O'Mara et al., 
2011) . 
 
For DMPK-A, DMPK-C, Ahlstrom 226 and Bond Elut a volcano effect in concentration 
distribution was observed, meaning that there was a higher concentration of analyte 
at the perimeter of the spot compared with the centre (not seen with DMPK-C in 
nonlabeled approach).  DMPK-B showed the opposite, with higher central 
concentrations compared with the perimeter. 
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From the results homogeneity can be impacted by: 
 
1. Card type 
2. Compound 
3. Hematocrit 
 
DMPK-A although still showed nonhomogeneity it was the least impacted by 
compound and hct levels. 
 
Nonhomogeneity is a major concern when using DBS to support TK and PK analysis.  
The assay can be severely impacted especially if a partial punch is taken.  During 
method development and validation homogeneity should be carefully assessed to 
ensure careful control and understanding. 
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2.7.4: Technical considerations and reflections 
 
The results from these experiments for both hct and homogeneity were predicted 
before the work was carried out.  Previously published work was not in doubt.  Both 
publications combined all issues associated with hct and homogeneity into two 
discrete publications from an industries perspective.  At the time GSK were concerned 
that they may be viewed as pushing the technology for the companies benefit and this 
was not the case.  Engagement with the EBF had begun many years earlier with the 
conception of a microsampling team and the first symposium in 2010 (Connecting 
Strategies on Dried Blood Spots).  The author has been heavily involved from the 
conception of the team. The EBF consortium was pivotal in having a single voice from 
the industry and helps the understanding across other disciplines e.g. regulatory 
perspective. 
 
Working in consortia as always has advantages and challenges.  The final output is 
extremely powerful and influential, but careful management is essential.  Choosing 
individual’s to represent their company’s views that have relevant expert knowledge is 
essential.  The view of all companies has to be taken into account and not just the 
companies that have the strongest opinions.  Planning experiments in a forum can be a 
lengthy experience with agreement necessary from all parties.  From the author’s 
experience, gaining commitment from all parties, with the understanding of what is 
expected, and delivering milestones to strict timelines is essential for the success of 
any consortium.  The author’s role included setting up the group, agreeing a common 
protocol, ensuring everyone had the correct supplies, gathering the data together and 
interpreting it, helping prepare the manuscript and sharing data at meetings. 
 
This work and previous hct work has encouraged the industry to seek opportunities to 
combat the hct effect.  Published options include: whole spot analysis, special filter 
substrates, measure or predict hct, and DPS (Leuthold et al., 2015, De Kesel et al., 
2014, De Kesel et al., 2013, Capiau et al., 2013). 
 
80 
 
2.8: Commentary paper 9 
 
Tina Panchal, Neil Spooner & Matthew Barfield.  Ensuring the collection of high-quality 
dried blood spot samples across multisite clinical studies. 
Bioanalysis (2017) 9(2), 209-213 
Recently published so no citation data available. 
2.8.1: Objectives 
 
To design and implement a simple way of training and verifying DBS spotting across 
multi-site clinical studies worldwide: 
 
1) To develop a surrogate for blood 
2) To design and develop a dried blood spot training kit 
3) Monitor the success rate of spotting using the new training regime    
 
What is felt simple and routine in a bioanalytical laboratory can be considered 
challenging to others who are unfamiliar.  Simple written instructions and DVDs can be 
ignored or misunderstood.  Sample quality is key, without ensuring the quality of 
sample collection, PK and TK data can be compromised with potentially dangerous 
consequences to patient safety.  Studies comprising of a single site centre are simpler 
to manage and ensure adequate training, however as compounds progress and patient 
groups need to be accessed, the number of sites increases as do the complexities.  The 
author compiled written training material and a simple video to help train individuals 
remotely.  However, in the first GSK multisite study over 30% of the DBS samples were 
unusable, which is not acceptable. 
 
This paper set out how to best train and validate the quality of personnel involved with 
DBS spotting. 
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2.8.2: Experimental design 
 
Due to the impracticalities of sourcing blood worldwide a suitable surrogate was 
designed.  Water and milk containing a red die were initially tested to produce the 
most realistic blood surrogate for test spotting.  The author developed a test kit which 
was shipped to sites containing all the necessary equipment and instructions for the 
test. 
 
The kit was initially tested on two people from GSK who had never been involved in 
DBS before to assess its usage.   These were non-scientific individuals who were not 
used to laboratory working.  The test proved to be easy to follow and provided 
encouraging results. 
 
The first multi-site study tested consisted of 15 sites across the US and Germany.  
Before actual sample collection all those involved had to complete the training and 
send pictures of spotting with the surrogate matrix for approval of the technique.
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Study Design: 
 Multi-site clinical centre across 15 sites 
 Remote training via DBS test kit 
 Evaluation of training  
Experimental: 
 Screen blood surrogates concentrating on easily accessible 
reagents e.g. milk and water.  Must behave as blood when 
spotted 
 Design a test kit containing all equipment necessary to facilitate 
training and validation of spotting 
 Evaluation of kit by local inexperienced staff to validate 
procedure 
 Kits provided to study sites.  Use material to self-train and send 
pictures of spotting for validation 
 
Conclusions: 
 Mixture of condensed milk powder, water and red die gave best 
blood like properties 
 Local testing validated the test kit using novice DBS users before 
testing in a clinical environment 
 15 clinical centres supporting one study were successfully 
trained remotely using the test kit 
 Subsequently 2 further multisite centres were supported.  All 
study centres had no DBS samples that could not be analysed 
  
   
 
  
 Access relevant scientific experiments 
to validate a clinical DBS method 
 Validation of a quantitative DBS 
method in human blood 
 Support a clinical study utilizing DBS 
 
 
 
 
 
Figure 24. Schematic of study design for paper 9 
Examples of poor spotting from 
multi-site studies 
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2.8.3: Validation and data output and impact 
 
The paper demonstrated that the ability to practice blood spotting prior to the 
collection of study samples is essential for quality sampling.  Utilising traditional 
training techniques, such as written instructions and DVDs, is not sufficient and can 
lead to samples of unacceptable quality which can result in jeopardizing entire studies. 
 
The ability to train individuals prior to spotting real samples is valuable and coupled to 
peer review; this has proven to be a reliable means of obtaining quality DBS samples.  
Historically failure rates of greater than 30% were typical.  Using the test kit and peer 
review, failure rates are now down to 0%, across three multi-site clinical studies 
utilizing DBS. 
 
2.8.4: Considerations and reflections 
 
The idea of actually validating individuals is key to success.  One development that has 
evolved during the work is the difficulties to ship what was first thought an innocuous 
material, milk powder.  As this is a food product for some countries it is not a 
straightforward process.  At the time local sourcing was envisaged, but this also proved 
problematic.  The final solution which can be sourced locally, shipped across borders 
and does not require refrigeration is red quality control glucose solution. This is used 
across the world as StatStrip™.  For future training this will be the product used. 
 
The lessons learned around training have been extremely valuable and can be applied 
to many areas.  Especially of interest are new microsampling devices that are 
continually being developed.  An important factor for any new device has to be the 
simplicity of use and ease of training.  Any training needs to be tailor made to the 
product and needs to have a way of checking the quality of the end product before 
committing to study samples. 
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3:  Impact of the work 
 
The initial two publications made the largest impact on the industry (190 and 277 
citations) with the subsequent publications exploring the practicalities and science 
behind the technique.  At the height of impact of DBS, a publications titled “Bioanalysis 
Using Dried Blood Spots: The Biggest Advancement in Bioanalysis Since LC–MS-MS?” 
(Paul D. Rainville, 2010) was released.  In a way this was true with the interest being 
widespread and perceived as an exciting development in the history of Bioanalysis.  
The impact can also be seen with the number of publications on the technique (Figure 
25) and also the global spread of publications (Figure 26) 
 
At the time of the initial publications, data on GSK compounds and novel techniques 
was not encouraged, as it could divulge sensitive information and destroy a possible 
competitive advantage.  DBS did offer GSK many possible competitive advantages.  
However, the advantages to animal welfare (reduction and refinement), paediatrics 
and home sampling overweighed any risks and the work was allowed to be shared 
with the industry as a whole. 
 
A publication strategy was developed to enable others to help develop the technique 
and probe deeper into the underlying science.  Also presentations around the globe 
were made to spread the word with most of the large relevant meetings having 
dedicated DBS/microsampling sessions.  A list of presentations made by the author are 
included in appendix 1. 
 
The impact of these works can be measured as a factor of: 
 Economic – including the money saved with less animal usage, less compound 
dosed, ambient shipping and storage, to the economy created from a 
microsampling industry, developing jobs and revenue in this area. 
 Knowledge – the in-depth scientific understanding of DBS.  Also brought 
together clinicians, toxicologists, animal technicians, bioanalysts etc.  This 
enabled better understanding for each other’s processes and constraints, 
which led to better processes e.g. unified rodent sampling, increased sample 
quality.  
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 Social – from the opportunity for less invasive sampling, potential to develop 
medicines that can be used for paediatrics, near patient sampling and the 
ability to access developing and 3rd World countries. 
 Regulatory – Regulators verbally encourage DBS and microsampling due to its 
ethical advantages.  FDA draft guidelines (Bioanalytical Method Validation, 
2013) set out requirements to validate a DBS assay.  ICH SA3 Focus on 
Microsampling and ICHM10 (industry and all main regulator) are currently 
discussing an overall guidance for method validation and this will cover 
microsampling. 
 Health – the ability to home sample and access to paediatrics. 
 
GSK invested heavily into the technique and also investigating its limitations.  GSK 
found the hct effect, which ultimately changed the industry’s views on DBS.  Initially it 
was seen as a replacement for conventional sampling; however it is now viewed as a 
niche technology, only used in certain applications e.g. paediatric studies and home 
sampling.  The search for a solution to microsampling is continuous, and the author 
and GSK have encouraged and challenged the industry to find future microsampling 
solutions.  As a result, an entire industry has been built around new microsampling 
techniques (figure 27 and table 11) with the largest drivers being 3Rs, paediatric 
support, and remote sampling. 
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Figure 25. The number of publications per year that contain “Dried Blood Spot”.  Source – Scopus (Elsevier) 
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Figure 26. The number of publications across the World that contain “Dried Blood Spot”.  Source – Scopus (Elsevier) (capped at 94 and 
showing Russia for interest) 
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Figure 27. Novel microsampling techniques since the conception of DBS for PK and TK analysis
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Date 
introduced 
Technique Description Pros Cons 
1:   
2011 
(Liu et al., 
2014, 
Manicke et 
al., 2016, 
Yannell et 
al., 2017) 
Paper Spray 
(PS) 
Blood sample applied 
to an integrated paper 
mounted device.  This 
is a total solution, 
sample collection, 
storage, shipping and 
direct analysis 
Complete 
solution 
 
-The device could be 
expensive 
-Dry vs wet 
comparison may be 
needed in all studies 
for regulatory 
acceptance 
-Still in development  
-Accurate volume of 
blood required  
- Effect of changing 
hct on signal 
2:  
2012-2013 
(Nilsson et 
al., 2013) 
Plasma 
Capillary 
Microsampling 
(AZ method) 
Blood sample 
collected into a 
capillary.   Plasma and 
blood separated by 
centrifugation and the 
capillary cut and the 
blood portion 
discarded. An accurate 
plasma volume is 
collected in a second 
capillary, which is 
placed in a tube and 
frozen ready for 
shipment and analysis. 
Analysis of a wet 
sample so mirrors 
established 
process.  No 
regulatory 
concerns 
-Approximately 50% of 
the sample is wasted 
-Requires freezers, 
cold storage and 
shipment 
-Time consuming to 
process samples and 
hard to automate, 
generally only used in 
preclinical 
-Not simple 
3: 
2012-2013 
(Li et al., 
2012, Kim et 
al., 2013) 
Plasma 
separation 
cards.  Blood 
filtration 
devices (e.g. 
Yorktest, 
Noviplex & 
Novilytics 
Blood sample (25-
50μL) 
is applied to a 
membrane based filter 
card.  The blood cell 
component is 
separated producing a 
DPS.  Sample is dried 
and ship/stored at 
ambient 
Hct issues for a 
dry sample 
negated (accurate 
volume and 
plasma) 
Cost savings: 
Ambient 
shipping/storage 
Produces a RBC 
free sample 
-Dry vs wet 
comparison may be 
needed in all studies 
for regulatory 
acceptance 
-Still in development  
Endogenous levels of 
plasma components 
(lipids,glycoprotein) 
may have a similar 
effect as varying 
haematocrit 
-Approximately 50% of 
the sample is wasted 
-What is the sample? 
Is it plasma? 
4: 
2013 
(Bowen et 
Plasma 
capillary 
Microsampling 
Blood sample 
collected into a 
capillary (75µL), 
Analysis of a wet 
plasma sample so 
mirrors 
-Approximately 50% of 
the sample is wasted 
-Requires freezers, 
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al., 2013) (Drummond) containing a 
thixotropic gel which 
acts as an interface 
between the blood 
and plasma fractions 
after centrifugation.  A 
Wiretrol™ device is 
used to expel the 
plasma from the 
capillary into a micro 
sample tube, and 
frozen.  Aliquots can 
be taken for analysis. 
established 
process.  No 
regulatory 
concerns 
cold storage and 
shipment 
-Time consuming to 
process samples and 
hard to automate  
5: 
2013 
(Ahmad et 
al., 2015, 
Ahmad, 
2013) 
Solid Phase 
Micro 
Extraction 
(SPME) 
Small fibre coated 
with an extracting 
phase inserted into 
the animal or human.  
The fibre is left in the 
circulation for 1 
minute to allow 
equilibrium to be 
reached and then can 
be shipped in a tube at 
ambient temperature 
 
No sample 
wastage and 
actually no blood 
loss. 
Potential to use 
fibre as a direct 
ionisation tool 
Simple to use, 
ambient shipping 
and storage 
-Totally new concept, 
so industry and 
regulatory acceptance 
required 
-Fibre is physically 
inserted into the 
subject which may be 
hard to implement for 
humans 
6: 
2014 
(Denniff and 
Spooner, 
2014) 
VAMS/MITRA
™ 
(Phenomenex) 
Device has a tip that 
absorbs a fixed 
volume of blood.  
Based around a 
pipette tip.  Dry 
sample technology 
-No sample 
wastage (blood) 
-Simple 
-Fixed volume so 
no issues with dry 
sample and hct 
-Cost 
savings:Ambient 
shipping/storage 
-Dry vs wet 
comparison may be 
needed in all studies 
for regulatory 
acceptance 
-Little data available 
-Hard to automate 
7: 
2014 
(Fobel et al., 
2014) 
Digital 
Microfluidics 
(DMF) 
Blood sample is 
applied to an 
integrated chip.  The 
device is a collection 
device, used for 
storage, shipping and 
analysis 
-Direct analysis, 
simple processing 
  
-Dry vs wet 
comparison may be 
needed in all studies 
for regulatory 
acceptance 
-Still in development  
-Accurate volume 
required 
8: 
2015 
(Lenk et al., 
2015) 
CapiTainer™ Uses dissolvable 
membranes to apply 
an accurate volume of 
blood to a card (DBS) 
Accurate volume 
of blood, remove 
hct issues 
-Simple 
- Apart from hct any 
other issues 
associated with DBS 
-Still in development  
 
9: 
2015 
(Leuthold et 
al., 2015) 
DBS System: 
HemaXis™ 
Incorporates a 
microfluidic platform 
linked to a DBS card 
-Accurate volume 
of blood, remove 
hct issues 
-Simple 
-Apart from hct any 
other issues 
associated with DBS 
-Still in development 
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10: 
2015 
(Mengerink 
et al., 2015) 
 
Qyntest™ by 
Qynion 
Polmer card with a 
layered design to 
minimise hct and 
homogeneity issues 
-Potentially 
overcomes hct 
and homogeneity 
issues 
-Benefits as DBS 
-Dry vs wet 
comparison may be 
needed in all studies 
for regulatory 
acceptance 
-Hard to punch and 
still in development 
11: 
2016 
(Capiau, 
2015) 
Trajan - 
hemaPENTM 
Utilises capillaries for 
accurate blood 
volume measurement 
and DBS technologies 
-Accurate volume 
of blood, remove 
hct issues 
-Simple 
-Expensive 
- Apart from hct any 
other issues 
associated with DBS 
-Untested, in 
development 
12: 
2016 
 
 
Boston 
Microfluidics 
(bmf) 
Uses microfluidics to 
accurately dispense 
blood on a DBS card 
-Accurate volume 
of blood, remove 
hematocrit issues 
-Untested 
-Dry vs wet 
comparison may be 
needed in all studies 
for regulatory 
acceptance 
-Untested, in 
development 
13. 
2017 
 
TAP™ – 
Seventh Sense 
A device to take pain 
free blood samples.  
Designed for home 
sampling and in the 
future will be coupled 
to DBS 
-Accurate volume 
of blood, remove 
hct issues 
-Simple 
-Expensive 
- Apart from hct any 
other issues 
associated with DBS 
-Untested, in 
development 
14. 
2017 
 
Wing device™ Device that collects 
blood which is then 
centrifuged and the 
tips can be broken off 
to give an accurate 
volume of plasma 
Very simple 
Analysis of a wet 
sample so mirrors 
established 
process.  No 
regulatory 
concerns 
-Approximately 50% of 
the sample is wasted 
-Hard to automate 
-Untested, in 
development 
 
Table 11. Descriptions of new microsampling techniques with pros and cons associated  
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4:  Conclusions 
 
This thesis sets out to detail the development of DBS in support of both TK and PK, through the 
author’s published work and brings together learnings, spanning the last 12 years.   The published 
works demonstrates fundamental understanding, scientific advancement of DBS as an application, 
and the investigation of best practice.  DBS has focused the industry on microsampling and the 
major benefits that can be gained, specifically in animal savings and ability to support previously 
unattainable clinical studies e.g. paediatric and remote areas.  The author has been pivotal from 
conception, planning and executing experiments, reporting and influencing the community. 
 
The major contributions to the knowledge detailed in the commentary were: (1) the first TK study 
supported by DBS which focused on the possible advantages; (2) the first PK study supported by 
DBS which focused on the possible advantages; (3) practical considerations of supporting clinical 
studies; (4) transferability of DBS assays across laboratories; (5) utilising ISR data to further 
understand the technology; (6) using paper technologies to support plasma; (7) investigating the 
impact of hct; (8) homogeneity of the sample; (9) procedure to train remotely. 
 
One area that has not been explored is the area of change management.  Introducing a new 
technology is not a straightforward process.  Scientists are generally thought as innovative and 
keen to explore new possibilities.  From the author’s experience this is not always the case and 
change management is a key to the introduction of any new technology or process.  The author’s 
role was to engage across GSK and externally, describe in detail the potential advantages and 
issues associated and deliver scientific data concisely that was understandable for all.    Also to 
seek individuals and teams who were keen to implement and try new technologies and further 
push the scientific understanding. 
 
Not only have advantages been reviewed but also a critical evaluation of the technique, detailing 
its limitations especially in a highly regulated environment.  DBS is now one of the many 
microsampling tools and is still currently in use at GSK and across the industry supporting late 
phase and niche studies.  With future advances in both paper technologies and/or accurate simple 
volumetric sampling, DBS could have the potential to be the primary sampling method for TK and 
PK.  DBS has started a microsampling industry and the impact has been across multiple disciplines.  
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An excellent example is a recent publication (Verhaeghe, 2017) which shows the elimination of TK 
satellites from GLP studies, with the first reference being commentary paper 3.  This demonstrates 
the continued influence the author’s work has had.  One certainty is that microsampling, born 
from DBS is routine and expected from both the industry and regulators. 
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Appendix 1: Invited speaker at International Conferences: 
  
 NC3Rs Conference, London, 2008 
 DMDG DBS Meeting, Manchester, 2008 
 DMDG (Drug Metabolism Discussion Group), Cambridge, UK, 2008 
 LASA (Laboratory Animal Science Association), Scotland, 2008 
 TKDG (Toxicokinetics Drug Discussion Group), Scotland, 2008 
 House of Lords NC3Rs, London, 2009 
 GSK DBS Day (International attendance), Ware, UK, 2009 
 Reid Bioanalytical Forum, Guildford, UK, 2009 
 DMDG, Cambridge, UK, 2009 
 Syngenta DMPK Forum, London, 2009 
 Unilever DMPK Forum, London, 2009 
 58th ASMS Conference, Salt Lake City, USA, 2010 
 EBF Focused Workshop, Brussels, 2010 
 EBF (Microsampling Consortium), Brussels, 2011 
 Reid Bioanalytical Forum, Guildford, UK, 2011 
 DMDG (organising committee for scientific programme, chaired a session titled ‘Novel 
Solutions in Bioanalysis’), Cambridge, UK, 2012 
 JPAG (Joint Pharmaceutical Analysis Group)/DMDG (Organiser), London, 2013 
 EBF Open (chaired microsampling session), Barcelona, 2016 
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confirming Matthew Barfield’s input to these papers and the work which they report.  These are 
for Commentary papers 2, 3, 4, 7, 8 and 9; Matthew Barfield was lead author on papers 1, 5 and 6. 
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for contribution to works and authorship of papers. 
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All of the work sponsored or conducted by GlaxoSmithKline, detailed in the papers included in this Commentary, 
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All GSK-sponsored studies were conducted in accordance with the guiding principles of the Declaration of Helsinki 
and in compliance with good clinical practices and local regulatory guidelines. The protocols and informed consent 
forms were approved by an institutional review board or independent ethics committee at each study site before any 
subject was enrolled or study procedure performed. All human biological samples were sourced ethically and, where 
applicable, patient consent was obtained for their use for research. Additionally subject anonymity was maintained 
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All GSK-sponsored animal studies were conducted in accordance with the relevant GSK Policy on the Care, Welfare 
and Treatment of Laboratory Animals and were reviewed by the Institutional Animal Care and Use Committee (or 
similar at the time of conduct) either at GSK or by the ethical review process at the institution where the work was 
performed.   
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previously demonstrated1. Introduction
Traditionally, the toxicokinetics (TK) of exposure to new chem-
ical entities in preclinical safety studies is reported in plasma, due
to the ease of sample collection and storage. In order to derive the
appropriate volumeof plasma required for quantitative bioanalysis,
relatively large volumes of blood (between 100 and 500L) need
to be taken from the animals. Due to the physiological and ethi-
cal limitations of obtaining multiple serial plasma samples from
individual animals, especially small or juvenile rodents [1], com-
posite sampling is often chosen. This leads to an increased number
of animals being utilised and may result in lower quality TK data.
Regulatory authorities have long acknowledged that blood is an
acceptable biological matrix for the measurement of drug expo-
sures [2,3]. However, due to practical difﬁculties with shipping and
storing blood samples, plasma is usually selected as the matrix of
choice. Filter paper blood sampling is an established technique for
the screening of in-born errors of metabolism [4,5]. There have
also been a number of reports on its use in humans for thera-
∗ Corresponding author. Tel.: +44 1920 882550; fax: +44 1920 884374.
E-mail address: Neil.Spooner@gsk.com (N. Spooner).
1570-0232/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.jchromb.2008.05.025method has been developed and validated for the quantitative bioanalysis
d spots (DBS) prepared from small volumes (15L) of dog blood. Samples
th methanol. Detection was by positive ion TurboIonSprayTM ionisation
n monitoring MS. The analytical concentration range was 0.1–50g/mL.
s values were both less than 15%. Acetaminophen was stable in DBS stored
st 10 days. The methodology was applied in a toxicokinetic (TK) study
DBS samples was physiologically comparable with results from duplicate
) with water) analysed using identical HPLC-MS/MS conditions. This work
analysis of a drug extracted from DBS can provide high quality TK data
f blood withdrawn from experimental animals, to an order of magnitude
the pharmaceutical industry. This is the ﬁrst reported application of DBS
ort of a safety assessment study. The success of this and similar, related
apply DBS technology as the recommended analytical approach for the
cs (PK)/TK for all new oral small molecule drug candidates, which have
cessful bioanalytical validation.
© 2008 Elsevier B.V. All rights reserved.
peutic drug monitoring and pharmacokinetic (PK) studies [6–13].
Dried blood spots (DBS) offers the advantage of less invasive sam-
pling, simpler matrix preparation and transfer (no centrifugation
to produce plasma) and easy storage and shipment to laborato-
ries (no requirement for freezers and dry ice). It is notable that
there are very few reports of application of this technology to pre-
clinical PK assessments [14–16]. For these studies, in addition to
the advantages associated with the clinical use of DBS, the small
blood volumes used for DBS facilitates increased PK data quality,
through the ability to take serial bleeds from the same animal, par-
ticularly when coupled with sensitive and selective HPLC-MS/MS
techniques. This beneﬁt becomes evenmore signiﬁcant as thephar-
maceutical industry focuses on the FDA requirement to evaluate
juvenile animals as part of the Safety Evaluation phase for drugs for
paediatricuse [17]. A further important consideration is that theuse
of DBS in pre-clinical rodent TK studies for the safety assessment
of new chemical entities has the potential to signiﬁcantly reduce
the number of animals required, giving signiﬁcant ethical and cost
beneﬁts.
This paper describes the development and validation of a
method for the quantiﬁcation of acetaminophen in dog blood, as a
DBS sample. The results of these tests were evaluated against inter-
nationally used acceptance criteria described by Shah et al. [18].
M. Barﬁeld et al. / J. ChromatoFig. 1. Chemical structures of acetaminophen and [2H4]-acetaminophen.
The subsequent use of themethod for the analysis of samples taken
from dogs in a routine TK dose range ﬁnding toxicology study fol-
lowing the oral administration of acetaminophen is described. This
workwas conducted in support of a current GSK drug development
programme. The methodology was validated in dog as this species
is to be used in the development of the molecule. Comparison of
the DBS data obtained from analysis of replicate whole blood sam-
ples (diluted with water (1:1, v/v)) using the same HPLC-MS/MS
conditions was used to validate the new technology. The outcome
demonstrates thepotential advantagesof furtherapplicationofDBS
in pre-clinical and regulated drug development.
2. Experimental
2.1. Chemicals and reagentsMethanol and water were of HPLC gradient grade and were
obtained from Fischer (Loughborough, UK). All other chemicals
were of AnalaR grade, supplied by VWR International Limited
(Poole, UK). Dog (Beagle) blood was supplied by Harlan (Hull, UK).
Acetaminophen (Fig. 1) was obtained from Aldrich (Poole, UK). The
stable isotopically labelled internal standard, [2H4]-acetaminophen
(Fig. 1) was produced by Isotope Chemistry, GlaxoSmithKline
(Stevenage, UK).
2.2. Equipment
FTA® Elute blood spot cards were supplied by Whatman
(Sanford, USA). Sample tubes were obtained from Micronics (Plati-
nastraat, TheNetherlands). Centrifuge (model 5810R)was supplied
by Eppendorf (Hamburg, Germany). Harris punch and cutting mat
was supplied by Whatman (Sanford, USA). Plastic bags for the stor-
age of blood spot cards were supplied by Fischer (Loughborough,
UK). Sachets of desiccant were obtained from Sud-Chemie (North-
wich, UK).gr. B 870 (2008) 32–37 33
2.3. Preparation of standard stock and working solutions
Primary stock solutions of acetaminophen (in duplicate)
and [2H4]-acetaminophen (internal standard) were prepared in
dimethylformamide (1mg/mL). Working standard solutions of
acetaminophen in H2O:acetonitrile (1:1, v/v) were prepared from
the primary stocks at concentrations of 100 and 10g/mL. Internal
standard working solutions (0.5g/mL) were prepared from the
primary stock using methanol for blood spot analysis and acetoni-
trile for blood/water analysis. All the solutions were stored at 4 ◦C
and brought to room temperature before use.
2.4. Preparation of calibration standards and quality control (QC)
samples
Calibration standardswere prepared fresh on the day of analysis
(for both validation and TK study sample analysis) by diluting the
appropriate working solutions with blankwhole dog blood for DBS
analysis and blank dog blood/water (1:1, v/v) for blood/water anal-
ysis. The concentrations for both DBS and blood/water calibrants
were 0.1, 0.2, 0.5, 2, 5, 20, 40 and 50g/mL whole blood.
QC samples for all analyses were prepared from a separate stock
solution to that used for the calibration standards. QC samples for
theDBS validationwere prepared bydiluting the appropriatework-
ing solutions with blank dog matrix to give concentrations of 0.1,
0.3, 5, 40 and 50g/mL whole blood. For the analysis of TK study
samples, QC’s were prepared with blank whole dog blood (DBS)
and blank dog blood/water (1:1, v/v) for blood/water analysis at
concentrations of 0.3, 5, 40g/mL whole blood.
For DBS analyses 15L aliquots of calibration standards and QC
samples were spotted onto FTA® Elute cards and allowed to dry at
room temperature for at least 2h prior to analysis. When required,
the DBS QCs were stored at room temperature in a sealed plastic
bag containing desiccant until analysis.
For blood/water analyses, 30L aliquots were transferred to a
clean tube, prior to analysis. When required, the blood/water QCs
were transferred to sample tubes for storage at −20 ◦C until analy-
sis.
2.5. Sample preparation
For DBS analyses, a 3mm diameter disk was punched from the
centre of the DBS into a clean tube. Methanol (100L) containing
internal standard ([2H4]-acetaminophen) was added and the tube
vortex mixed for approximately 30 s. The tube was centrifuged for
5min at 3000× g and the supernatant transferred to a clean tube
and a portion injected onto the HPLC-MS/MS system.
For blood/water analyses, a 30L aliquot was extracted
with 300L acetonitrile containing internal standard ([2H4]-
acetaminophen). This was vortexmixed for approximately 30 s and
then centrifuged for 5min at 3000× g and a portion of the super-
natant injected onto the HPLC-MS/MS system.
2.6. HPLC-MS/MS analysis
The HPLC-MS/MS system consisted of a CTC HTS PAL autosam-
pler (Presearch, Hitchin, UK) with fast wash, an Agilent 1100 binary
pump (Palo Alto, CA, USA) with integrated column oven and divert
valve, and a Polaris Amide C18, 3m, 50mm×3.2mm i.d. HPLC
column (Varian Limited, Oxford, UK). The post column ﬂow was
diverted to waste for ﬁrst 0.5min of each chromatographic run.
During this time, ﬂow(0.25mL/min,methanol:water (1:1, v/v))was
provided to the MS by a Knauer pump (Presearch, Hitchin, UK).
The chromatographic separation was achieved using a solvent
gradient employing the mobile phases 10mM ammonium formate
omato
of a control DBS double blank is shown in Fig. 2.
The lower limit of quantiﬁcation (LLQ) for the analysis of DBS
sample extracts was 0.1g/mL. This was deﬁned as the lowest con-
centration that gave accuracy within 15% of nominal and precision
not exceeding 15% for n=6 replicates. Representative mass chro-
matograms of blank and LLQ samples are shown in Figs. 3 and 4,
respectively. The suppression of the response for the stable iso-
tope labelled internal standard when analysing DBS extracts by
HPLC-MS/MS was 76%.
3.1.2. Accuracy and precision
The accuracy (%bias) andprecision (%CV) of theDBSmethodwas
evaluated using QC samples at ﬁve concentrations analysed against
calibration standards prepared from a separate stock solution. Each
QC was analysed in replicate (n=6) in a single validation batch.
Accuracy was assessed by calculating the percent deviation from
the theoretical concentration. Precision was determined by calcu-
lating the coefﬁcient of variation for intra-day replicates. Table 1
shows a summary of the individual QC concentration data obtained
during the validation. The maximum accuracy and intra-day preci-34 M. Barﬁeld et al. / J. Chr
containing 0.3% ammonia (A) and methanol (B). Following sample
injection (3L) the mobile phase was held at 98% A for 0.2min. A
ballistic gradient to 5% A at 0.3min, was followed by an isocratic
period at 5% to 0.8min. The mobile phase was then returned to
98% A by 0.9min and was held at this composition until 1.5min,
before the injection of the next sample. The ﬂow ratewas 1mL/min,
the column was maintained at 40 ◦C. The HPLC efﬂuent was split
approximately 1:3 before entering the ion source.
MSdetectionwasby a SciexAPI-3000 (AppliedBiosystems/MDS
Sciex, Canada) equipped with a TurboIonsprayTM ion source. The
source temperaturewas450 ◦Cwith a turbo gasﬂowof 7 L/min (N2)
and a nebuliser gas setting of 10 (N2). The curtain gas and collision
gas settings were 10 and 6, respectively (both N2). The characteris-
tic precursor [M+H]+ to product ions transitions, m/z 152–110 and
156–114were consistentwith the structures of acetaminophen and
the internal standard (loss of CH2CO), respectively, and were used
as selected reaction monitoring transitions to ensure high selectiv-
ity. A dwell time of 200mswas used for both transitions. The pause
time was 5ms.
HPLC-MS/MS data were acquired and processed (integrated)
using Analyst software (v1.4.1 Applied Biosystems/MDS Sciex,
Canada). Concentrationsweredetermined fromthepeakarea ratios
of analyte to internal standard using the in-house laboratory infor-
mation management system, SMS2000 (v1.6, GlaxoSmithKline,
UK).
2.7. Assessment of matrix suppression effects
Toassess the suppressionofHPLC-MS/MSdetector responsedue
to matrix components associated with DBS, the peak areas of the
internal standard in extracts of replicate DBS QC samples at 0.3, 5
and 40g/mL whole blood, were compared to those of the same
concentration of internal standard spiked directly into methanol.
2.8. Application of the DBS assay to a toxicokinetic study
Onemale and one female dog received a single daily oral gavage
administration of a suspension of acetaminophen at a target dose of
50mg/kg for 7 days. Blood samples (1mL)were collected by jugular
venepuncture into EDTA tubes on days 1 and 7 at 0.5, 1, 2, 4, 8, 12
and 24h after administration.
For DBS analyses, replicate (n=3 for each time point) 15L
aliquots from each blood sample were spotted onto FTA® Elute
paper and allowed to dry at room temperature for 2h. These were
then stored and shipped at room temperature in a sealed plastic
bag containing desiccant before analysis.
For blood/water analyses, a further 15L of blood from each
sample was aliquoted into a tube containing 15L of HPLC grade
water. The tubes were mixed by inversion and frozen immediately
over carbon dioxide. The diluted blood samples were stored and
shipped at −20 ◦C before analysis.
3. Results and discussion
3.1. Method validation
3.1.1. Linearity, selectivity and sensitivity
A calibration plot of analyte/internal standard peak area ratio
versus the nominal concentration of acetaminophen was con-
structed and a weighted 1/x2 linear regression applied to the
data. Linear responses were observed for DBS over the range
0.1–50g/mL dog blood. This is represented by the following lin-
ear regression equation: y=1.56×10−5x+7.68×10−4, r2 =0.9947,
where y represents the peak area ratio of acetaminophen to thatgr. B 870 (2008) 32–37
of IS and x represents the concentration of acetaminophen in
g/mL.
The selectivity of the blood spot method was established by the
analysis of samples of control dog blood from six individual beagle
dogs extracted from FTA® Elute paper. No unacceptable interfer-
ences, i.e. thosewithpeakareasof >20%of that observed for theLLQ,
at the retention times of acetaminophen or its internal standard
were observed in any of these lots. A representative chromatogramFig. 2. Representative HPLC-MS/MS chromatograms of a double blank dried dog
blood spot sample.
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Mean 0.108 0.344 5.452 38.976 44.999
S.D. 0.011 0.030 0.463 2.785 1.565
Precision (%CV) 10.4 8.6 8.5 7.1 3.5
Accuracy (%bias) 8.3 14.5 9.0 −2.6 −10.0
blood samples spiked at 40g/mL and stored for 4h at 37 ◦C, with
those of the fresh samples. Samples (30L) were extracted by the
addition of acetonitrile (300L) containing IS. The difference was
2.2% (Table 2), indicating no acetaminophen instability under the
conditions of storage.
The stability of acetaminophen in blood dried on the FTA® Elute
paper for the maximum period a sample was likely to be storedFig. 3. Representative HPLC-MS/MS chromatograms of a blank dried dog blood spot
sample.
sion values observed were 14.5% and 10.4%, respectively, which are
well within internationally recognised acceptance criteria for assay
validations [11].
3.1.3. Stability
The stability of acetaminophen in matrix during the process of
collecting the blood sample, and spotting and drying on the paper,
was assessed by comparing peak area ratios of replicate (n=6) dog
Fig. 4. RepresentativeHPLC-MS/MS chromatogramof a drieddogblood spot sample
at the LLQ (0.1g/mL acetaminophen).gr. B 870 (2008) 32–37 35
Table 1
Accuracy, precision and individual validation sample concentrations for
acetaminophen in dried dog blood spot samples
Nominal
concentrations
(g/mL)
QC 1 QC 2 QC 3 QC 4 QC 5
0.1 0.3 5 40 50
0.099 0.350 5.828 34.886 44.264
0.096 0.391 5.298 42.138 45.588
0.107 0.301 6.145 38.045 44.223
0.105 0.345 5.432 40.821 47.384
0.126 0.348 5.103 40.954 42.852
0.117 0.326 4.903 37.009 45.682before being analysed, was assessed by comparing concentrations
of replicate (n=6) dog blood samples spiked at 0.3 and 40g/mL
after storage of the DBS at room temperature for 7 days, with those
of the same samples extracted immediately after initial spotting
and drying. The difference was less than 15% (Table 3), indicating
no acetaminophen instability under the conditions of storage.
Table 2
Stability of acetaminophen in whole dog blood stored at 37 ◦C for 4h
Peak area ratio
Fresh 4h at 37 ◦C
0.973 0.962
0.995 0.988
0.903 0.905
0.943 0.928
0.879 0.990
0.915 0.959
Mean 0.935 0.955
S.D. 0.044 0.033
Precision (%CV) 4.7 3.5
Difference (%) 2.1
Table 3
Stability of acetaminophen in dried dog blood spots on Whatman FTA® Elute paper
stored at room temperature for 7 days
Nominal concentrations
0.300g/mL 40g/mL
Fresh Stored Fresh Stored
0.293 0.299 38.947 36.503
0.314 0.289 40.548 35.584
0.295 0.272 37.431 35.241
0.267 0.228 38.772 37.062
0.307 0.232 40.625 33.492
0.328 0.225 39.247 35.280
Mean 0.301 0.258 39.262 35.527
S.D. 0.021 0.033 1.200 1.233
%CV 7.0 12.9 3.1 3.5
%Bias 0.2 −14.2 −1.8 −11.2
%Difference −14.4 −9.5
36 M. Barﬁeld et al. / J. ChromatoFig. 5. RepresentativeHPLC-MS/MS chromatogramof a drieddogblood spot sample
obtained 0.5h following daily oral administration of 50mg/kg acetaminophen to a
male dogs for 7 days (corresponding to the maximum observed peak concentration
(Cmax)).
3.2. Application of the DBS assay to a toxicokinetic study
A representative mass chromatogram of a DBS sample extract,
corresponding to a Cmax sample is shown in Fig. 5. TK anal-
ysis of the DBS and blood/water concentration data obtained
was performed by non-compartmental pharmacokinetic analysis
using WinNonlinTM, Enterprise Edition Version 4.1. The systemic
exposure of acetaminophen was determined by calculating the
area under the concentration–time curve (AUC) from the start
of dosing to the last quantiﬁable time point (AUC0-t) using the
Table 4
Toxicokinetic parameters obtained from the analysis of dried blood spot and
blood/water (1:1, v/v) samples obtained following daily oral administration of
50mg/kg acetaminophen to dogs for 7 days
Period Sex AUC (gh/mL) Cmax (g/mL)
Blood/water Blood spot Blood/water Blood spot
Day 1 Male 58.8 71.3 29.9 37.9
Female 55.9 60.4 31.4 41.5
Day 7 Male 65.7 81.6 33.8 44.0
Female 57.6 64.7 37.1 43.5
Fig. 6. Blood concentrations of acetaminophen obtained from the analysis of dried
blood spot and blood/water (1:1, v/v) samples obtained following daily oral admin-
istration of 50mg/kg acetaminophen to dogs for 7 days.gr. B 870 (2008) 32–37
linear-logarithmic trapezoidal rule. The maximum observed peak
concentration (Cmax)was determinedby inspection of the observed
data. The AUC and Cmax results obtained are presented in Table 4.
As only one male and one female dog were used in the TK study,
it is inappropriate to employ statistical methods to compare the
data obtained from DBS and blood/water samples. However, data
generated from such small group sizes overmany years in our labo-
ratories formultiple new chemical entities suggest that TK data can
vary by up to two-fold and still be considered comparable. Hence,
the <1.4-fold variability in data obtained fromDBS and blood/water
samples in this study demonstrates that TK exposure parameters
for acetaminophen by DBS analysis are physiologically compara-
ble to those obtained from direct analysis of blood/water. This is
also illustrated graphically in the blood concentration–time plots
shown in Fig. 6.
4. Conclusion
DBS has been reported to be a convenient matrix, readily
amenable to measurement of biomarkers and drugs like the
anti-malarials, in blood for both clinical and pre-clinical studies.
However, this is the ﬁrst reported application of DBS analysis for
the assessment of TK in a pre-clinical safety assessment study
with all the potential advantages this technology allows. This paper
describes the validation of an acetaminophenmethod in dog blood
by combining extraction of the drug from DBS and HPLC-MS/MS
quantiﬁcation. The method was selective for acetaminophen and
linear over the concentration range 0.1–50g/mL using only 15L
of blood, with intra-day precision and bias of less than 12%. The
stability of acetaminophen in dog blood spotted onto the FTA Elute
paper and stored at room temperature was demonstrated for at
least 10 days. The methodology has been successfully employed
in a TK study following daily oral administration of 50mg/kg
acetaminophen to dogs for 7 days. The resultant TK data from DBS
samples are physiologically comparable with that obtained from
duplicate blood/water samples analysed using identical analytical
conditions. This work demonstrates the capability of DBS analysis
to provide high quality TK information using signiﬁcantly smaller
volumes of blood than are conventionally required. Further, the
reduction in blood volume leads to a decrease in animal numbers
used, through serial rather than composite sampling regimes, giv-
ing ethical beneﬁts and an increase in data quality. In addition,
if continued through the life-cycle of a new drug, the technology
offers the advantage of simpler sample collection, storage and ship-
ment for both preclinical and clinical study samples, leading to
notable ethical and ﬁnancial beneﬁts. The success of this and simi-
lar, related studies has led to the intent top apply DBS technology as
the recommended analytical approach for the assessment of PK/TK
data for all new oral small molecule drug candidates, which have
previously demonstrated a successful bioanalytical validation.
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Dried Blood Spots as a Sample Collection
Technique for the Determination of
Pharmacokinetics in Clinical Studies:
Considerations for the Validation of a Quantitative
Bioanalytical Method
Neil Spooner,* Rakesh Lad, and Matt Barfield
PreClinical Development Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development,
Ware, Hertfordshire SG12 0DP, U.K.
A novel approach has been developed for the quantitative
determination of circulating drug concentrations in clini-
cal studies using dried blood spots (DBS) on paper, rather
than conventional plasma samples. A quantitative bioana-
lytical HPLC-MS/MS assay requiring small blood volumes
(15 µL) has been validated using acetaminophen as a tool
compound (range 25 to 5000 ng/mL human blood). The
assay employed simple solvent extraction of a punch taken
from the DBS sample, followed by reversed phase HPLC
separation, combined with selected reaction monitoring
mass spectrometric detection. In addition to performing
routine experiments to establish the validity of the assay
to internationally accepted criteria (precision, accuracy,
linearity, sensitivity, selectivity), a number of experiments
were performed to specifically demonstrate the quality of
the quantitative data generated using this novel sample
format, namely, stability of the analyte and metabolites
in whole human blood and in DBS samples; effect of the
volume of blood spotted, the device used to spot the
blood, or the temperature of blood spotted. The validated
DBS approach was successfully applied to a clinical study
(single oral dose of 500 mg or 1 g acetaminophen).
Conventionally, plasma has been used for the determination
of exposures and pharmacokinetics (PK) of new chemical entity
drugs in clinical trials because of its ease of handling, shipping,
and storage compared to whole blood. However, it is notable that
regulatory authorities acknowledge that blood is an acceptable
biological matrix for the measurement of drug exposures.1,2 The
collection of blood samples on paper, known as dried blood spots
(DBS), is an established technique for the screening of in-born
errors of metabolism.3,4 There have also been a number of reports
on its use in humans for therapeutic drug monitoring and PK
studies.5-27
The collection of whole blood samples as DBS for PK studies
offers a number of advantages over conventional plasma sampling.
The small blood volumes required for DBS samples (less than
100 µL, compared to >0.5 mL blood which are usually obtained
for conventional plasma analyses) make this a particularly suitable
approach for the collection of blood samples for pediatric studies.
In addition, it offers the advantage of less invasive sampling (finger
or heel prick, rather than conventional venous cannula) which
enables recruitment of subjects for clinical studies. Further, the
simpler matrix preparation and transfer (no refrigerated centrifu-
gation to produce plasma) and easy storage and shipment to
analytical laboratories (no requirement for freezers and dry ice)
offer further benefits. In addition, these requirements lead to
notable environmental benefits. The transport and storage of
samples is further simplified by the antimicrobial properties of
the DBS sample, removing the requirements for special biohazard
arrangements.28 The significant reduction in blood volume re-
quired for DBS, allows for the simplification of current approaches
to the determination of drug exposure (toxicokinetics (TK)) in
pre-clinical animal studies and leads to significant benefits in the
3Rs (reduction, refinement, and replacement) for animal use in
drug development.29
For these reasons, GlaxoSmithKline (GSK) is currently utiliz-
ing DBS sampling as the technique of choice for the evaluation
of TK and PK for all new oral small molecule drugs selected as
drug development candidates, which have previously demon-
strated a successful validation of the bioanalytical method.
This manuscript describes the development and validation of
a method for the quantification of drugs in human blood, as a
DBS sample, using acetaminophen as a tool compound. The
results of these tests were evaluated against internationally used
acceptance criteria described by Shah et al.30 A similar approach
has been previously described for the abbreviated validation of a
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method for determination of acetaminophen TK in a safety
assessment dose range finding (non GLP) dog study.29 This
manuscript describes a full clinical validation of a DBS method
and in addition, describes a number of important experiments not
included in current guidances,30 which the authors consider
should be performed to assess factors specifically associated with
the use of DBS for the measurement of the circulating concentra-
tions of new chemical entities in clinical trials (i.e., influence of
volume of blood spotted, influence of device used for spotting,
influence of whole blood temperature, analyte stability in DBS,
stability of acetaminophen sulfate and glucuronide metabolites in
DBS and whole blood). The validated method was subsequently
used for the analysis of samples taken from a clinical study
designed to investigate the practicalities of the use of DBS samples
in human drug trials, further details of which are published
elsewhere.31
EXPERIMENTAL SECTION
Chemicals and Reagents.Methanol and water were of HPLC
gradient grade and were obtained from Fisher Scientific Ltd.
(Loughborough, U.K.). All other chemicals were of AnalaR grade,
supplied by VWR International Limited (Poole, U.K.). Control
human blood was supplied by GSK volunteers in accordance with
current GSK policies on informed consent and ethical approval.
Acetaminophen (Figure 1) was obtained from Aldrich (Poole,
U.K.). [2H4]-Acetaminophen (Figure 1) was produced by Isotope
Chemistry, GSK (Stevenage, U.K.). Glucuronide and sulfate
metabolites of acetaminophen were both obtained from Sigma
(Poole, U.K.).
Equipment. FTA blood spot cards were supplied by Whatman
(Sanford, U.S.A.). Sample tubes were obtained from Micronics
(Platinastraat, The Netherlands). Centrifuge (model 5810R) was
supplied by Eppendorf (Hamburg, Germany). Harris punch and
cutting mat was supplied by Whatman (Sanford, U.S.A.). Plastic
bags for the storage of blood spot cards were supplied by Fisher
Scientific Ltd. (Loughborough, U.K.). Sachets of desiccant were
obtained from Su¨d-Chemie (Northwich, U.K.). The repeater
multipipette used for spotting blood was obtained from Eppendorf
(Cambridge, U.K.). EDTA coated capillaries were from Sarstedt
(Leicester, U.K.).
Preparation of Standard Stock and Working Solutions.
Primary stock solutions of acetaminophen (in duplicate) and [2H4]-
acetaminophen (internal standard) were prepared in dimeth-
ylformamide (DMF, 1 mg/mL). Working standard solutions
of acetaminophen in H2O-acetonitrile (1:1, v/v) were prepared
from the primary stocks at concentrations of 100, 10, and 1
µg/mL. Internal standard working solutions (0.25 µg/mL) were
prepared from the primary stock using H2O-methanol (1:1,v/
v) for blood spot analysis and acetonitrile for blood/water
analysis.
Primary stock solutions of acetaminophen glucuronide and
sulfate metabolites were prepared in DMF (1 mg/mL). Working
solutions of both metabolites at 100, 10, and 1 µg/mL were
individually prepared in H2O-acetonitrile (1:1, v/v) from the
primary stock solutions.
All the solutions were stored at 4 °C and brought to room
temperature before use.
Preparation of Calibration Standards and Quality Control
(QC) Samples. Calibration standards were prepared fresh on the
day of analysis by diluting the appropriate working solutions with
blank whole human blood. The concentrations of calibrants were
25, 50, 100, 500, 1000, 2000, 4000, and 5000 ng/mL whole blood.
QC samples for all analyses were prepared from a separate
stock solution to that used for the calibration standards. QC
samples were prepared by diluting the appropriate working
solutions with blank whole human blood to give concentrations
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Figure 1. Chemical structures of acetaminophen and [2H4]-acetami-
nophen.
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of 25, 100, 1000, 4000, and 5000 µg/mL whole blood. For the
analysis of study samples, QC’s were prepared at concentrations
of 100, 1000, and 4000 ng/mL whole blood.
Blood Spotting. Aliquots (15 µL) of calibration standards and
QC samples were spotted onto FTA cards with a repeater pipet
and allowed to dry at room temperature for at least 2 h prior to
analysis. When required, the QCs were stored at room temper-
ature in a sealed plastic bag containing desiccant until analysis.
DBS Sample Processing. A 3 mm diameter disk was
punched from the center of the DBS into a clean tube. This was
then extracted by the addition of 100 µL internal standard working
solution, followed by vortex mixing for approximately 20 s. The
tube was centrifuged for 1 min at 3000 × g, and the supernatant
transferred to a clean tube for analysis by HPLC-MS/MS.
HPLC-MS/MS Analysis. The HPLC-MS/MS system con-
sisted of a CTC HTS PAL autosampler (Presearch, Hitchin, U.K.)
with fast wash, an Agilent 1100 binary pump (Palo Alto, CA,
U.S.A.) with integrated column oven and divert valve, and a YMC-
Pack ODS AQ, 3 µm, 50 mm × 4.0 mm i.d. HPLC column (YMC
Europe, GmbH). The post column flow was diverted to waste for
the first 1.0 min of each chromatographic run. During this time,
flow (0.25 mL/min, methanol-water (1:1, v/v)) was provided to
the MS by a Knauer pump (Presearch, Hitchin, U.K.).
The chromatographic separation was achieved using a solvent
gradient employing the mobile phases ammonium acetate (10
mM; adjusted to pH 10 with ammonia) (A) and methanol (B).
Following sample injection (5 µL) the mobile phase was held at
100% A for 0.08 min. A ballistic gradient to 0% A at 1.08 min was
followed by an isocratic period at 0% A to 1.25 min. The mobile
phase was then returned to 100% A by 1.26 min and was held at
this composition until 2.0 min, before the injection of the next
sample. The flow rate was 0.8 mL/min, and the column was
maintained at room temperature.
MS detection was by a Sciex API-5000 (Applied Biosystems/
MDS Sciex, Canada) equipped with a TurboIonspray ion source.
The source temperature was 700 °C. The gas 1 and gas 2 settings
were 50 and 40 psi, respectively (both N2). The curtain gas and
collision gas settings were 25 and 5, respectively (both N2).
The characteristic precursor [M - H]- to product ions
transitions, m/z 150 to 107 and 154 to 111 were consistent with
the structures of acetaminophen and the internal standard (loss
of CH3CO), respectively, and were used as selected reaction
monitoring transitions to ensure high selectivity. A dwell time
of 150 msec was used for both transitions. The pause time was
5 msec.
HPLC-MS/MS data were acquired and processed (integrated)
using Analyst software (v1.4.1 Applied Biosystems/MDS Sciex,
Canada). Concentrations were determined from the peak area
ratios of analyte to internal standard using the in-house laboratory
information management system, SMS2000 (v2.0, GSK, U.K.).
Validation Procedures. Linearity. Calibration standards were
prepared in duplicate for each analytical run. Calibration plots of
the analyte peak area ratio to that of the internal standard versus
the nominal concentration in blood were constructed.
Selectivity and Matrix Suppression Effects. Total blank and blank
DBS’s were derived from 15 µL aliquots of control blood from 6
individual subjects and from matrix pools. Total blank samples
Figure 2. Representative HPLC-MS/MS selective reaction monitor-
ing chromatograms of (A) a blank human DBS sample, (B) a human
DBS sample spiked with acetaminophen at the LLQ (25 ng/mL human
blood), (C) a human DBS sample obtained 1.5 h following a single
oral administration of 500 mg acetaminophen to a volunteer (corre-
sponding to the maximum observed peak concentration (Cmax)), and
(D) the internal standard ([2H4]-acetaminophen).
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(n ) 1 for each subject or pool) were processed as outlined above,
in the absence of internal standard.
To assess the suppression of HPLC-MS/MS detector response
due to matrix components associated with DBS, the peak areas
of the internal standard in extracts of replicate DBS QC samples
at 100, 1000, and 4000 ng/mL whole blood were compared to those
of the same concentration of internal standard spiked directly into
methanol-water (1:1, v/v).
Accuracy and Precision. The intra- and inter- assay accuracy
and precision of the method were determined by assaying six
replicates of each of the five concentrations of validation QC
samples on three separate occasions. Concentrations were deter-
mined from the appropriate calibration plot within each analytical
run. Accuracy was assessed for each concentration by calculating
the percent deviation from the theoretical (nominal) concentration.
The precision was determined for each concentration by calculat-
ing the percent coefficient of variation (%CV; relative standard
deviation) for each set of replicates.
Stability in Stock Solutions. The HPLC-MS/MS peak area ratios
(analyte to internal standard) of replicate (n ) 6) 1 mg/mL
samples stored for 109 days at 4 °C were compared with those of
the fresh samples. When analyzing the samples, a 25 µL aliquot
was diluted to 50 mL with a 500 ng/mL solution of internal
standard ([2H4]-acetaminophen) in H2O-methanol (1:1, v/v).
Stability in Whole Blood. The HPLC-MS/MS peak area ratios
(analyte to internal standard) of replicate (n ) 6) control whole
human blood samples at 100 ng/mL and 4000 ng/mL stored for
24 h at room temperature were compared with those of aliquots
of the same samples when fresh. Immediately prior to extraction,
samples (25 µL) were diluted with an equal volume of water. The
entire diluted sample was then extracted with 150 µL acetonitrile
containing internal standard. This was vortex mixed for ap-
proximately 20 s and then centrifuged for 10 min at 3000 × g. An
aliquot (50 µL) of the supernatant was transferred to a clean tube
containing 100 µL H2O and vortex mixed for approximately 5 s.
Stability in Dried Blood Spot on FTA Paper. Replicate (n ) 6)
15 µL human blood samples at 100 and 4000 ng/mL were spotted
Table 1. Intra- and Inter-Assay Performance Data for Acetaminophen in Human DBS Samples (n ) 6 for Each
Concentration Level in Each Individual Run)
nominal concentration (ng/mL) 25 100 1000 4000 5000
Individual (Intra-Run) Statistics
run 1 mean concentration (ng/mL) 24.2 98.0 950.6 3959.0 4955.1
SD. 2.6 2.0 30.7 54.7 174.1
precision (%CV) 10.9 2.1 3.2 1.4 3.5
accuracy (% bias) -3.1 -2.0 -4.9 -1.0 -0.9
run 2 mean concentration (ng/mL) 22.9 99.5 940.1 4049.3 4952.2
SD. 2.6 5.4 14.0 81.3 70.9
precision (%CV) 11.2 5.4 1.5 2.0 1.4
accuracy (% bias) -8.4 -0.5 -6.0 1.2 -1.0
run 3 mean concentration (ng/mL) 25.6 103.4 1041.9 4019.1 4884.5
SD. 2.1 6.6 70.7 273.2 189.1
precision (%CV) 8.2 6.4 6.8 6.8 3.9
accuracy (% bias) 2.5 3.4 4.2 0.5 -2.3
Overall (Inter-Run) Statistics
mean concentration (ng/mL) 24.2 100.3 977.6 4009.1 4930.6
SD. 2.6 5.3 63.4 162.1 148.4
overall precision (%CV) 10.6 5.3 6.5 4.0 3.0
average accuracy (% bias) -3.0 0.3 -2.2 0.2 -1.4
average intra-run precision (%) 10.1 5.1 4.6 4.2 3.1
inter-run precision (%) Negligible Negligible 5.4 Negligible Negligible
Table 2. Influence of the Volume of Human Blood Spotted on FTA Paper on the Precision and Accuracy of the
Assay at Two Concentration Levels (n ) 6 Replicates)a
nominal concentration 100 ng/mL 4000 ng/mL
volume of human blood spotted onto FTA paper 10 µL 15 µL 20 µL 10 µL 15 µL 20 µL
mean concentration (ng/mL) 100.3 99.5 104.8 3852.8 3959.0 4129.9
SD. 9.7 5.4 7.1 110.8 54.7 207.0
precision (%CV) 9.6 5.4 6.8 2.9 1.4 5.0
accuracy (% bias) 0.3 -0.6 4.8 -3.7 -1.0 3.2
difference from 15 µL Spot (%) 0.9 5.4 -2.7 4.3
a Concentrations were measured against a calibration line prepared with 15 µL human blood.
Table 3. Influence of Device Used to Spot 15 µL Human
Blood onto FTA Paper on the Precision and Accuracy
of the Assay at Three Concentration Levels (n ) 6
Replicates)
spotting device
pipette glass capillary
nominal concentration
(ng/mL) 100 4000 10000a 100 4000 10000a
mean concentration
(ng/mL)
103.0 4358.6 10158.5 103.6 4081.0 10160.4
SD. 3.3 128.4 677.2 6.6 65.7 583.2
precision (%CV) 3.2 2.9 6.7 6.4 1.6 5.7
accuracy (% bias) 3.0 9.0 1.6 3.6 2.0 1.6
a Sample extract diluted 1/10 with extract of blank human DBS.
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on FTA paper and stored desiccated at room temperature for 113
days. The measured concentrations were compared to those of
the same samples extracted and analyzed immediately after initial
spotting and drying.
Stability in Processed Samples. Extracts from a DBS validation
run were reinjected after storage at room temperature for 24 h,
against freshly prepared calibration standard extracts.
Stability of Metabolites. Control human blood samples contain-
ing either the glucuronide or the sulfate metabolites of acetami-
nophen were prepared at 100 and 4000 ng/mL. Aliquots (15 µL)
of the blood were spotted onto FTA paper and left for 24 h at
room temperature. These samples were then processed and
analyzed for acetaminophen. Further aliquots (25 µL) of the whole
blood samples were kept for 6 h at room temperature. These
samples were diluted with water (1:1 v/v) prior to extraction with
150 µL acetonitrile containing internal standard. Extracts were
qualitatively analyzed for the presence of the metabolites and
acetaminophen using HPLC-MS/MS.
Dilution of Samples Above the Higher Limit of Quantification
(HLQ). Control human blood was spiked at 10000 ng/mL (2 ×
HLQ) and six replicate 15 µL aliquots were spotted onto FTA
paper. After drying at room temperature for 2 h, a 3 mm diameter
punch was taken from each spiked DBS sample. Each punch was
individually extracted with 100 µL of methanol-water (1:1, v/v),
containing internal standard. Diluent was prepared by individually
extracting 10 × 3 mm punches taken from replicate spots of blank
human DBS’s on FTA paper with 100 µL aliquots of methanol-
water (1:1, v/v) containing internal standard. These blank diluent
extracts were then pooled. A 10 µL aliquot of each individual
spiked sample extract was then diluted with 90 µL of pooled blank
extract diluent. Concentrations of acetaminophen in these indi-
vidual extract dilution samples were determined by LC-MS/MS
and corrected for the dilution factor.
Blood Spot Size. Replicate (n ) 6) 10, 15, and 20 µL aliquots of
control human blood at 100 and 4000 ng/mL were spotted onto
FTA paper. After drying, a 3 mm punch was taken from the center
of each sample for extraction and analysis. Concentrations of
acetaminophen were determined from a calibration line consisting
of standards derived from 15 µL DBS.
Influence of Spotting Device. Replicate (n ) 6) 15 µL aliquots
of single 1000 µL pools of control human blood at 100, 4000,
and 10000 ng/mL were spotted onto FTA paper using either a
multipipette or a capillary (a fresh tip being used for each
sample and a fresh capillary being used for each spot,
respectively). Concentrations of acetaminophen were deter-
mined in DBS extracts versus a calibration line spotted with a
pipet. The 10000 ng/mL DBS sample extracts were diluted as
described above.
Influence of the Temperature of Blood Spotted. Control human
blood was spiked at 100, 4000, and 10000 ng/mL. Replicate 1000
µL pools were maintained for 30 min at either room temperature,
on wet-ice, or at 37 °C. Replicate (n ) 6) 15 µL aliquots of each
were then spotted onto FTA paper. Concentrations of acetami-
nophen were determined in DBS extracts versus a calibration line
Table 4. Influence of the Temperature of Blood Spotted onto FTA Paper on the Precision and Accuracy of the Assay
(n ) 6 Replicates)
blood storage conditions
room temperature on ice 37 °C
nominal concentration (ng/mL) 100 4000 10000a 100 4000 10000a 100 4000 10000a
mean concentration (ng/mL) 99.5 3811.6 10239.1 103.8 3854.9 9975.9 108.7 4125.4 9680.5
SD. 6.5 138.3 815.5 4.2 148.6 769.3 7.0 227.8 265.1
precision (%CV) 6.5 3.6 8.0 4.0 3.9 7.7 6.5 5.5 2.7
accuracy (% bias) -0.5 -4.7 2.4 3.8 -3.6 -0.2 8.7 3.1 -3.2
a Sample extract diluted 1/10 with extract of blank human DBS.
Figure 3. PK profiles of acetaminophen obtained from human DBS samples taken from a subject after a single oral administration of 500 mg
(visit 1) and 1 g (visit 2) acetaminophen on two separate occasions.
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spotted with standards at room temperature. The 10000 ng/mL
DBS sample extracts were diluted as described above.
Application of the DBS Assay to the Analysis of Samples from a
Clinical Study. Blood spot samples were obtained from a two-
period, single dose, single center, open label study designed to
evaluate the practicalities of using DBS technology for blood
sample collection at multiple time-points in the context of a phase
I clinical trial in healthy human volunteers.31 The study design
was reviewed and approved by the local Ethics Committee, and
informed consent was obtained from the subjects prior to the
study.
Acetaminophen was administered to the volunteers in two
doses; 500 mg in the first session and 1 g in the second session.
Blood samples from the peripheral venous cannula were collected
at 0.5, 1, 1.5, 3, and 5 h post-dose. Replicate (n ) 3) 15 µL aliquots
were spotted onto FTA cards with a repeater pipet and allowed
to dry at room temperature for at least 2 h prior to shipping to
the analytical site. Dilution of samples above the HLQ of the assay
was performed with extract of blank human DBS as outlined
above, that is, individual sample extracts were diluted with pooled
extract of blank blood spots.
RESULTS AND DISCUSSION
Method Validation. Linearity, Selectivity and Matrix Suppres-
sion Effects. Calibration plots of analyte/internal standard peak area
ratio versus the nominal concentration of acetaminophen in blood
were constructed and a weighted 1/x2 linear regression applied
to the data. Linear responses were observed for DBS over the
range 25 to 5000 ng/mL human blood. This is represented by
the following linear regression equation (average of all 3
validation runs): y ) 8.49 × 10-5 x + 2.98 × 10-4, r2 ) 0.9972
where y represents the peak area ratio of acetaminophen to
that of IS and x represents the concentration of acetaminophen
in ng/mL.
The selectivity of the method was established by the analysis
of blank and double blank DBS samples of control human blood
from both six individual subjects and from pooled samples. No
unacceptable interferences, that is, those with peak areas of >20%
of that observed for the lower limit of quantification (LLQ), at
the retention times of acetaminophen or its internal standard were
observed in any of these samples. A representative mass chro-
matogram of a control DBS blank sample is shown in Figure 2.
The suppression of the response for the stable isotope labeled
internal standard when analyzing DBS extracts by HPLC-MS/
MS was negligible (less than 5%).
Accuracy, Precision, and Sensitivity. The intra- and inter-run
performance data are summarized in Table 1. All values obtained
were well within internationally recognized acceptance criteria for
assay validations11 and were within the pre-defined 15% limits
required.
The LLQ for the analysis of DBS sample extracts was 25 ng/
mL human blood. This was defined as the lowest concentration
that gave accuracy and precision values within the pre-defined
limits of 15%. A representative mass chromatogram of a LLQ
sample is shown in Figure 2.
Stability. The difference in peak area ratios between a stock
solution after storage for 109 days and the freshly prepared
solution was -0.3%, indicating that acetaminophen is stable in
solutions of DMF stored at 4 °C for at least 109 days.
To determine whether there were any issues with the stability
of acetaminophen between the collection of the blood sample and
spotting an aliquot onto FTA paper, a comparison was made
between whole blood samples stored for 24 h at 37 °C and the
fresh samples. The differences in peak area ratios were -5.0%
and 3.0% at 100 and 4000 ng/mL, respectively, indicating that
acetaminophen is stable in whole human blood for this length of
time.
To determine the stability of acetaminophen in DBS samples
on FTA paper, a comparison was made between samples stored
with desiccant for 113 days at room temperature and the fresh
samples. The differences were -1.8 and 0.4% at 100 and 4000 ng/
mL human blood, respectively, indicating that acetaminophen is
stable under the conditions of storage.
The accuracy, precision, and sensitivity of processed human
DBS validation samples were found to be acceptable (precision
and accuracy within the pre-defined 15% limits) on re-injection
with freshly prepared calibration standards, after storage at room
temperature for 24 h. This demonstrates that processed samples
were stable when stored under these conditions.
DBS and whole blood samples spiked individually with ac-
etaminophen glucuronide and sulfate metabolite standards showed
no detectable formation of acetaminophen after storage for 24 and
6 h at room temperature, respectively. Further, a qualitative
assessment of the peak areas for the metabolites showed no
notable decrease with time. This indicates that these metabolites
are stable in DBS on FTA paper and as whole blood samples and
will therefore not interfere with the quantification of acetami-
nophen. Further, chromatographic separation of acetaminophen
(1.5 min) from the sulfate (1.4 min) and glucuronide (0.7 min)
metabolites was obtained to ensure that any in-source fragmenta-
tion of the metabolites did not contribute to an enhancement of
the acetaminophen signal during HPLC-MS/MS analyses.
Dilution of Samples Above the HLQ. The ability to dilute
samples containing acetaminophen at concentrations above the
HLQ was demonstrated by performing replicate 10-fold dilutions
of extracts of human DBS samples with extracts of blank human
DBS. The bias and within-run precision values were less than the
pre-defined acceptance limits of 15% and were therefore accept-
able. It is important to note that when diluting DBS samples for
analysis by HPLC-MS/MS, the diluent used should be obtained
by the extraction of blank matrix from the same species as the
sample to be diluted. If neat solvent, or an extract of the same
matrix from another species is used, there is a risk that suppres-
sion effects (of either the analyte or the internal standard) during
HPLC-MS/MS analysis would give the incorrect concentration
value. The effects can be minimized by the use of isotopically
labeled internal standards and/or adequate chromatography. In
the case of this study, no such suppression effects were observed.
Blood Spot Size. The accuracy and precision of quantitation of
acetaminophen extracted from a 3 mm diameter punch taken from
a DBS sample derived from 10, 15, and 20 µL aliquots of human
blood are presented in Table 2. For all blood sample volumes
examined, the within-volume precision and accuracy values for
calculated concentrations were less than or equal to the pre-
defined acceptance criteria of 15% and are therefore acceptable.
Further, the differences between the accuracy values for extracts
from 10 and 20 µL spots compared to those from 15 µL were all
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less than 5.5%. This indicates that there is no notable difference
in distribution of analyte and blood across spots derived from
blood volumes between 10 and 20 µL, when a 3 mm punch is
taken from the center of the blood spot.
Influence of Spotting Device. The accuracy and precision data
for DBS samples derived from spotting blood with either a pipet
or capillaries are presented in Table 3. For all concentrations
examined, the parameters were within the pre-defined 15%
acceptance criteria, demonstrating that the spotting device does
not have an influence on the concentration determined. This is
an important consideration for studies where accurate pipettes
may not be readily available at the Study Centre, and EDTA coated
capillaries offer an affordable and convenient alternative.
Influence of the Temperature of Blood Spotted. The accuracy and
precision data for DBS’s derived from acetaminophen spiked blood
stored for 30 min at either, room temperature, on-ice, or at 37 °C
prior to spotting are presented in Table 4. For all concentrations
examined, the parameters were within the pre-defined 15%
acceptance criteria, demonstrating that the temperature of the
blood spotted does not have an influence on the concentration
determined. This allows for flexibility in local practice for storage
of blood samples at different Study Centers and in the analytical
laboratory.
Application of the DBS Assay to the Analysis of Samples from a
Clinical Study. PK profiles obtained for acetaminophen using DBS
samples taken from human volunteers after the administration of
a single dose of 500 mg and 1 g acetaminophen on two occasions
is shown in Figure 3.
CONCLUSION
A simple and rapid assay has been developed and validated
for the determination of acetaminophen in human DBS samples
by HPLC-MS/MS. The validated method was demonstrated to
be accurate, precise, and robust and complied with the most recent
regulatory guidelines.30 In addition to the factors normally tested
under these guidelines, a number of other parameters associated
exclusively with the utility of DBS samples were also validated,
leading to greater confidence in the robustness and utility of the
technique. The stability of the analyte in whole blood provides
reassurance that there is no degradation of acetaminophen from
the time of collection of the blood sample to it being dried on the
blood spot paper. Data demonstrating that there is no quantitative
difference between DBS samples derived from samples stored on-
ice, at room temperature, or at 37 °C, or on the spotting device
used, or of the size of spot obtained allows for flexibility in sample
processing procedures between different Study Centers. This data
also indicates that obtaining blood samples from a finger, or heel
prick, rather than venous cannula is also feasible. The stability of
acetaminophen in DBS samples stored desiccated at room tem-
perature for 113 days demonstrates that samples in this form can
be stored for long periods of time before analysis, without the
need for refrigeration, thus reducing costs and increasing flex-
ibility in selection of Study Centers and bioanalytical laboratories.
The authors suggest that performing these experiments be
considered by others when developing and validating quantitative
bioanalytical methods for the measurement of drugs in pre-clinical
and clinical studies using dried blood spots as the sample
collection media.
The validated method for analysis of acetaminophen in DBS
samples has been applied to the support of a study to investigate
the utility of this sample format for the determination of exposure
and PK in clinical studies.31 The outcome of this and related pre-
clinical studies29 and the advantages afforded by the use of DBS
(small blood volumes, simplified sample processing, storage, and
shipment, etc.) has led to the recommendation that DBS samples
be used as GSK’s preferred analytical approach for the assessment
of PK and TK for all new oral small molecule drug candidates,
which have previously demonstrated a successful bioanalytical
validation. At the time of publication, quantitative bioanalytical
methods using DBS samples have been validated and used for
study support for more than 50 different molecules in our
laboratories.
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Conventionally, drug exposures in preclinical 
studies and clinical trials have been determined 
from plasma samples. However, it is notable 
that measuring drug concentration from whole 
blood (WB) is acknowledged by the regulatory 
authorities to be a suitable alternative [1,2]. Dried 
blood spot (DBS) samples are recognized as a 
convenient technique for the collection and 
storage of WB. The approach was first docu-
mented in the early 1960s for the detection of 
phenylketonuria in newborns [3] and has since 
been widely used for the detection of a number 
of inborn errors in metabolism. More recently, 
DBS sampling has been used in a variety of 
applications, including the quantitative deter-
mination of circulating drug concentrations for 
therapeutic drug monitoring and clinical trials, 
particularly in remote areas, for example anti-
malaria therapies [4–6]. The technique involves 
spotting the blood sample onto a filter card, 
which are available in a variety of formats. The 
particular format of card used for this study is 
shown in Figure 1. After spotting, the card is 
then dried at room temperature and later ana-
lyzed. The current practice in our studies is to 
apply three replicate blood spots (i.e., one drop 
of blood in each circle on the DBS card) for 
each time point onto a single card, with one 
spot being used for the primary analysis in sin-
glicate and the other two being available for 
repeat analysis if required.
Dried blood spot samples offer a number of 
advantages over conventional blood and plasma 
samples, specifically:
n	Small sample volumes for DBS (10–20 µl 
blood per spot, compared with more than 
0.5 ml blood for conventional plasma analy-
ses) make this particularly useful for the deter-
mination of pharmacokinetics (PK) in clini-
cal studies where the availability of blood 
volume may be limited, for example pediatric 
studies and studies in critically ill patients;
n	Minimal blood volume requirements enable 
reductions in animal numbers and refine-
ments in their use, for toxicokinetic assess-
ments during safety assessment studies in drug 
development [7];
n	Simplified blood sampling, for example by 
finger-prick (FP) rather than conventional 
cannula;
n	Simpler matrix preparation at the site of col-
lection, as refrigerated centrifugation to pro-
duce plasma and subsequent transfer of the 
supernatant is not required;
Use of DBS sample collection to determine 
circulating drug concentrations in clinical trials: 
practicalities and considerations
Background: A clinical investigation was performed into the practicalities of the collection of blood samples for the 
determination of drug exposures on filter paper, known as dried blood spot (DBS) sampling using a two-period, 
single-dose, open-label trial conducted in 11 healthy volunteers who received a single oral dose of paracetamol. 
Questionnaires relating to the blood sampling and spotting process and tolerability were completed by staff and 
volunteers. Paracetamol concentrations in DBS samples obtained by venous cannula (DBS-Can) were compared 
against those from fingerprick (DBS-FP) and fresh whole blood obtained from a cannula (WB-Can). Results: The 
questionnaires demonstrated that FP and blood spotting was easy to perform and well tolerated and compared 
favorably with cannula sampling. Paracetamol concentrations in DBS-Can were greater than those in WB-Can (positive 
bias) except below 8000 ng/ml when both were interchangeable. When comparing DBS-FP to DBS-Can, both the 
bias and variability differed significantly across the five sampling time points. Conclusion: The study has shown that 
the DBS technique is practical in the context of a clinical trial. Interchangeability of drug concentrations between 
blood sampling site and mode of blood collection has to be checked and taken into account when designing 
pharmacokinetic studies for other compounds.
Neil Spooner†1, 
Y Ramakrishnan2, 
M Barfield1, O Dewit2 & 
S Miller3
1Platform Technologies and Science 
Drug Metabolism and 
Pharmacokinetics, GlaxoSmithKline 
Research and Development, Ware, 
Hertfordshire, SG12 0DP, UK 
2Addenbrooke’s Center for Clinical 
Investigation, GlaxoSmithKline 
Research and Development, 
Cambridge, UK 
3Discovery Analytics, GlaxoSmithKline 
Research and Development, Hills 
Road, Cambridge, UK 
†Author for correspondence: 
Tel.: +44 920 882 550 
Fax.: +44 920 884 374 
E-mail: neil.spooner@gsk.com
Special FocuS: DrieD BlooD SpotS
reSearch article
For reprint orders, please contact reprints@future-science.com
Place label here FTA® Do
 n
ot
 to
uc
h 
or
 c
on
ta
m
in
at
e 
filt
er
 p
ap
er
 in
sid
e
reSearch article | Spooner, Ramakrishnan, Barfield, Dewit & Miller
Bioanalysis (2010) 2(8)1516 future science group
Key Terms
Dried blood spot samples: 
A technique for the collection, 
transport and storage of blood 
on cellulose-based 
‘filter’ papers.
Pharmacokinetics: Study of 
the drug dose–circulating 
concentration relationship 
within the body over a period  
of time.
Paracetamol: Also called 
acetaminophen. Drug used to 
relieve mild headache or muscle 
and joint pain and to 
reduce fever.
n	Easy storage and shipment to analytical labo-
ratories, as there is no requirement for freezers 
and dry ice and the DBS samples are consid-
ered safe to ship without recourse to special-
ized shipping considerations [101]. This offers 
particular advantages for multicenter studies 
in Phases I, II and III. 
The logistics and acceptability to staff and sub-
jects of collecting and spotting WB samples from 
clinical studies, especially in the context of a study 
with numerous time points, should be evaluated 
before DBS technology can be used reliably in 
clinical trials, and this was the primary objective 
of this study. We investigated this by the use of 
questionnaires for all staff and subjects involved 
in the study. The secondary objective was to com-
pare paracetamol concentrations in DBS samples 
(derived from FP and venous cannula) against 
samples obtained by more conventional means, 
for example fresh WB obtained from cannula. 
The compound tested was paracetamol, 
because its safety profile is known and its plasma 
PK and metabolism are well characterized in the 
literature [8]. The drug is completely excreted in 
1 day and is not known for high interindividual 
variability. Furthermore, the recommended clini-
cal dose reaches a high circulating blood concen-
tration, enabling the use of a simple method for 
the quantitative determination of drug concen-
tration in the limited sample volumes (15 µl) 
obtained for each sample in the study.
A particular consideration of the study was that 
the DBS technology involves the measurement 
of concentrations in WB fixed on filter paper. 
There was therefore a requirement to measure 
paracetamol concentrations in conventional WB 
samples not spotted on filter paper, to determine 
the validity of the spotting approach. However, 
unlike plasma, we have found that WB cannot 
be readily manipulated (e.g., subaliquotted) after 
frozen storage. The only way we have found to 
readily store WB samples and still be able to work 
with them is to dilute them with water (1:1 v/v) 
prior to freezing.
Experimental
	n Clinical study design
A two-period, single-dose, open-label trial using 
paracetamol was conducted in 11 healthy male 
(n = 8) and female (n = 3) volunteers (one sub-
ject completed period 1 only and was replaced). 
This study design was reviewed and approved by 
the local Cambridge 3 Ethics Committee and 
informed consent was obtained from the subjects 
prior to the study.
Paracetamol was administered orally; 500 mg 
in the first period and 1 g in the second period 
(~1 week apart). These two different doses were 
given in order to achieve a wider range of con-
centrations for comparison between measurement 
methods, rather than to compare one dose to the 
other. Blood was sampled at 30, 60, 90, 180 and 
300 min post-dose from both FP (three drops of 
15 µl) and cannula (6 ml into an EDTA tube). 
FP samples were taken with a single-use lancing 
device. Once an adequate sample of blood was 
formed on the skin, this was sampled using a 
20-µl EDTA-coated capillary marked with a line 
for approximately 15 µl, attached to a holder and 
bulb. The blood from FP was spotted onto FTA 
filter paper (DBS-FP) directly from the collection 
capillary. Blood from the cannula (Can) was split 
into two groups: collection on filter paper (three 
aliquots of 15 µl spotted using a repeater pipette 
[DBS-Can]) and the remainder diluted 1:1 (v/v) 
with deionized water (to facilitate freezing of WB 
[WB-Can]). DBS samples were allowed to dry at 
room temperature for at least 2 h prior to ship-
ping to the analytical site in sealed plastic bags (all 
the samples from a single subject in a single bag) 
containing a sachet of desiccant. No particular 
precautions were taken to control the tempera-
ture of the DBS samples during their shipment 
(~30 km). They were stored at laboratory tem-
perature and humidity until analysis. WB samples 
were shipped frozen on dry ice to the analytical 
site, where they were stored at -20°C until analy-
sis. Quality control samples were prepared and 
stored with the study samples within 1 week of 
their receipt.Figure 1. Whatman FTA
® blood spot card used in the study.
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	n Questionnaires
In order to assess the acceptability and prac-
ticalities of collecting PK samples by DBS, on 
each study day, study staff (n = 16) completed 
a questionnaire relating to the ease of the blood 
spotting, blood sampling and blood dilution pro-
cedures, and volunteers (n = 11) answered ques-
tions relating to the tolerability of blood sampling 
procedures. A copy of which is available at www.
Future-Science.com/Doi/Suppl/10.4155/Bio.10.105/
Suppl _ File/Suppl _ queStionnaire _ 1.pDF. 
	n Analytical methods
Concentrations of paracetamol in DBS and blood 
water samples were determined in singlicate using 
quantitative bioanalytical methods validated to 
internationally accepted criteria [9,10]. DBS sam-
ples were analyzed in singlicate for paracetamol 
using a validated method based on extraction 
of a 3-mm diameter disc taken from the center 
of the DBS, by addition of methanol, followed 
by HPLC–MS/MS analysis [11]. Human blood/
water (1:1 v/v) samples (50 µl) were analyzed 
for paracetamol using a validated analytical 
method based on protein precipitation, followed 
by HPLC–MS/MS analysis [GlaxoSmithKline, 
Unpublished Data]. For both assays, the LLOQ 
was 25 ng/ml and the HLOQ was 5000 ng/
ml. Both assays were linear over the analytical 
range, with acceptable precision and accuracy 
being observed over the entire analytical range. 
Samples above the HLOQ of the assay were ana-
lyzed after dilution with blank matrix extract for 
DBS, or human blood/water (1:1 v/v) for blood/
water samples.
	n Statistical analysis
Questionnaires of the relative merits of the 
sample collection methods were analyzed quali-
tatively and using simple summary statistics. 
No formal comparisons between methods were 
made owing to low power as a result of relatively 
small subject numbers. 
Paracetamol concentrations were compared in 
a pair-wise manner (DBS-Can versus WB-Can; 
DBS-FP versus DBS-Can) using an extension 
of the approach of Bland and Altman [12,13]. 
Data were log-transformed for analysis because 
differences were observed to increase propor-
tionally with the mean, as is usually the case 
with concentration measurements. Results were 
subsequently back-transformed, so differences 
are expressed as ratios or percentage differences, 
averages as geometric-means and standard devia-
tions as coefficients of variation (CVs). For each 
pair-wise comparison, an analysis of covariance 
model was built with the ratio of the two con-
centrations as the dependent variable, the geo-
metric mean concentration as a covariate, time 
point and dose as categorical factors and using 
variance components to account for the repeated 
measurements on the same subject. Each model 
was then simplified by dropping terms that did 
not contribute significantly (e.g., p < 0.05) to 
the model. This approach allowed quantification 
of the bias (e.g., systematic difference between 
the methods) and CV (i.e., inconsistent/noisy 
difference between the methods) and identi-
fied factors which influenced these quantities. 
Subsequently, limits of agreement were calcu-
lated (bias ± 1.96 CV), that provide a range by 
which one method can be expected to give a 
result above or below the other. Results were also 
displayed graphically plotting ratio against geo-
metric mean and overlaying the estimated limits 
of agreement. All statistical analysis was carried 
out in SAS (Windows V9.1; SAS Institute Inc., 
NC, USA).
The gender balance (three female, eight male) 
was not considered appropriate to draw conclu-
sions regarding any gender differences. No for-
mal pharmacokinetic analysis of paracetamol 
was carried out (e.g., estimation of C
max
 or AUC).
	n Materials
Paracetamol tablets were obtained from John 
Bell, Croyden. The Unistik single-use lancing 
device was obtained from Owen Mumford Ltd 
(Oxford, UK). EDTA-coated capillaries (20 µl) 
were obtained from Sarstedt Ltd (Leicester, 
UK) and the capillary holders and bulbs from 
Brand GMBH & Co. (Wertheim, Germany). 
Sample tubes were obtained from Micronics 
BV (Platinastraat, The Netherlands). FTA® fil-
ter paper cards were sourced from Whatman 
(Maidstone, UK). The particular format of DBS 
collection cards is also available from Whatman 
in a nonproprietary format as FTA DMPK A [102]. 
Plastic bags for storage and shipping of blood 
spot cards were supplied by Fischer Scientific Ltd 
(Loughborough, UK). Sachets of desiccant were 
obtained from Süd-Chemie Ltd (Cheshire, UK). 
The repeater multipipette was obtained from 
Eppendorf UK Ltd (Cambridge, UK).
Results & discussion
	n Questionnaires 
Of the 21 occasions when samples were collected 
from the 11 subjects, the subjects preferred FP 
19 times, cannula once and on one occasion 
Key Term
HPLC–MS/MS: Analytical 
methodology routinely used 
for the detection and 
quantification of circulating 
drug concentrations.
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no preference was expressed. taBle 1 shows the 
overall pain/discomfort reported for the two col-
lection methods. All subjects reported that they 
would tolerate at least two FPs per time point 
and at least six time points in any given session 
(study day).
taBle 2 shows how staff who carried out each 
step rated the ease of sample collection by the 
two methods. It is notable that staff required 
minimal training (2–3 h familiarization) to 
perform blood spotting (labeling blank card, 
spotting on paper, drying blood spot and stor-
ing the card into the bag). None of the staff 
had training prior to this brief practical session. 
The fact that those with limited experience 
with the DBS technique could then perform 
the technique in the clinical setting suggests 
that this technique can be learnt rapidly.
	n Concentration–time profiles
Typical concentration–time profiles for an 
individual subject after the single oral admin-
istration of paracetamol at two doses (500 mg 
and 1 g) on two occasions are shown in 
Figure 2.
	n Statistical analysis
Data from all 11 subjects from both dosing 
periods and all sampling time points were com-
bined for statistical analysis. The majority (79%) 
of measured concentrations were in the range 
1000–10,000 ng/ml, with 11% of values over 
10,000 ng/ml (generally at the 1- and 1.5-h time 
points) and 10% less than 1000 ng/ml (gener-
ally at the 0.5-h time point). Conclusions are 
therefore more robust for concentrations in the 
1000 to 10,000 ng/ml range.
A Bland–Altman plot comparing DBS con-
centrations to those in WB, where both samples 
were taken from a peripheral venous cannula, 
is shown in Figure 3. The final model included 
mean concentration as a covariate, but found 
no effect of dose or time point. A bias was 
observed such that DBS-Can gave a value 6% 
higher than WB-Cannula at concentrations of 
1000 ng/ml and this bias increased slightly with 
concentration to 16% for concentrations of 
10,000 ng/ml. There was no significant change 
in variability across the range of concentrations, 
with a constant CV of 11.8% (95% CI for CV: 
10.3–13.8%). As observed from Figure 3, there 
was increasing bias when comparing DBS-Can 
concentrations to those in WB-Can. The com-
bination of increasing bias with constant CV 
meant that the lower and upper 95% limits of 
agreement increased from (-15% and +32%) 
for a concentration of 1000 ng/ml to (-7% and 
+44%) for a concentration of 10,000 ng/ml. 
When validating bioanalytical methods for the 
determination of circulating drug concentra-
tions, a limit of ±15% for bias and 15% for 
CV is considered acceptable [9,10]. Taking these 
limits into account, only concentrations below 
8000 ng/ml could be considered interchange-
able between the two measurement methods. 
Exploration of factors such as the temperature 
of the blood spotted, the pipetting device used, 
the method used to dilute samples into the ana-
lytical range and the stability of paracetamol 
metabolites, did not provide explanations for 
the bias [11]. Other factors, such as the process 
of diluting the WB samples with water prior 
to storage and ana lysis, or any changes in vis-
cocity with sampling time could have had an 
Table 1. Degree of pain/discomfort recorded by subjects during blood sampling via either finger-prick or 
venous cannula.
Number of subjects responding
Overall pain/discomfort None Mild Moderate Severe Extreme
Finger-prick 5 15 1 0 0
Cannula 2 11 8 0 0
Questionnaires were completed by 11 subjects after the single oral administration of paracetamol at two doses (500 mg and 1 g) on two occasions.
Table 2. Staff response to ease of performing processes associated with taking blood samples.
Number responding
Staff rating of sample collection step Extremely easy Easy Neither Difficult Extremely difficult
Taking blood by finger-prick 3 9 3 0 0
Taking blood by cannula 7 6 2 0 0
Blood spotting onto card 2 14 0 0 0
Questionnaires were completed by 16 study staff after the single oral administration of paracetamol at two doses (500 mg and 1 g).
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effect on the results for these samples. However, 
these factors were not investigated as part of 
this study. 
In the analysis comparing DBS concentrations 
from samples collected by FP to those taken by 
cannula, the time point at which the sample 
was taken was found to significantly influence 
the ratio of concentrations and the relationship 
of this ratio to the mean concentration (i.e., an 
interaction), but no effect of dose was found. A 
series of Bland–Altman plots demonstrating this 
are shown in Figure 4, with a separate panel for 
each time point. The 0.5-h samples gave concen-
trations up to fourfold higher by DBS-FP than 
DBS-Can, with the largest biases at the lower 
concentrations. The 1- and 1.5-h samples also 
showed positive bias (33 and 14%, respectively, 
at a concentration of 3000 ng/ml), while the 
subsequent 3- and 5-h samples showed negative 
bias (-17 and -10%, respectively). The CV also 
varied across the sampling time points: 36.2, 
22.8, 19.3, 20.7 and 11.6%, at 0.5, 1, 1.5, 3 and 
5 h, respectively.
When comparing DBS-FP to DBS-Can, both 
the bias and CV varied across the five sampling 
time points. The finding that blood concentra-
tions of paracetamol vary with sampling site, that 
is, between capillary and venous blood, is consis-
tent with data from blood samples also collected 
by FP and cannula presented by Mohammed 
and co-workers [14]. In that study, paired FP and 
venous blood samples were taken at 0, 15, 30 and 
60 min following a 1 g oral dose of paracetamol, 
from eight adult subjects. Paracetamol concen-
tration was determined using HPLC and UV 
detection with a LLOQ of 2200 pg on column. 
At 15 min post-dose, there was a significant 
difference between the paracetamol concentra-
tions obtained from FP and venous samples. At 
30 min post-dose the FP paracetamol concentra-
tion was approximately 20% greater than the 
venous concentration. However, by 60 min post-
dose any significant differences had disappeared. 
It was demonstrated that for paracetamol, the 
two sampling methods do not give comparable 
results and may not be used interchangeably 
until 60 min post-dose.
This discrepancy between venous and FP sam-
ples is not borne out in clinical studies with tacro-
limus [15] and cyclosporine [16]. However, Chiou 
has described significant or marked blood sam-
pling site dependence in concentration for at least 
42 compounds in animal and human studies [17]. 
Reasons outlined for the differences between arte-
rial and venous c oncentrations include:
n	Differences in the early phase after 
administration may be due to diffusion of the 
drug into the extravascular space through the 
capillary membrane, giving higher arterial than 
venous concentrations for early time points;
Figure 2. Paracetamol concentration–time profiles for a typical subject 
after the single oral administration of paracetamol at two doses on two 
occasions. DBS samples were obtained by either FP or venous Can.
Can: Cannula; DBS: Dried blood spot; FP: Finger prick; WB: Whole blood.
Figure 3. Bland–Altman plot comparing concentrations of paracetamol in 
DBS to WB samples, both obtained from a venous Can. Bias is seen to 
increase with concentration (solid line). Limits of agreement increase in parallel 
with bias (dotted line). The line of identity (ratio = 1) is also shown (dashed line). 
Can: Cannula; DBS: Dried blood spot; WB: Whole blood.
Mean concentration (ng/ml)
R
at
io
 o
f c
on
ce
nt
ra
tio
ns
 (D
BS
-F
P:
DB
S-
Ca
n)
10
0
10
00
10
00
0
10
0
10
00
10
00
0
10
0
10
00
10
00
0
10
0
10
00
10
00
0
10
0
10
00
10
00
0
0.5 h 1 h 1.5 h 3 h 5 h
1
0.8
0.6
1.5
2
3
4
5
reSearch article | Spooner, Ramakrishnan, Barfield, Dewit & Miller
Bioanalysis (2010) 2(8)1520 future science group
n	Differences in the late (terminal) phase after 
administration may be attributed to a 
decrease in the arterial concentration due to 
elimination and distribution into other 
extravascular tissues, whilst drug retained by 
tissues may begin to diffuse through the cap-
illary wall into the venous system, giving 
higher venous than  arterial concentrations 
for late time points;
n	Concentrations for capillary blood should lie 
between the concentrations of arterial and 
venous blood.
The above may help to explain the high bias of 
DBS-FP (capillary) versus DBS-Can (venous) 
for early time points and the opposite for later 
time points (Figure 4).
Conclusion
We have demonstrated in staff and volunteers 
that the procedures involved in FP sampling 
combined with blood spotting are an accept-
able method for the collection of blood samples 
and that this approach compares favorably with 
more conventional cannula WB collection. 
Furthermore, we have demonstrated that suf-
ficient samples can be collected by FP to enable 
the performance of PK studies.
The study data showed that quantitative drug 
exposure data can be generated using DBS sam-
pling. However, when collecting venous sam-
ples from a cannula, switching the sample type 
from WB to DBS can make a small difference 
in the measured concentrations. Furthermore, 
when using DBS samples, switching the col-
lection technique from cannula to FP makes a 
major difference on the low concentrations of 
paracetamol and the early post-dose time points.
The lack of interchangeability observed 
between both sampling site (FP and cannula) 
and sample type (DBS and WB) may not be 
limited to paracetamol. This should therefore 
be taken into account when designing PK stud-
ies and may need to be investigated as part of 
the study design.
Future perspective
The DBS sample format has been demonstrated 
to be a viable approach for the collection of sam-
ples for the determination of circulating drug 
concentrations in animal and clinical studies in 
place of plasma samples. This and the numer-
ous advantages over current practice will inevi-
tably lead to the more widespread adoption of 
the technique for clinical trials and therapeutic 
drug monitoring. However, many factors still 
require investigation before this novel approach 
will be fully accepted by all involved in the drug 
development process. These factors include, 
but are not limited to, the potential effects of 
Figure 4. Bland–Altman plot comparing concentrations of paracetamol in 
DBS samples obtained from FP to DBS obtained from venous Can at each 
sampling time point. Bias is positive at time points up to 1.5 h and negative 
subsequently (solid lines). Limits of agreement (dotted lines) and the line of 
identity (ratio = 1) are also shown (dashed line). 
Can: Cannula; DBS: Dried blood spot; FP: Finger prick.
Executive summary
	n Dried blood spots (DBS) sampling is a viable approach for the determination of clinical drug 
pharmacokinetics.
	n The technique is acceptable to both staff and study subjects.
	n Differences in drug concentrations can be observed between blood storage methods for samples 
taken from the same sampling site (diluted whole blood versus DBS from venous cannula).
	n Differences in drug concentrations can be observed between DBS samples taken from different 
sampling sites (finger prick versus venous cannula).
	n This lack of interchangability needs to be taken into account when designing the pharmacokinetic 
aspects of clinical studies.
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hematocrit, homogeneity of the blood spots, 
variability of drug recovery, and the stabil-
ity of the drug and/or metabolites during the 
collection, drying, transport and storage of 
DBS s amples. Another aspect is that the DBS 
approach is generally considered to be more 
complex for the bioanalytical laboratory, com-
pared with c onventional plasma assays; for 
example, multiple paper substrate types and 
extraction solvents need to be investigated as 
part of method development, and assay sensi-
tivity is limited by the smaller sample volumes 
employed. However, recent progress in the direct 
analysis of DBS samples [18,19] without the need 
for offline punching and extraction of the sample 
prior to analysis is pointing the way to a more 
simplified analytical process in the future.
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Pioglitazone is a prescription drug with hypo­
glycemic action from the thiazolidinedione 
class of compounds used in the treatment of 
diabetes mellitus (Type 2) and related diseases. 
Pioglitazone is administered orally at a dosage of 
15 or 30 mg/day, with titration to 45 mg/day if 
necessary [1]. The compound is absorbed quickly 
from the gastrointestinal tract and shows bio­
availablity of greater than 80%, giving maxi­
mum plasma concentrations (Cmax) within 2 h 
(tmax) of dosing [2]. A variety of methods have 
been established for the quantitative bioana­
lysis of pioglitazone in plasma and serum to 
determine ng/ml levels of the compound [3–6].
The dried blood spots (DBS) approach to 
toxicokinetic (TK) and pharmacokinetic (PK) 
sampling has recently received considerable 
attention owing to the inherent advantages of 
the technique. Preclinical DBS sampling has 
ethical advantages in the reduction and refine­
ment of animal use; less blood is sampled at 
each timepoint than for plasma or serum ana­
lysis meaning that serial, rather than compos­
ite, TK profiles can be obtained from individ­
ual animals [7]. Another advantage of the DBS 
approach is the potential to utilize finer needles 
to sample the blood, thereby causing less distress 
to the animals. The use of DBS in the clini­
cal arena has the advantage that it may elimi­
nate the requirement for sampling by venous 
cannula as it is feasible to sample peripheral 
blood (e.g., from a finger­prick) [8]. Less inva­
sive, simpler sampling would be of great benefit 
when conducting pediatric studies and would 
also allow home sampling by patients taking part 
in clinical trials. When compared with plasma 
or serum, the approach has a low biohazard risk, 
minimal post­collection processing with lower 
cost sample transport and storage [9–11] making 
PK sampling far easier in remote locations.
Bioanalytical methods for the ana lysis of 
compounds in DBS have been published for a 
number of drugs including acetaminophen, met­
formin, piperaquine, rifampicin, tacrolimus and 
dextromethorphan [7,12–16]. Considerations when 
developing a DBS assay are the type of card to 
utilize (different card materials and chemical 
treatments), the spot diameter to be sampled 
from the card, the solvent to remove the analyte 
of interest from the paper, on­card stability of 
the analyte of interest during storage and how to 
dilute samples into the assay range, if required.
In this study, LC–MS/MS assays for the 
quantitative ana lysis of pioglitazone in DBS in 
the range 5 to 2500 ng/ml were established in 
two laboratories. Both assays were validated to 
conform to internationally recognized accep­
tance criteria [17]. A consideration when assess­
ing the accuracy and precision of bioanalytical 
results of unknown samples is whether the 
Application of the DBS methodology to a 
toxicokinetic study in rats and transferability 
of analysis between bioanalytical laboratories 
Background: There are little published data on either the comparison of liquid blood and dried blood spots (DBS) 
analyses or the ability to generate comparable DBS data at different analytical laboratories. We assess the 
comparative results of samples stored as liquid blood and DBS. We also determine the transferability of DBS 
samples by comparing the ana lysis at two laboratories. Results: Bioanalytical methods for the ana lysis of pioglitazone 
in DBS and liquid blood samples were validated to US FDA guidelines. Pharmacokinetic data generated from DBS 
and liquid blood samples demonstrated area under the time-concentration profile (0–24 h) values within 3% of 
each other and maximum plasma concentration values within 7% of each other. Comparing DBS sample results at 
different laboratories showed more than 99% of results agreeing within 20%. Conclusions: The results indicate 
that comparable concentration results are obtained from DBS and whole blood samples within the same laboratory, 
indicating that changing between the two matrices is viable. The comparable results of DBS samples analyzed at 
two laboratories using different analytical methodologies demonstrate that the technique is robust and transferable.
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ana lysis procedure is having an effect on the 
results. As there is no evidence in the literature 
that incurred DBS samples give comparable 
results when assayed by different methods, we 
assessed the transferability of DBS samples by 
analyzing the sample set at two laboratories. The 
two sets of results were compared to determine 
interlaboratory comparability of the DBS sam­
pling and ana lysis technique when using differ­
ent bioanalytical methods on the same study, 
as advised in the regulatory guidance [18]. The 
ability to directly compare results from liquid 
and dried blood samples was considered impor­
tant as larger sample volumes may be necessary 
when developing clinical assays to reach the 
required limits of quantification. Achieving a 
larger sample volume by changing the matrix to 
plasma is not considered suitable as the blood 
cell binding factor means that results from 
blood and plasma are not directly comparable. 
An additional comparison was made to deter­
mine whether dried and liquid blood samples 
gave comparable results by using two sampling 
techniques (DBS and blood:water 1:1 v/v) for 
harvesting PK blood samples following a single 
oral (gavage) administration of pioglitazone to 
the rat. 
Experimental
 Chemicals & reagents
Pioglitazone (Figure 1) and stable isotopi­
cally labelled internal standard (IS) [2H
4
]­
pioglitazone, were obtained from Toronto 
Research Chemicals (Toronto, Canada). 
Acetone, methanol and 2­propanol were of 
HPLC grade and were obtained from Rathburn 
Chemicals (Walkerburn, UK) and Sigma­
Aldrich (Poole, UK). Acetonitrile was of HPLC 
grade and obtained from Fisher Scientif ic 
(Loughborough, UK) and Sigma­Aldrich. Water 
was of ultra­pure grade produced in­house using 
a Millipore Super­Q™ osmosis system (MA, 
USA) and Chromasolv®Plus for HPLC was 
obtained from Sigma­Aldrich. All other chemi­
cals were of Analar grade and were supplied by 
Sigma­Aldrich. Rat blood (sodium heparin) was 
supplied by Harlan Laboratories (Shardlow, UK) 
and B&K Universal Ltd (Hull, UK). 
Equipment
 Laboratory 1 (Covance) 
FTA® Elute blood spot micro cards, sachets of 
desiccant, Harris Uni­Core 3.0­mm punches 
and Harris cutting mats were supplied by 
Whatman (Maidstone, UK). CoStar 96­well 
sample plates were obtained from Corning 
(NY, USA). Centrifuge (model Rotanta 460R) 
was supplied by Hettich (Tuttingen, Germany). 
Flexus liquid handling system was supplied by 
Anachem (Luton, UK). Disposable glass 20­µl 
capillary pipettes of containing sodium hepa­
rin were supplied by Hirschmann Laborgerate 
(Eberstadt, Germany).
 Laboratory 2 (GlaxoSmithKline)
FTA® Elute blood spot cards, sachets of desic­
cant, Harris Uni­Core 3.0­mm punches and 
Harris cutting mats were supplied by Whatman. 
Alphanumeric 1.4­ml U­bottom sample tubes 
were obtained from Micronic (Lelystad, The 
Netherlands). Centrifuge (model 5810R) was 
supplied by Eppendorf (Cambridge, UK). 
Hamilton liquid handling system was supplied 
by Hamilton (Bonaduz, Switzerland). 
HPLC–MS/MS analysis
 Laboratory 1
The HPLC–MS/MS system consisted of an 
Acquity UPLC system (PA, USA) coupled with 
a Sciex API­4000 (Applied Biosystems/MDS 
Sciex, Canada). Chromatographic and MS 
conditions are detailed in taBleS 1 & 2, respec­
tively. HPLC–MS/MS data were acquired and 
processed using Analyst 1.4.2 software (Applied 
Biosystems). The chromatographic conditions 
utilized gradient chromatography with sepa­
ration achieved on an Acquity BEH C18 (50 
× 2.1 mm, 1.7 µm) column with an aqueous 
mobile phase of 0.1% formic acid in 10 mM 
ammonium acetate and an organic mobile phase 
of 0.1% formic acid in methanol. The retention 
time of pioglitazone was 2.0 min.
 Laboratory 2
The HPLC–MS/MS system consisted of an 
Acquity UPLC system coupled with a Sciex 
API­5000. Chromatographic and MS condi­
tions are detailed in taBleS 1 & 2, respectively. 
HPLC–MS/MS data were acquired and pro­
cessed using Analyst 1.4.2 software. The 
chromatographic conditions utilized isocratic 
chromatography with separation achieved on 
an Acquity BEH C18 (50 × 2.1 mm, 1.7 µm) 
column with a mobile phase of 70/30 0.1% 
Key Terms
Cmax: Maximum observed 
concentration in a 
pharmacokinetic or 
toxicokinetic profile.
tmax: Time point at which 
C
max
 occurred.
Dried blood spots: Means of 
storing blood samples in a dried, 
rather than the traditional 
liquid, format.
Transferability: Ability to 
transfer samples between 
laboratories and/or assays and 
achieve comparable results.
Figure 1. Pioglitazone (HCl salt).
Key Term 
1:1 blood:water (v/v): Means 
of storing frozen blood samples 
whilst keeping them in a liquid 
and homogeneous state.
DBS methodology for a toxicokinetic study & transferability between laboratories | reSearch article
www.future-science.com 1491future science group
formic acid in 10 mM ammonium acetate/
acetonitrile (v/v). The retention time of 
p ioglitazone was 0.8 min.
Validated DBS & 1:1 blood:water (v/v) 
ana lysis procedures
DBS methods were validated at both laboratories 
to US FDA guidelines [17] to include determina­
tion of precision and accuracy on three occasions, 
on­card stability assessment, determination of 
assay specificity and extract re­injection viability.
The analytical method for 1:1 blood:water 
(v/v) was validated at laboratory 1 to include 
determination of precision and accuracy on one 
occasion, freeze–thaw and room temperature 
stability assessment, determination of assay 
specificity and extract re­injection viability.
 Laboratory 1
Stock solutions of pioglitazone were prepared 
in methanol (0.25 mg/ml) IS stock solutions of 
[2H
4
]­pioglitazone (0.1 mg/ml) were prepared in 
methanol. All the solutions were stored at 4°C 
and brought to room temperature before use.
Calibration standards were prepared fresh on 
the day of ana lysis by diluting the stock solu­
tions into appropriate concentration working 
solutions (with methanol), then spiking into 
blank whole rat blood to give a calibration line 
with standards at 5, 10, 20, 100, 250, 1000, 
2000 and 2500 ng/ml, ensuring that the volume 
of the working solution remained less than 5% 
of the total standard volume. QC samples for 
all analyses were prepared from a second stock 
solution and were prepared by diluting the stock 
solution into appropriate concentration work­
ing solutions (with methanol), then spiking into 
blank whole rat blood to give QCs at 5 (valida­
tion only), 15, 125, 1800 and 12500 (valida­
tion only) ng/ml. For DBS analyses, 20 µl of 
calibration standards and QC samples were 
spotted onto FTA Elute cards and allowed to 
dry at room temperature for at least 2 h prior 
to ana lysis. 
Table 1. Chromatographic conditions at laboratories 1 and 2.
Laboratory 1
Analytical column Acquity BEH C18, 50 x 2.1 mm, 1.7 µm
Column oven temperature (°C) Nominal 40
Mobile phase A 0.1% formic acid in 10 mM ammonium acetate
Mobile phase B 0.1% formic acid in methanol
Time A (%) B (%) Flow rate (ml/min)
0.0 70 30 0.6
0.2 70 30 0.6
1.5 50 50 0.6
2.1 50 50 0.6
2.2 2 98 0.8
4.5 2 98 0.8
4.6 70 30 0.6
Autosampler weak wash 0.1% formic acid in 10 mM ammonium acetate:methanol (80:20 v/v)
Autosampler strong wash Methanol:acetone:water:trifluoroacetic acid (50:40:10:0.1 v/v/v/v)
Run time (min) 5
Injection volume (µl) 10
Laboratory 2
Analytical column Acquity BEH C18, 50 x 2.1 mm, 1.7 µm
Column oven temperature (°C) Nominal 60
Mobile phase A 0.1% formic acid in 10 mM ammonium acetate
Mobile phase B Acetonitrile
Isocratic settings A/B 70:30 at 0.8 ml/min
Weak wash 0.1% formic acid
Strong wash Acetonitrile:propan-2-ol:water:formic acid (40:30:30:0.1 v/v/v/v)
Run time (min) 1.2
Injection volume (µl) 2
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A 3.0­mm diameter disk was punched from 
the center of the DBS into a 2­ml 96­well plate 
and 200 µl of methanol containing 50 ng/ml 
IS ([2H
4
]­pioglitazone) was added. The plate 
was gently vortex mixed for approximately 15 
min then centrifuged for 5 min at 3000 × g. A 
20­µl aliquot of supernatant was transferred 
to a clean 1.2­ml 96­well plate using a Flexus 
robot and 180 µl of 0.1% formic acid in 10 
mM ammonium acetate/methanol (80/20 v/v) 
added. A 10­µl volume was then injected onto 
the HPLC–MS/MS system.
The ability to switch from DBS ana lysis 
to ana lysis of whole blood at a later date of 
the drug development process was also inves­
tigated. The blood ana lysis involved tak­
ing 20 µl of 1:1 blood:water (v/v) and add­
ing 200 µl of methanol containing 50 ng/
ml IS ([2H
4
]­pioglitazone). The samples 
were vortex mixed followed by centrifuga­
tion. A 20 of µl aliquot of the supernatant 
was transferred to a second 96­well plate to 
which 180 of µl 0.1% formic acid in 80:20 
10 mM ammonium formate:methanol (v/v) 
was added. The samples were vortex mixed 
followed by centrifugation and submitted for 
HPLC–MS/MS ana lysis.
 Laboratory 2
Stock solutions of pioglitazone were prepared 
in dimethyl formamide (1 mg/ml). IS stock 
solutions of [2H
4
]­pioglitazone (1 mg/ml) were 
prepared in dimethyl formamide. All the solu­
tions were stored at 4°C and brought to room 
temperature before use.
Calibration standards were prepared fresh on 
the day of ana lysis by diluting the stock solu­
tions into appropriate concentration working 
solutions (with 50:50 acetonitrile:ultra­pure 
water v/v), then spiking into blank whole rat 
blood to give a calibration line with standards 
at 5, 10, 20, 100, 250, 1000, 2000 and 2500 ng/
ml, ensuring that the volume of the working 
solution remained less than 5% of the total 
standard volume. QC samples for all analyses 
were prepared from a second stock solution and 
Table 2. MS/MS conditions at laboratories 1 and 2.
Laboratory 1: mass spectrometer parameters API 4000
Mode of operation APCI (positive ion; MS/MS)
Collision gas setting (arbitrary units) 9
Curtain gas setting (arbitrary units) 40
Ion source gas 1 (arbitrary units) 35
Nebuliser current (µA) 3.0
Temperature (°C) 500
Pause time (ms) 5
Collision gas Nitrogen
Compound name Ions monitored Dwell time (ms) Declustering potential (V) Collision energy (V)
Pioglitazone 357.2 → 134.1 100 85 45
[2H
4
]-pioglitazone 361.2 → 134.1 100 85 45
Laboratory 2: mass spectrometer parameters API 5000
Mode of operation Turbo ion spray (positive ion; MS/MS)
Collision gas setting (arbitrary units) 7
Curtain gas setting (arbitrary units) 15
Ion source gas 1 (arbitrary units) 50
Ion source gas 2 (arbitrary units) 50
Ion spray Voltage (V) 1500
Temperature (°C) 750
Pause time (ms) 5
Collision gas Nitrogen
Compound name Ions monitored Dwell time (ms) Declustering potential (V) Collision energy (V)
Pioglitazone 357.4 → 134.2 150 100 38
[2H
4
]-pioglitazone 361.4 → 138.2 100 100 38
Key Term
Serial profile:  
Pharmacokinetic or 
toxicokinetic profile composed 
of samples at all timepoints in 
single individuals.
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were prepared by diluting the stock solutions 
into appropriate concentration working solu­
tions (with 50:50 acetonitrile:ultra­pure water 
[v/v]), then spiking into blank whole rat blood 
to give QCs at 5 (validation only), 20, 250, 
2000, 2500 (validation only) and 5000 (vali­
dation only) ng/ml. For DBS analyses, 15 µl 
of calibration standards and QC samples were 
spotted onto FTA Elute cards and allowed to 
dry at room temperature for at least 2 h prior 
to ana lysis. 
A 3.0­mm diameter disk was punched from 
the center of the DBS into a 1.4­ml Micronics 
tube and 100 µl of methanol containing 
100 ng/ml IS ([2H
4
]­pioglitazone) was added. 
The plate was gently vortex mixed for approxi­
mately 30 min then centrifuged for 5 min at 
3000 × g. A 50­µl aliquot of supernatant was 
transferred to a clean 1.4­ml Micronics tube 
using a Hamilton robot and 150 µl of 50:50 
acetonitrile:water (v/v) added. A 2­µl volume was 
then injected onto the HPLC–MS/MS system.
In vivo test system
Female rats (six per group; HsdHan: WIST 
strain) were housed in a single, exclusive room, 
air­conditioned to provide a minimum of 
15 air changes/h. Female rats were specifically 
selected to assess any effects of the sampling 
procedures on smaller animals. The tempera­
ture and relative humidity ranges were main­
tained in the specified ranges of 19–25°C and 
40–70%, respectively. Fluorescent lighting was 
controlled automatically to give a cycle of 12 h 
light (0600 h –1800 h) and 12 h dark and the 
animals were housed in groups of three.
Throughout the study the animals had 
access ad  libitum to SQC Rat and Mouse 
Maintenance Diet No 1, Expanded, (Special 
Diets Services Ltd, Witham, UK) and mains 
water was provided ad libitum via water bot­
tles. Bedding was provided on a weekly basis 
to each cage by use of clean Aspen wood 
chips (Datesand Ltd, Manchester, UK) or 
European softwood bedding (BetaBed Grade 
6, Datesand Ltd Manchester, UK). The diet, 
water and bedding was analyzed for specific 
contaminants and the results confirmed no 
contaminants were present at levels that might 
have interfered with achieving the objective of 
the study.
The animals were individually identified by 
electronic implant as follows:
Group 1F: animals one to six
Group 2F: animals seven to 12
Ora l piog l it a zone formulat ion at 
30 mg/kg was administered at a dose volume 
of 10 ml/kg and was selected to provide mea­
surable blood concentrations of pioglitazone, 
but was not expected to result in any toxicity. 
It was formulated as a suspension in 0.6 (w/w) 
gelatine and 0.9% sodium carboxymethylcel­
lulose in purified water and stored at 2–8°C in 
a sealed container. The formulation was stirred 
c ontinuously before and throughout dosing.
Blood sampling procedures
A single oral (gavage) dose at 30 mg/kg was 
administered to Group 1F. After dosing, DBS 
samples (three × 20 µl; three separate samples 
were taken at each timepoint with less than 
30 s between the start of sample one and the 
end of sample three) were collected from the 
lateral caudal vein of each animal over a 24 h 
period. Each DBS sample was collected via a 
disposable 20­µl glass capillary tube, onto a 
labelled FTA Elute sample card, allowed to air 
dry for a minimum of 2 h before being stored 
in sealed polypropylene bags/boxes contain­
ing desiccant sachets, these were kept at room 
temperature. In addition, whole blood samples 
(0.1 ml) were also collected from Group 1F 
over a 24 h period into tubes containing lith­
ium heparin. Samples (50 µl) of whole blood 
were added to purified water (50 µl), mixed 
gently by hand and placed on a cooled rack 
prior to storage at ­20°C.
A single oral (gavage) dose at 30 mg/kg was 
administered to Group 2F. After dosing, DBS 
samples (three × 20 µl; three separate samples 
were taken at each timepoint with less than 30 s 
between the start of sample one and the end of 
sample three) were collected from the lateral 
caudal vein of each animal over a 24­h period 
and processed as described above.
Blood was sampled at the following 
timepoints:
Group 1F: animals one to three at 0, 1, 2, 3.5, 
5 and 7 h post dose (liquid blood and DBS);
Group 1F: animals four to six at 0.5, 1.5, 2.75, 
4.25, 6 and 24 h post dose (liquid blood and 
DBS);
Group 2F: animals seven to 12 at 0, 0.5, 1, 1.5, 
2, 2.75, 3.5, 4.25, 5, 6, 7, 24 h post­dose (DBS).
The data from Group 1F was used to generate 
composite PK profiles. The data from Group 2F 
was used to generate serial PK profiles.
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Results & discussion
 DBS validations
All intra­ and inter­assay precision and accuracy 
data at both laboratories were within the pre­
defined 15% limits (20% at the LLOQ) and are 
presented in taBleS 3 & 4.
 Effect of aliquot volume
Variation of the blood aliquot volume of up to 
±25% of the 20­µl target volume in laboratory 1 
and ±33% of the target 15­µl target volume in lab­
oratory 2 did not affect the quantification of pio­
glitazone, indicating that the blood spot volume 
did not significantly affect the amount of analyte 
in the punched blood spot disk (taBleS 3 & 4).   
 Response
The response of the detector to pioglitazone 
was linear for both laboratories methods over 
the concentration range 5 to 2500 ng/ml with 
a weighted 1/x2 linear regression applied to 
the data (mean R2 value 0.9968 and 0.9981 at 
laboratories 1 and 2, respectively). The analyte 
response (peak height) at the LLOQ was greater 
than five­times the blank blood spot response. 
Representative chromatograms are presented in 
Figure 2 (laboratory 1) and Figure 3 (laboratory 2) 
demonstrating an excellent signal­to­noise ratio 
at the LLOQ and lack of significant interferences 
at the retention time of pioglitazone.
 Selectivity
Neither method displayed significant interfer­
ent peaks (>20% of the mean utilized LLOQ) 
in matrix blanks in the retention window of 
pioglitazone and IS, respectively. There were no 
significant interferent peaks (>20% of the mean 
utilized LLOQ) detected in the six individual 
blank samples in the retention window of piogli­
tazone and IS, respectively. Matrix effects causing 
suppression and enhancement were determined to 
be less than 3.5% when comparing peak areas of 
post­spiked QC extracts (n = 6) to pure standards 
(n = 6) of theoretical equivalent concentrations. 
Recovery was calculated at more than 75% when 
comparing peak areas of extracted QCs (n = 6) 
to post­spiked QC extracts (n = 6) of theoretical 
equivalent concentrations.
Table 3. Intra- and inter-assay precision and accuracy quality control performance data for pioglitazone in rat 
dried blood spots and effect of blood aliquot volume on precision and accuracy of QC sample data at 
laboratory 1.
Intra-assay QC 5 ng/ml
(LLOQ QC)
QC 15 ng/ml
(LQC)
QC 125 ng/ml
(MQC)
QC 1800 ng/ml
(HQC)
QC 12500 ng/ml
(DiQC)†
QC 2500 ng/ml
(DiQC)‡
Mean (ng/ml) 4.86 14.1 126 1730 12100 11200
Accuracy (%) 97.2 94.0 100.8 96.1 96.8 89.6
RSD (%) 4.3 6.2 3.4 4.2 3.8 2.1
n 6 6 6 6 6 6
Inter-assay QC 5 ng/ml
(LLOQ QC)
QC 15 ng/ml
(LQC)
QC 125 ng/ml
(MeQC)
QC 1800 ng/ml
(HQC)
Mean (ng/ml) 5.19 14.4 122 1720
Accuracy (%) 103.8 96.0 97.6 95.6
RSD (%) 9.7 6.9 3.8 3.8
n 18 18 18 18
Quality control sample data
Concentration (ng/ml) 125
Blood spot size (µl) 15 25
Spot size deviation from 
20 µl assay volume (%)
-25 25
Mean observed 
concentration (ng/ml)
115 126
Standard deviation (n - 1) 3.54 6.68
RSD (%) 3.1 5.3
Accuracy (%) 92.0 100.8
n 6 6
†Analyzed after tenfold dilution with extracted blank rat blood spots.
‡Analyzed after tenfold dilution post-extraction with internal standard.
DiQC: Diluted QC; HQC: High QC; LQC: Low QC; MQC: Medium QC; RSD: Relative standard deviation.
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 Processed sample viability
Viability of pioglitazone in the extracts produced 
via laboratory 1 was found to be acceptable when 
stored at nominal 4°C and reinjected 3 days after 
initial injection (precision and accuracy within the 
predefined 15% limits). The viability of pioglita­
zone in the extracts from laboratory 2 was accept­
able when stored at room temperature and rein­
jected 96 h after the initial injection (precision and 
accuracy within the predefined 15%).
 Storage stability of pioglitazone in DBS
Pioglitazone exhibits acceptable stability in 
DBS when stored at room temperature for up to 
4 months (taBle 5).
 Validation of 1:1 blood:water (v/v) 
(laboratory 1)
A partial validation of a method for the determi­
nation of pioglitazone in 1:1 blood:water (v/v) 
was performed to assess intra­assay precision 
and accuracy (single batch), response, selec­
tivity, room temperature stability in matrix, 
freeze–thaw (three cycles) stability in matrix and 
processed extract viability. Intra­assay precision 
and accuracy (single batch) data were within the 
predefined 15% limits (20% at the LLOQ).
 Response
The response of the detector to pioglitazone 
was linear over the concentration range 
Table 4. Intra- and inter-assay precision and accuracy quality control performance data for pioglitazone in rat 
dried blood spots and effect of blood aliquot volume on precision and accuracy of QC sample data at 
laboratory 2.
QC 5 ng/ml
(LLOQ QC)
QC 20 ng/ml QC 250 ng/ml QC 2000 ng/ml QC 2500 ng/ml
(HQC)
QC 5000 ng/ml
(DiQC)†
Intra-assay
Mean (ng/ml) 4.35 19.8 262 2010 2440 5150
Accuracy (%) 87.1 98.9 104.8 100.3 97.4 103.0
%CV 7.8 6.6 4.7 2.7 3.1 2.7
n 6 6 6 6 6 6
Inter-assay
Mean (ng/ml) 4.67 19.5 255 1900 2330
Accuracy (%) 93.4 97.5 102.0 95.0 93.2
%CV 7.7 6.5 5.1 6.1 6.7
n 18 18 18 18 18
Quality control sample data
Concentration (ng/ml)          QC 20           QC 2000
Blood spot size (µl) 10 20 10 20
Spot size deviation from 
15 µl assay volume (%)
-33 33 -33 33
Mean observed 
concentration (ng/ml)
18.2 20.6 1810 1960
Standard deviation (n - 1) 0.42 0.82 54.1 77.6
%CV 2.3 4.0 3.0 4.0
Accuracy (%) 91.0 103.0 90.5 98.0
n 6 6 6 6
†Analyzed after tenfold dilution with extracted blank rat blood spots.
CV: Coefficient of variation; DiQC: Diluted QC; HQC: High QC.
Table 5. Long-term stability of pioglitazone in dried blood spots stored at room temperature (data generated 
at laboratory 1).
Quality control 
level (ng/ml)
Baseline stability samples 1.5 months (46 days) storage 4 months (120 days) storage
Mean observed 
concentration (ng/ml)
Mean (ng/ml) Difference from 
nominal (%)
Mean (ng/ml) Difference from 
nominal (%)
15 14.6 (±5.9%) 15.9 (±1.8%) 6.0 16.5 (±7.8%) 10.0
1800 1710 (±4.3%) 2000 (±2.1%) 11.1 1940 (±2.6%) 7.8
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5–2500 ng/ml. The analyte response (peak 
height) at the LLOQ was greater than five­times 
the blank 1:1 blood:water (v/v) response.
 Selectivity
There were no significant interferent peaks 
(>20% of the mean utilized LLOQ or >5% of 
IS response) detected in reagent, matrix blanks 
and ULOQ calibration standard (without IS) 
in the retention window of pioglitazone and IS, 
respectively. There were no significant interfer­
ent peaks (>20% of the mean utilized LLOQ 
or >5% of IS response) detected in the six indi­
vidual blank samples in the retention window of 
pioglitazone and IS respectively. The accuracy 
values of each of the six spiked individual matrix 
samples were within 85–115% of the theoreti­
cal value. Therefore, individual matrix samples 
do not affect the quantification of pioglitazone.
 Room temperature stability of 
pioglitazone in matrix
The data indicate that pioglitazone has accept­
able stability in 1:1 blood:water (v/v) stored at 
room temperature for up to 25 h (precision and 
accuracy within the predefined 15% limits).
 Freeze–thaw stability of pioglitazone  
in matrix
The data indicate that pioglitazone has accept­
able stability in 1:1 blood:water (v/v) when 
exposed to up to three additional freeze/thaw 
cycles (precision and accuracy within the 
predefined 15% limits).
 Processed sample viability
The viability of pioglitazone in the extracts was 
found to be acceptable when stored at nominal 
4°C and reinjected 69 h after the initial injection 
(precision and accuracy within the predefined 
15% limits).
 PK results (laboratory 1)
Blood concentrations of pioglitazone were quan­
tifiable in samples after dosing from all animals 
in Groups 1F and 2F, confirming systemic expo­
sure; the PK parameters are presented in taBle 4. 
Figure 2. Representative HPLC–MS/MS 
selective reaction monitoring 
chromatograms. Data from Laboratory 1 of 
(A) a blank plus internal standard rat dried 
blood spots (DBS) sample, (B) a rat DBS 
sample spiked with pioglitazone at the LLOQ 
(5 ng/ml) and (C) a rat DBS sample spiked 
with the internal standard ([2H
4
]-pioglitazone).
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Following a single oral (gavage) administration 
of pioglitazone, blood concentrations increased 
rapidly to reach maximum levels at sampling 
times between 1 and 2 h post­dose. The sys­
temic exposure of pioglitazone was independent 
of sampling technique with AUC
(0­t)
 and C
max 
values being similar for both blood spot and 1:1 
blood:water (v/v) samples (Figure 4 & taBle 6). 
AUC(0–24 h) values for dried and liquid blood 
samples were within 3% and C
max
 values were 
within 7%.
 Between-laboratory ana lysis of  
PK samples
There was a good correlation (R2 = 0.97) 
between DBS PK profile data generated at 
the two laboratories from the same samples 
(FigureS 5 & 6). The correlation highlights the 
stability of pioglitazone in DBS samples as 
they were stored at room temperature for over 
3 months between analyses at the two laborato­
ries. The acceptance criteria for demonstrating 
that an assay is adequate in terms of incurred 
sample reproducibility (ISR), where the same 
samples are analyzed on different occasions 
with the same assay, is that two thirds of results 
should be within 20% of each other. As differ­
ent occasions and laboratories with different 
methods and analysts for this work we are not 
demonstrating ISR, however, we demonstrate 
that the data generated at the two laboratories 
shows more than 99% of results are within 
20% of each other, proving excellent correla­
tion on reana lysis of DBS samples. The correla­
tion is well within that deemed acceptable for 
ISR despite having far more variables. 
Conclusion
A quantitative procedure for the determina­
tion of pioglitazone in DBS over the concen­
tration range 5 to 2500 ng/ml is demonstrated. 
Stability investigations carried out demonstrate 
that pioglitazone is stable in DBS for up to 
4 months when stored at room temperature, 
enabling blood spot samples to be collected and 
stored prior to transportation. Blood spot vol­
ume does not need to be accurate as long as the 
Figure 3. Representative HPLC–MS/MS 
selective reaction monitoring 
chromatograms. Data from laboratory 2 of 
(A) a blank plus internal standard rat dried 
blood spots (DBS) sample, (B) a rat DBS 
sample spiked with pioglitazone at the LLOQ 
(5 ng/ml) and (C) a rat DBS sample spiked 
with the internal standard ([2H
4
]-pioglitazone).
Key Terms
AUC(0–24 h): Area under the 
time–concentration profile from 
t = 0 – 24 h.
Composite profile: 
Pharmacokinetic or 
toxicokinetic profile composed 
of samples at different 
timepoints in 
different individuals.
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same size core is taken from the spot, thereby 
allowing flexibility of blood spot preparation at 
the PK sampling stage allowing a capillary to be 
used rather than a calibrated pipette.
Collection of DBS samples from dosed ani­
mals enabled up to 12 samples to be taken from 
a single rat in a 24­h period, with considerably 
less distress to the animal as smaller sample vol­
umes are required. The technique was shown to 
be a viable alternative to the current procedures 
used for PK/TK sampling from rats. Using DBS, 
an entire PK/TK profile can be obtained from 
a single rat, rather than composite profiles, 
which should improve the quality of the data 
obtained and also reduce the number of rats 
used in a study.
The data presented indicate a good correlation 
between DBS PK profile data analyzed at two 
laboratories, successfully demonstrating the ana­
lytical inter­laboratory reliability of the DBS sam­
pling and ana lysis technique when using different 
bioanalytical methods on the same study.
Future perspective
Pharmacokinetic data generated gives a good 
correlation between blood concentration data 
from the two sample types DBS and liquid 
blood, demonstrating that DBS ana lysis is a 
suitable alternative to the more traditional liq­
uid sample type and that DBS samples provide 
comparable exposure data to conventional blood 
samples. Therefore, if required at a later stage in 
the drug development process (e.g., moving from 
preclinical to clinical sample ana lysis and the 
associated lower concentration levels) switching 
DBS sampling to whole blood sampling is pos­
sible. The good correlation between the DBS PK 
data  generated at the two laboratories indicates 
that ISR should not cause issues when using the 
DBS approach.
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Figure 5. Correlation between 
pharmacokinetic profile data analyzed at 
two laboratories (n = 6 rats).
Figure 6. Blood concentration–time 
profiles following a single, 30 mg/kg oral 
dose of pioglitazone as determined by 
dried blood spots methodology in two 
separate laboratories.
Figure 4. Correlation between 
pharmacokinetic profile data for DBS and 
whole blood sampling techniques 
analyzed at laboratory 1.
n = 6 rats. 
DBS: Dried blood spots.
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Executive summary
 Methods were determined at two laboratories to determine pioglitazone in dried blood spots (DBS) over the range of 5–2500 ng/ml.
 A method was also determined at one laboratory to determine pioglitazone in 1:1 blood:water (v/v) over the range of 5–2500 ng/ml.
 All methods displayed results within regulatory acceptance criteria.
 Serial profiles were able to be constructed for individual rats using the DBS method.
 Accurate blood sampling was shown to be unnecessary.
 Storage stability of pioglitazone in DBS was shown for at least 4 months.
 The transferability of DBS ana lysis between laboratories using different analytical instrumentation, personnel and methodology showed 
excellent correlation with more than 99% of results within 20% of each other.
 Pharmacokinetic data generated by liquid blood and DBS sampling analyses gave excellent correlation.
Table 6. Pharmacokinetic parameters for pioglitazone.
Dose level (mg/kg) Matrix Profile type AUC(0–24 h) (ng.h/ml) Cmax (ng/ml) tmax (h)
30 (Group 1F) 1:1 blood:water (v/v) Composite 15900 2580 1
30 (Group 1F) Blood spot Composite 15500 2410 1.5
30 (Group 2F) Blood spot Serial (n = 6) 16200 (±20.2%) 2330 (±9.7%) 1.5
Group 1F sampled by liquid blood and dried blood spots over a 24-h period.
Group 2F sampled by dried blood spots over a 24-h period.
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The use of dried blood spot (DBS) samples 
for the determination of drug concentrations in 
pharmacokinetic (PK) and toxicokinetic (TK) 
studies is still a new technique compared with 
conventional plasma ana lysis and the method­
ology continues to evolve and develop [1–7]. The 
industry’s experience of incurred sample reana­
lysis (ISR) for plasma samples is extensive, but 
ISR for DBS samples is still a much debated 
subject owing to the infancy of the technique 
and its relatively limited use across the industry. 
GlaxoSmithKline (GSK) is rapidly gaining more 
experience with ISR data for DBS samples and 
has built up a large dataset from a host of dif­
ferent study designs and across a varied range of 
compounds from different chemical space. This 
article sets out to detail some of these experiences, 
and with this information we continue to build 
on the confidence that DBS is a valuable tech­
nique to quantify drug concentrations in whole 
blood as long as good practice is observed. 
GSK’s ISR strategy
Incurred sample reana lysis is not a new validation 
criteria and has been requested as far back as 1992 
following the publication of the Shah paper [8]. 
This has been even more routine with bioavailabil­
ity and bioequivalence (BE) studies and for these 
requests GSK would historically use pooled sam­
ples to conduct the ana lysis. The US FDA became 
interested in ISR as a result of observing widely 
different concentrations from original results 
when PK repeats were carried out. These differ­
ences were sometimes noted as being as much 
as 300%. Many publications have covered the 
subject of ISR [9–11] and a very recent publication 
from the European Bioanalytical Forum gives an 
excellent account and makes sound recommenda­
tions [12]. GSK has followed the recommendations 
from the 2008 AAPS/FDA ISR guidance [13].
GSK’s strategy is to perform ISR for all clinical 
studies and one study in each preclinical species. 
The acceptance criteria are; more than 66.7% of 
the incurred sample results must be within the 
limits of ±20% of the mean of the reana lysis 
result and its corresponding original result.
It is important to note that the acceptance 
criteria are only a guide and scientific judgement 
must be used. A particular example of this is tak­
ing note of the bias and, even if the acceptance 
criteria is met, if a dataset shows a directional 
bias we would investigate further.
Incurred sample reana lysis is carried out as 
soon as is practical after the original ana lysis has 
been accepted. The time between original ana­
lysis and ISR is kept to a minimum because it is 
ISR that is measured and not incurred sample 
stability (ISS).
Advantages of DBS compared with 
conventional techniques
The collection of whole blood samples as 
DBS for TK and PK studies offers a number 
of advantages over conventional plasma sam­
pling. The small blood volumes required for 
DBS samples (between 30 and 80 µl, compared 
with >0.5 ml blood as is usually obtained for 
conventional plasma analyses) makes this a 
particularly suitable approach for the collec­
tion of blood samples from preclinical animals 
and pediatric studies. For nonclinical studies, 
the reduction in sampled blood volume leads 
to a significant benefit in the reduction, refine­
ment and replacement (3Rs) for animal use 
in drug development. Animals need no pre­
warming, PK samples can be taken directly 
from the safety animals meaning a reduction 
in animal use, a direct correlation with safety 
and PK as well as cost savings. In addition, 
the smaller sample volume reduces the need 
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sample reana lysis for dried blood spot samples
Dried blood spots are becoming a popular alternative to plasma for many different applications. This has been 
driven by animal ethics but also by ease of use and cost savings. Recent regulatory guidance now has a requirement 
for incurred sample reana lysis. This article details three examples of incurred sample reana lysis using dried blood 
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for composite sampling, meaning better data 
quality. For pediatric studies, DBS offers the 
advantage of less invasive sampling (finger or 
heel prick, rather than conventional venous 
cannula), which enables recruitment of subjects 
for clinical studies. Furthermore, the simpler 
matrix preparation and transfer (no refriger­
ated centrifugation to produce plasma) and 
easy storage and shipment to analytical labora­
tories (no requirement for freezers and dry ice) 
offer further benefits, primarily for late­stage 
clinical studies.
As with all techniques still in their relevant 
infancies, there are and will always be disadvan­
tages and issues to evaluate (e.g., hematocrit), 
but to date the advantages continue to push the 
DBS technique forward.
Methodology
One of the many advantages of DBS lies in its 
simplicity. There are typically two ways to col­
lect a sample and both processes work in the 
preclinical and clinical arena. The first involves 
collecting blood into a blood tube, mixing 
and then spotting using a pipette. The second 
method involves collecting the blood sample 
into an EDTA­coated capillary and then using 
the capillary to spot directly onto the card. 
Typically three 15 µl samples of whole blood 
are spotted onto the card, but this volume is 
dictated from the assay validation. A variety of 
cards are available. The examples used in this 
paper utilized either Whatman (now part of 
GE Healthcare) FTA or FTA elute (now called 
FTA DMPK A and B, respectively), which 
were both designed for nucleic acid ana lysis, 
or Alstom 226, an untreated card. The blood 
spot is allowed to dry at ambient temperature 
(10–30°C) away from direct sunlight and in 
controlled laboratory conditions for at least 
2 h and then typically a 3 mm diameter disk 
is punched from the center of the DBS into a 
clean tube. The punched spot is then extracted 
by the addition of internal standard working 
solution in methanol (e.g., 100 µl), followed by 
vortex mixing for approximately 20 s. The tube 
is centrifuged for 1 min at 3000 × g, and the 
supernatant transferred to a clean tube for ana­
lysis by means of HPLC–MS/MS. Further detail 
of the entire process can be found in [6–7].
50:50 blood:water samples are processed by 
taking an aliquot (25 µl), and extracted by the 
addition of internal standard working solution in 
acetonitrile (e.g. 75 µl), followed by vortex mix­
ing for approximately 20 s. The tube is centri­
fuged for 1 min at 3000 × g, and the supernatant 
transferred to a clean tube for ana lysis by means 
of HPLC–MS/MS.
Fundamental differences between 
DBS ISR & conventional liquid 
matrix ISR
There are many differences when dealing with 
any liquid sample and a DBS sample, and as a 
result the different sample types have different 
issues and areas of concern. 
n	For DBS there are two ways to collect a sam­
ple, which could lead to differences, whereas 
with a liquid samples there is only one; 
n	For liquid samples, if ISR is not carried out on 
the same day as the original sample ana lysis a 
further freeze–thaw is required. As DBS trans­
portation and storage is at ambient temperature 
freeze–thaw is never an issue; 
n	A liquid sample, if treated correctly, will 
always be a single homogenous sample, 
whereas a DBS sample is normally three dis­
crete samples (spots). It is possible to take one 
larger spot, but this can make the spotting 
process harder and could lead to 
homogeneity issues; 
n	The sample volume accuracy for a liquid sam­
ple is dependent on a pipette, a punch dictates 
the volume accuracy for a DBS sample;
Key Terms
Dried blood spot samples: 
A technique for the collection, 
transport and storage of blood 
on cellulose-based 
‘filter’ papers.
Pharmacokinetics: Study of 
the drug dose–circulating 
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of time.
Incurred sample stability: 
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incurred samples to 
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Figure 1. Percentage difference of reana lysis result versus mean result for 
a study utilizing dried blood spots derived from EDTA-coated capillaries.
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n	Contamination of the DBS card is more 
likely than a liquid sample as a lid is used to 
protect the liquid sample but a card is only 
sealed from the atmosphere after a 2 h 
drying period; 
n	With rodent studies, and especially juveniles 
or transgenic animals, the liquid plasma sam­
ple volume is not sufficient for repeat ana lysis, 
as the analytical method typically requires 
25–100 µl of plasma. This can sometimes lead 
to only sufficient sample for a single ana lysis. 
For DBS, three samples are always supplied 
due to the limited amount of matrix required 
(15 µl for each spot). 
The following three examples attempt to 
answer some of the concerns between liquid and 
DBS samples.
Difference between 
sampling techniques
A concern with using capillary sampling is that 
for each time point, three individual capillaries 
are used and each sample is separated by a small 
amount of time. As every spot is only sampled 
once, it is necessary to take three samples to allow 
for any analytical or PK repeats and ISR experi­
ments. Some would argue that this could have 
an effect and each sample could give a different 
result. The alternative approach is to sample into a 
sampling tube, mix and then spot using a pipette. 
The second approach should be more accurate 
but leads to some wastage of matrix since excess 
is needed when pipetting. During validation, 
variable spot size is investigated, when sampling 
15 µl it is investigated whether a 10 and 20 µl 
spot gives the same result within ±15% so variance 
in volume should not be an issue [5,6]. ISR would 
immediately show if in fact there is a difference 
between spots. Looking at recent data generated 
and comparing studies using both sample collec­
tion methods there is actually no difference in the 
quality of ISR. The examples given (Figures 1 & 2) 
show a dataset for the capillary collection and a 
dataset for the tube collection. Both methods 
show excellent comparison with extremely tight 
data and no results outside the 20% cut off. 
Effect of card contamination 
highlighted by ISR
Initially this example looked like the assay 
was unreliable, but further investigation actu­
ally proved gross contamination at the sam­
ple collection stage. During ana lysis some of 
the cards were noted to have traces of fur on 
them. In addition, when reviewing the data, 
many of the controls had quantifiable levels 
well above the lower limit of quantification. 
ISR ana lysis failed (Figure 3) with a wide spread 
of data, and differences observed being greater 
that 150%. On investigation and because of 
controls and physical contamination seen on 
the cards, samples were taken from unspotted 
regions of the cards to see if actual compound 
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Figure 3. Percentage difference of reana lysis result versus mean result for 
a study with contamination of the dried blood spot cards.
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Figure 2. Percentage difference of reana lysis result versus mean result for 
a study utilizing dried blood spots derived from tubes.
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had contaminated the whole of the card. This 
confirmed that many of the cards had been con­
taminated, which resulted in a portion of the 
study being repeated.
For the new study extra precautions when 
sampling animals and spotting were put into 
place. These included using three different labo­
ratory areas to sample, spot and dry. Different 
people were used to sample and spot. All these 
extra precautions led to a successful study, with 
clean controls and acceptable ISR data (Figure 4).
Differences seen between liquid ISR & 
DBS ISR
Before DBS had become fully accepted as a 
routine means of collecting, shipping and stor­
ing of whole blood samples, to gain experience 
and build confidence both DBS and 50:50 
blood:water samples were routinely taken for 
each time point. The liquid samples were then 
used to validate the DBS methodology. ISR in 
these cases was conducted on both types of sam­
ple and in one case the 50:50 blood: water sam­
ple actually showed a large negative bias, with 
more than 40% of the results differing by more 
than 20%, (Figure 5), which was not observed 
with the DBS samples (Figure 6). Due to recent 
publications [14–16] showing greater stability of 
DBS samples compared with liquid samples, the 
immediate investigation was to access the stabil­
ity of 50:50 blood:water. Instability proved not 
to be an issue and 100 days storage at ­20°C was 
obtained for both DBS and 50:50 blood:water. 
Other investigations included looking at differ­
ent sources of blood and also the types of tubes 
used, but these proved to be nonconclusive. 
Further work to solve this issue is still ongoing.
Conclusion
GlaxoSmithKline have carried out 42 DBS ISR 
investigations to date, two of which have failed. 
One was due to contamination, but resolved 
when extra precautions were employed, and the 
second is currently under investigation. From 
the data obtained, no observed differences 
between collection types have been seen and 
this is compelling evidence to conclude that 
both collection by tube or directly into cap­
illaries are acceptable and valid for obtaining 
DBS samples. 
Unfortunately, no conclusions can be 
made as to why in one instance for the same 
method DBS ISR passed whereas ISR for 50:50 
blood:water failed. It can only be concluded 
that this was not due to stability, tubes or a 
matrix effect. When an issue occurs with an 
ISR study and the investigation is nonconclu­
sive, it places in question which data to believe 
and this is true for any ISR study independent 
of matrix.
Any assay, be it liquid or on card, is only as 
good as the sample provided and all possible pre­
cautions should be included with every study 
design. ISR not only tests the rigidity of the 
assay, but also that of the samples and acts as a 
further tool to enhance and probe at the quality 
of both TK and PK ana lysis.
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Figure 5. Percentage difference of reana lysis result versus mean result for 
a 50:50 blood:water study showing a large negative bias.
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Figure 4. Percentage difference of reana lysis result versus mean result for 
a study with sampling, spotting and drying conducted in separate areas.
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Future perspective
Application of DBS in the industry is still in its 
infancy, but is rapidly growing in favor and its 
use is becoming more widespread throughout 
the pharmaceutical industry. The vast major­
ity of benefits associated with DBS are easily 
obtainable and are not just limited to DBS, 
but can be applied to any liquid sample that 
can be collected on a paper format. The future 
of dry matrix samples is dependent on solv­
ing issues such as the effect of hematocrit for 
DBS and, also, building confidence throughout 
the industry with good quality data. The use 
of direct elution tools within the bioana lysis 
laboratory will also help to embed the tech­
nique, simplifying the process for the analyst. 
ISR is now an expected part of the regulated 
bioana lysis package and as such its future is 
a forgone conclusion and should always be a 
necessary requirement.
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Executive summary
	n 2008 AAPS/US FDA incurred sample reanalysis (ISR) guidance set out the industry standard for ISR acceptance and study conduct, this is 
the approach GlaxoSmithKline has adopted.
	n Advantages of dried blood spots (DBS) include: ethical advantages due to smaller sample volumes (refinement and reduction); improved 
quality of data; simplified sample collection, which aids pediatric studies; and, in late-stage studies, reduced costs.
	n DBS pros and cons 
	n Two different ways of collecting DBS samples; freeze–thaw is never an issue with DBS; accuracy is dependent on a punch; 
contamination is more likely if good practice is not followed.
	n Liquid samples pros and cons 
	n When mixed, liquid samples are always homogenous; accuracy is dependent on a pipette; larger sample volumes can lead to a lack 
of sample for ana lysis.
	n No difference (utilizing ISR data) can be observed between sampling techniques.
	n Contamination is more of an issue with DBS, but by following simple rules, contamination issues can be rectified.
	n ISR not only tests the rigidity of the assay but also that of the samples and acts as a further tool to enhance and probe the quality of 
both toxicokinetic and pharmacokinetic ana lysis.
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Use of Dried Plasma Spots in the Determination of
Pharmacokinetics in Clinical Studies: Validation of
a Quantitative Bioanalytical Method
Matthew Barfield* and Robert Wheller
Platform Technologies and Science, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and
Development, Ware, Hertfordshire, SG12 0DP, U.K.
A novel approach has been developed for the quantitative
determination of circulating drug concentrations in clini-
cal studies using dried plasma spots (DPS) on paper
substrates, rather than conventional plasma samples. A
quantitative bioanalytical high-pressure liquid chromato-
graphy-tandem mass spectrometry (HPLC-MS/MS) as-
say has been validated using paroxetine as a tool com-
pound (range 0.2-200 ng/mL human plasma). The assay
employed simple solvent extraction of a punched disk
taken from the DPS sample, followed by reversed phase
HPLC separation, combined with multiple reaction moni-
toring mass spectrometric detection. In addition to per-
forming routine experiments to establish the validity of
the assay to internationally accepted criteria (precision,
accuracy, linearity, sensitivity, selectivity), experiments
are included to assess the effect of the volume of plasma
spotted and the use of an indicating paper. The validated
DPS approach was successfully applied to a clinical study
utilizing pooled samples and a direct comparison of DPS
and plasma was made (single oral dose of 37.5 mg of
paroxetine).
Conventionally, plasma has been used for the determination
of exposures and pharmacokinetics (PK) of new chemical entity
drugs in clinical trials. The collection of plasma samples on paper,
known as dried plasma spots (DPS), is an established technique
for viral load determination, e.g., HIV-1v.1-3 More recently, the
use of dried blood spot (DBS) samples for toxicokinetic (TK) and
PK analysis is rapidly becoming the method of choice, as it offers
significant advantages over conventional plasma analysis.4-7
However, many compounds in development or marketed already
utilize plasma. Unfortunately, blood and plasma data cannot be
readily interconverted without prior detailed knowledge of distri-
bution in these two fluids. Demonstrating that dried plasma spots
(DPS) work for the determination of PK parameters would give
many of the benefits of DBS sampling for quantitative bioanalysis.
The collection of whole plasma samples as DPS for TK and
PK studies offers a number of advantages over conventional
plasma sampling. Considerable cost savings in late phase studies
are due to easy storage and shipment to analytical laboratories
(no requirement for freezers and dry ice). In addition, these
requirements lead to notable environmental benefits. The trans-
port and storage of samples is further simplified by the antimi-
crobial properties of the DPS sample which is also a benefit of
DBS,8 removing the requirements for special biohazard arrange-
ments. The ability to utilize direct analysis tools such as a thin
layer chromatography MS interface (CAMAG),9-12 direct elu-
tion,13,14 desorption electrospray ionization (DESI),15-18 and direct
analysis in real time (DART)19,20 is also presented, in turn
generating an increased market for these tools, hence encouraging
manufacturers to develop new interfaces. These advantages
benefit all areas of drug discovery through development. For these
reasons, GlaxoSmithKline (GSK) is currently investigating DPS
sampling as a technique for the evaluation of TK and PK for late
stage compounds currently utilizing plasma methods.
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Because of the color of blood, DBS samples are easily
distinguishable on paper. However plasma is not so highly colored,
which could lead to problems in distinguishing the DPS on paper.
A developmental grade of untreated FTA DMPK paper containing
a colored indicator has been evaluated to counter this
concern.
This manuscript describes the development and validation of
a method for the quantification of drugs in human plasma, as a
DPS sample, using paroxetine which historically has been quanti-
fied by means of conventional plasma analysis.21 The results of
these tests were evaluated against internationally used acceptance
criteria.22,23 Further to this, samples from an ethically approved
clinical trial were prepared using the DPS and a validated plasma
method and the PK parameters were compared. Details of the
validated plasma method are also presented.
Chemicals and Reagents.Methanol and water were of HPLC
gradient grade and were obtained from Fisher Scientific Ltd.
(Loughborough, U.K.). All other chemicals were of AnalaR grade,
supplied by VWR International Limited (Poole, U.K.). Control
human blood was supplied by GSK volunteers in accordance with
current GSK policies on informed consent and ethical approval.
Paroxetine (Scheme 1) was obtained from Aldrich (Poole, U.K.).
[2H6]-paroxetine (Scheme 1) was produced by Isotope Chemistry,
GSK.
Equipment. Ahlstrom grade 226 paper for blood spots was
supplied by ID Biological Systems (Abbots Langley, U.K.) and
the developmental grade of untreated indicating FTA DMPK
(indicating FTA DMPK) paper was supplied by GE Healthcare
(formally Whatman) (Kent, U.K.). Sample tubes were obtained
from Micronics (Platinastraat, The Netherlands). The centrifuge
(model 5810R) was supplied by Eppendorf (Hamburg, Germany).
The Harris punch and cutting mat was supplied by GE Healthcare
(formally Whatman) (Sanford). Plastic bags for the storage of
blood spot cards were supplied by Fisher Scientific Ltd. (Lough-
borough, U.K.). Sachets of desiccant were obtained from Sud-
Chemie (Northwich, U.K.). The repeater multipipet used for
spotting blood and plasma was obtained from Eppendorf (Cam-
bridge, U.K.).
Preparation of Standard Stock and Working Solutions.
Primary stock solutions of paroxetine (in duplicate) and [2H6]-
paroxetine (internal standard) were prepared in dimethylfor-
mamide (DMF, 1 mg/mL). Working standard solutions of
paroxetine in H2O-acetonitrile (50:50, v/v) were prepared from
the primary stocks at concentrations of 10 000, 1 000, 100, and
10 ng/mL. Internal standard working solutions (2.0 ng/mL)
were prepared from the primary stock using 70:30, methanol-
water, (v/v) for plasma spot analysis and acetonitrile for plasma
analysis. All the solutions were stored at 4 °C and brought to
room temperature before use.
Preparation of Calibration Standards and Quality Control
(QC) Samples. Calibration standards were prepared fresh on the
day of analysis by diluting the appropriate working solutions with
blank whole human plasma. The concentrations of calibrants were
0.2, 0.4, 0.8, 2, 8, 20, 160, and 200 ng/mL whole plasma.
QC samples for all analyses were prepared from a separate
stock solution to that used for the calibration standards. QC
samples were prepared by diluting the appropriate working
solutions with blank whole human plasma to give concentrations
of 0.2, 0.8, 10, 160, and 200 ng/mL whole plasma. For the analysis
of study samples, QCs were prepared at concentrations of 0.8,
10, and 160 ng/mL whole plasma. The volume of organic solution
added to each calibration standard and QC was less than or equal
to 5% of the total volume.
Plasma Spotting. Aliquots (20 µL) of calibration standards
and QC samples were spotted onto 226 and indicating FTA DMPK
paper with a repeater pipet and allowed to dry at room temperature
for at least 2 h prior to analysis (see Figure 1). When required,
the QCs were stored at room temperature in a sealed plastic bag
containing dry desiccant until analysis.
(21) Naidong, W.; Eerkes, A. Biomed. Chromatogr. 2003, 18, 28–36.
(22) Shah, V. P.; Midha, K. K.; Findlay, J. W. A.; Hill, H. M.; Hulse, J. D.;
McGilveray, I. J.; McKay, G.; Miller, K. J.; Patnik, R. N.; Powell, M. L.;
Tonicelli, A.; Vishwanathan, C. T.; Yacobi, A. Pharm. Res. 2000, 17, 1551–
1557.
(23) Bansal, S.; DeStefano, A. AAPS J. 2007, 9, 109–114.
Scheme 1. Chemical Structures of Paroxetine and
[2H6]-Paroxetine
Figure 1. Illustrations of (A) a side on and (B) a top down view of
two extracted DPS samples, indicating FTA DMPK paper on the left
and 226 paper on the right using 100 µL of 70:30 methanol-water
(v/v); (C) three 20 µL dried plasma spots on indicating FTA; and (D)
three 20 µL dried plasma spots on 226 paper.
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DPS Sample Processing. A 6 mm diameter disk was
punched from the center of the DPS into a clean tube. This
was then extracted by the addition of 100 µL internal standard
working solution, followed by vortex mixing for approximately
20 s. The tube was centrifuged for 1 min at 3000g, and the
supernatant was transferred to a clean tube for analysis by high-
pressure liquid chromatography-tandem mass spectrometry
(HPLC-MS/MS).
Plasma Sample Processing. 50 µL of sample was added to
a clean tube. This was extracted with 150 µL of acetonitrile
containing 2.0 ng/mL internal standard, followed by vortex mixing
for 20 s. The tube was centrifuged for 10 min at 3000g, and the
supernatant was transferred to a clean tube for analysis by
HPLC-MS/MS.
HPLC-MS/MS Analysis. The HPLC system consisted of an
Acquity (pump, autosampler, and column oven) (Waters, Watford,
U.K.), and a Phenomenex Synergi, 4 µm, 50 mm × 3.0 mm i.d.
HPLC column (Phenomenex, Macclesfield, U.K.). The postcolumn
flow was diverted to waste for the first 0.6 min of each chromato-
graphic run. During this time, flow (0.25 mL/min, 50:50,
methanol-water, (v/v)) was provided to the MS by a Knauer
pump (Presearch, Hitchin, U.K.).
The chromatographic separation was achieved using an isocratic
system at a composition of 61:39 A-B employing the mobile phases
water containing 0.1% (v/v) formic acid (A) and acetonitrile containing
0.5% (v/v) formic acid (B). The flow rate was 0.8 mL/min, the column
was maintained at 60 °C, and 5 µL of extract was injected.
MS detection was by a Sciex API-5000 (Applied Biosystems/
MDS Sciex, Canada) equipped with a TurboIonspray ion source.
The source temperature was 700 °C. The gas 1 and gas 2 settings
were 60 and 60 psi, respectively (both N2). The curtain gas and
collision gas settings were 25 and 4, respectively (both N2).
The characteristic precursor [M + H]+ to product ions
transitions, m/z 330 to 192 and 336 to 198 were consistent with
the structures of paroxetine and the internal standard, respec-
tively, and were used as selected reaction monitoring transitions
to ensure high selectivity. A dwell time of 100 ms was used for
both transitions. The pause time was 5 ms.
HPLC-MS/MS data were acquired and processed (integrated)
using Analyst software (v1.4.2 Applied Biosystems/MDS Sciex,
Canada). Concentrations were determined from the peak area
ratios of analyte to internal standard using the in-house laboratory
information management system, SMS2000 (v2.2, GSK, U.K.). PK
data interpretation was achieved using WinNonLin (Enterprise
v4.1, Pharsight).
Validation Procedures. Selectivity and Matrix Suppression
Effects. Total blank and blank DPS and plasma samples were
derived from respective 20 and 50 µL aliquots of control plasma
from 6 individual subjects and from matrix pools. Total blank
samples (n ) 1 for each subject or pool) were processed as
outlined above, in the absence of internal standard.
To assess the suppression of HPLC-MS/MS detector re-
sponse due to matrix components and/or paper substrate com-
ponents, six separate sources of blank matrix 226 paper and
plasma samples were extracted and spiked with paroxetine at 0.8,
10, and 160 ng/mL. These extracts were compared to those of
the same concentration spiked directly into 70:30, methanol-water
(v/v) for DPS or acetonitrile for plasma.
A postcolumn infusion was utilized to assess the difference in
suppression effects caused by injecting three blank extracted
samples from 226 paper, indicating FTA DMPK paper, and plasma.
This was investigated by infusing paroxetine at a concentration
of 50 ng/mL and a flow of 0.1 mL/min into the LC flow after the
HPLC column24 and injecting the three extracted blanks.
Accuracy and Precision. The intra- and inter-assay accuracy and
precision of the method were determined by assaying six
replicates of each of the five concentrations of validation QC
samples on three separate occasions using 226 paper and plasma
and on one occasion using indicating FTA DMPK paper. Con-
centrations were determined from the appropriate calibration plot
within each analytical run. Accuracy was assessed for each
concentration by calculating the percent deviation from the
theoretical (nominal) concentration. The precision was determined
for each concentration by calculating the percent coefficient of
variation (% CV; relative standard deviation) for each set of
replicates.
Stability in Stock Solutions. A stock solution of 1 mg/mL stored
for 183 days at 4 °C was compared to a freshly prepared stock.
From each stock, replicate dilutions (n ) 6) in acetonitrile at a
concentration of 200 ng/mL were prepared prior to comparing
the HPLC-MS/MS peak area ratios (analyte to internal standard)
of the samples.
Stability in Dried Plasma Spot on 226 Paper. Replicate (n ) 6)
15 µL human plasma samples at 0.8 and 160 ng/mL were spotted
onto 226 paper and stored desiccated at room temperature for 35
days. The measured concentrations were compared to those of
the same samples extracted and analyzed immediately after initial
spotting and drying.
Freeze/Thaw Stability in Plasma. The stability of paroxetine
in spiked human plasma samples after three freeze-thaw cycles
from -20 °C to room temperature was assessed at 0.8 and 160
ng/mL (in replicates of 6) by comparing the mean concentrations
against those of the freshly prepared spiked samples.
Stability in Human Plasma. The stability of paroxetine in spiked
human plasma stored at room temperature was assessed at 0.8
and 160 ng/mL (in replicates of 6) by comparing the mean
concentrations of samples extracted after storage for 24 h against
those of the samples extracted immediately upon spiking.
Stability in Processed Samples. Extracts from a validation run
on 226 paper and in plasma were reinjected after storage at room
temperature for 24 and 72 h, respectively, against freshly prepared
calibration standard extracts.
Dilution of Samples above the Higher Limit of Quantification
(HLQ). Control human plasma was spiked at 400 ng/mL (2 ×
HLQ), and six replicate 20 µL aliquots were spotted onto 226
paper. After drying at room temperature for 2 h, a 6 mm diameter
punch was taken from each spiked DPS sample. Each punch was
individually extracted with 100 µL of 70:30 methanol-water, (v/
v) containing an internal standard. Diluent was prepared by
individually extracting 10 × 6 mm punches taken from replicate
spots of blank human DPSs on 226 paper with 100 µL aliquots of
70:30 methanol-water (v/v) containing internal standard. These
blank diluent extracts were then pooled. A 10 µL aliquot of each
individual spiked sample extract was then diluted with 90 µL of
(24) Bonfiglio, R.; King, R. C.; Olah, T. V.; Merkle, K. Rapid Commun. Mass
Spectrom. 1999, 13, 1175–1185.
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pooled blank extract diluent. Concentrations of paroxetine in these
individual extract dilution samples were determined by LC-MS/
MS and corrected for the dilution factor. The ability to dilute
plasma samples at concentrations above the HLQ was demon-
strated by performing 6 replicate 10-fold dilutions of human plasma
samples spiked at 200 ng/mL.
Volume of Plasma Spotted. Replicate (n ) 6) 15, 20, and 25 µL
aliquots of control human plasma at 0.8 and 160 ng/mL were
spotted onto 226 substrate. After drying, a 6 mm punch was taken
from the center of each sample for extraction and analysis.
Concentrations of paroxetine were determined from a calibration
line consisting of standards derived from 20 µL of DPS.
Recovery. Replicate (n ) 6) 4 µL human plasma samples at
0.8, 10, and 160 ng/mL were spotted on 226 paper and the whole
spot punched using a 6 mm punch, while replicate (n ) 6) 50 µL
aliquots were spiked at the same concentrations for whole plasma
extraction. Samples were extracted according to their respective
methods and the measured concentrations were compared against
matrix blank samples spiked after extraction with analyte at the
same concentrations.
Application of the DPS Assay to the Analysis of Samples from a
Clinical Study. Plasma samples were obtained from an open-label,
randomized, single dose, two-period crossover study which was
ethically approved. Paroxetine was administered to the volunteers
as a single 37.5 mg oral dose, and venous blood samples were
collected at 0, 2, 4, 6, 8, 10, 12, 15, 18, 24, 32, 48, 72, 120, and
168 h and transferred to tubes containing 2.4 µg/mL EDTA.
Samples were centrifuged at 1500g for 10 min under chilled
conditions (approximately +4 °C), and the resultant plasma was
transferred into appropriately labeled plastic 1.4 mL matrix tubes
and stored frozen. Samples were transferred on dry ice to the
analytical site for analysis. Because of the nature of this study, a
pooled profile was constructed, consisting of five pooled samples
from individual subjects per time point. For DPS, 20 µL of plasma
was spotted onto 226 paper with a repeater pipet and allowed to
dry at room temperature for at least 2 h prior to analysis; this
process was carried out at the analysis site. Both DPS and plasma
samples were extracted as per their respective validated methods
and analyzed with their respective calibrants and QCs on the same
day.
RESULTS AND DISCUSSION
Method Validation. Linearity, Selectivity, and Matrix Suppres-
sion Effects for 226 Paper. Calibration standards were prepared in
duplicate for each analytical run for each type of paper substrate
and whole plasma. Calibration plots of the analyte peak area ratio
to that of the internal standard versus the nominal concentration
in plasma were constructed.
Calibration plots of analyte/internal standard peak area ratio
versus the nominal concentration of paroxetine in plasma were
constructed and a weighted 1/x2 linear regression applied to the
data. Linear responses were observed for DPS and whole
plasma over the range 0.2-200 ng/mL human plasma. Regres-
sion equations for the three validation runs using 226 paper
and whole plasma as well as the single validation run using
indicating FTA DMPK paper are presented in Table 1.
The selectivity of the method was established by the analysis
of blank and double blank 226 paper and whole plasma samples
from both six individual subjects and from pooled samples. No
unacceptable interferences at the retention times of paroxetine
or its internal standard were observed in any of these samples.
An unacceptable interference would constitute a peak with an area
of >20% of that observed for the lower limit of quantification (LLQ).
A representative mass chromatogram of a control 226 paper blank
sample is shown in Figure 2. Blank chromatograms from indicat-
ing FTA DMPK paper and plasma samples were comparable.
Postcolumn infusions of paroxetine at a concentration of 50
ng/mL and a flow of 0.1 mL/min into the LC flow after the HPLC
column24 while injecting extracted blank samples showed little
difference between 226 paper, indicating FTA DMPK paper, and
plasma. No unacceptable interferences were seen at the retention
time of paroxetine or its internal standard. The data is shown in
Figure 3.
Matrix effects from using the stated DPS extraction method
on 226 paper when monitoring for the paroxetine MRM transition
at concentrations of 0.8, 10, and 160 ng/mL contributed between
37.2% and 41.7% suppression. Matrix effects in plasma were
monitored at the same concentrations with suppression values
between 2.8% and 24.6%. Precision values calculated for each
concentration in DPS or plasma did not exceed 15% and therefore
met predefined acceptance criteria.
Accuracy, Precision, and Sensitivity. The intra- and inter-run
performance data are summarized in Tables 2-4. All values
obtained were within internationally recognized acceptance criteria
for assay validations22,23 and within the predefined 15% limits
required.
The LLQ for the analysis of whole plasma and DPS extracts
on 226 and indicating paper was 0.2 ng/mL human plasma. This
was defined as the lowest concentration that gave accuracy and
precision values within the predefined limits of 15%. A representa-
tive mass chromatogram of an LLQ sample on 226 paper is shown
in Figure 2. The retention time for indicating FTA DMPK paper
samples was identical with comparable sensitivity. The extracted
plasma samples eluted 3 s earlier than the DPS samples. The
reason for this difference in elution time was due to the higher
organic content of the plasma samples, consisting of 100%
Table 1. Linear Regression Equations for the Three Validation Runs on 226 Paper and in Whole Plasma and the
Single Validation Run on Indicating FTA DMPK Papera
linear regression equation
226 paper whole plasma indicating FTA DMPK paper
validation run 1 y ) 0.0127x + 0.000 373, r ) 0.9962 y ) 0.0375x + 0.000 402, r ) 0.9987 y ) 0.0135x + 0.000 815, r ) 0.9975
validation run 2 y ) 0.0128x + 0.000 689, r ) 0.9945 y ) 0.0376x + 0.000 597, r ) 0.9989
validation run 3 y ) 0.0125x + 0.000 245, r ) 0.9951 y ) 0.0381x + 0.000 817, r ) 0.9994
a y represents the peak area ratio of paroxetine to that of IS, and x represents the concentration of paroxetine in nanograms/millilter.
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acetonitrile, whereas the DPS samples consisted of 70:30,
methanol-water, (v/v).
Characteristics of Plasma Spots on Paper Substrates. Plasma
samples when spotted onto 226 paper are initially visible when
wet; however, when the card dries the definition of the spot
becomes less clear, and this could cause a potential issue with
study samples because if a sample is incorrectly spotted, either
in the wrong position or the wrong volume is used, the analyst
may not identify the issue from visual inspection and proceed to
punch an area of the paper that may not be completely saturated
with plasma. This issue could be negated through the use of
indicating FTA DMPK paper, which initially is purple in color;
however, when plasma is spotted it turns a lighter shade making
the sample easily distinguishable when dry. The viscosity of
plasma is lower than blood and, as such, plasma samples disperse
onto a larger area of paper than spotted blood samples using the
same aliquot volume. With the use of the 226 paper, a 15 µL aliquot
of plasma gave a 9 mm diameter spot, while a 20 µL aliquot was
12 mm and a 25 µL aliquot was 14 mm. In comparison, a 15 µL
aliquot of blood gave a 7 mm diameter, 20 µL aliquot gave an 8
mm diameter, and a 25 µL aliquot gave a 10 mm diameter.
Stability. The difference in peak area ratios between a stock
solution after storage for 183 days and the freshly prepared
solution was-1.2%, indicating that paroxetine is stable in solutions
of DMF stored at 4 °C for at least 183 days.
Figure 2. Representative HPLC-MS/MS multiple reaction monitor-
ing (MRM) chromatograms on 226 paper of (A) a blank human DPS
sample, (B) a human DPS sample spiked with paroxetine at the LLQ
(0.2 ng/mL human plasma), (C) a human DPS sample obtained 12 h
following a single oral administration of 37.5 mg of paroxetine to a
volunteer (corresponding to the maximum observed peak concentra-
tion (Cmax)), and (D) the internal standard ([2H6]-paroxetine).
Figure 3. HPLC-MS/MS chromatograms of blank samples ex-
tracted from 226 paper, indicating paper, and plasma while running
a postcolumn of 50 ng/mL paroxetine at 0.1 mL/min. HPLC-MS/MS
chromatogram of an extracted plasma QC at 160 ng/mL overlaid to
provide retention time reference, in order to assess possible ion
suppression or enhancement.
Table 2. Intra- and Inter-Assay Performance Data for
Paroxetine in Human DPS Samples on 226 Paper (n ) 6
for Each Concentration Level in Each Individual Run)
nominal concentration
(ng/mL) 0.2 0.8 10 160 200
Individual (Intra-Run) Statistics
run 1 mean concentration (ng/ml) 0.202 0.826 9.57 170 217
SD 0.030 0.066 0.77 9.2 4.3
precision (% CV) 14.6 8.0 8.0 5.4 2.0
accuracy (% bias) 0.8 3.3 -4.3 5.9 8.3
run 2 mean concentration (ng/ml) 0.226 0.848 9.41 169 212
SD 0.023 0.070 0.77 11 5.4
precision (% CV) 10.1 8.2 8.2 6.3 2.6
accuracy (% bias) 13.1 6.0 -5.9 5.4 5.9
run 3 mean concentration (ng/ml) 0.226 0.748 9.61 164 210
SD 0.031 0.081 0.54 14 6.2
precision (% CV) 13.7 10.9 5.6 8.7 2.9
accuracy (% bias) 13.0 -6.5 -3.9 2.3 4.7
Overall (Inter-Run) Statistics
mean concentration (ng/mL) 0.218 0.807 9.53 167 213
SD 0.029 0.081 0.67 11 5.9
overall precision (% CV) 13.2 10.1 7.0 6.7 2.8
average accuracy (% bias) 9.0 0.9 -4.7 4.5 6.3
average intrarun precision (%) 12.9 9.0 7.4 6.9 2.5
inter-run precision (%) 3.8 5.4 <0.1 <0.1 1.4
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To determine the stability of paroxetine in DPS samples on
226 paper, a comparison was made between samples stored with
desiccant for 35 days at room temperature and the fresh samples.
The differences were -8.1 and 7.0% at 0.8 and 160 ng/mL human
plasma, respectively, indicating that paroxetine is stable under the
conditions of storage.
The accuracy, precision, and sensitivity of processed human
validation samples in whole plasma and on 226 paper were found
to be acceptable (precision and accuracy within the predefined
15% limits) on reinjection with freshly prepared calibration
standards, after storage at room temperature for 72 and 24 h,
respectively. This demonstrates that processed samples were
stable when stored under these conditions.
The freeze-thaw stability of paroxetine was determined from
spiked human whole plasma samples after three freeze-thaw
cycles from -20 °C to room temperature. The difference of stored
samples compared to fresh samples was -1.6% and 1.4% at 0.8
and 160 ng/mL, respectively.
The stability of paroxetine in spiked human plasma stored at
room temperature was assessed. Differences of -3.9% and -2.0%
at 0.8 and 160 ng/mL were evident when comparing stored
samples against fresh samples.
Dilution of Samples Above the HLQ. The ability to dilute
samples containing paroxetine at concentrations above the HLQ
was demonstrated by performing replicate 10-fold dilutions of
extracts whole human plasma as well as human DPS samples on
226 paper. The bias and within-run precision values were less than
the predefined acceptance limits of 15% and were therefore
acceptable. It is important to note that when diluting DPS samples
for analysis by HPLC-MS/MS, the diluent used should be
obtained by the extraction of blank matrix from the same species
as the sample to be diluted. If neat solvent or an extract of the
same matrix from another species is used, there is a risk that
suppression effects (of either the analyte or the internal standard)
during HPLC-MS/MS analysis would give the incorrect concen-
tration value. The effects can be minimized by the use of
isotopically labeled internal standards and/or adequate chroma-
tography. In the case of this study, no such suppression effects
were observed.
Volume of Plasma Spotted. The accuracy and precision of
quantitation of paroxetine extracted from a 6 mm diameter punch
taken from a DPS sample on 226 paper derived from 15, 20, and
25 µL aliquots of human plasma are presented in Table 5. For all
plasma sample volumes examined, the within-volume precision
and accuracy values for calculated concentrations were less than
or equal to the predefined acceptance criteria of 15% and are
therefore acceptable. Further, the differences between the ac-
curacy values for extracts from 15 and 25 µL spots compared to
those from 20 µL were all less than 9.2%. This indicates that there
is no notable difference in distribution of analyte and plasma across
spots derived from plasma volumes between 15 and 25 µL, when
a 6 mm punch is taken from the center of the plasma spot, and
thus allowing for inaccurate spotting.
Recovery. Recovery of paroxetine from DPS using the stated
extraction method was carried out on 226 paper at concentrations
of 0.8, 10, and 160 ng/mL and yielded recoveries of between 60.2%
and 76.7%. Plasma recoveries were calculated at 0.8 and 160 ng/
mL and were 93.8% and 92.6%, respectively. Precision values
calculated for each concentration in DPS or plasma did not exceed
15% and are therefore acceptable.
Table 3. Intra- And Inter-Assay Performance Data for
Paroxetine in Human Whole Plasma Samples (n ) 6 for
Each Concentration Level in Each Individual Run)
nominal concentration
(ng/mL) 0.2 0.8 10 160 200
Individual (Intra-Run) Statistics
run 1 mean concentration
(ng/mL)
0.209 0.826 10.8 166 202
SD 0.010 0.027 0.34 4.4 6.1
precision (% CV) 4.8 3.2 3.1 2.6 3.0
accuracy (% bias) 4.7 3.2 7.6 3.6 0.9
run 2 mean concentration
(ng/mL)
0.206 0.814 10.7 163 199
SD 0.0062 0.023 0.24 3.3 7.1
precision (% CV) 3.1 2.8 2.3 2.0 3.6
accuracy (% bias) 2.9 1.7 6.6 1.9 -0.5
run 3 mean concentration
(ng/ml)
0.199 0.823 10.2 168 212
SD 0.012 0.017 0.22 2.8 12
precision (% CV) 5.9 2.0 2.2 1.7 5.9
accuracy (% bias) -0.3 2.8 2.2 5.1 6.2
Overall (Inter-Run) Statistics
mean concentration
(ng/mL)
0.205 0.821 10.5 166 204
SD 0.010 0.022 0.35 4.0 10
overall precision
(% CV)
4.9 2.6 3.4 2.4 5.1
average accuracy
(% bias)
2.4 2.6 5.2 3.5 2.2
average intrarun
precision (%)
4.7 2.7 2.7 2.2 4.4
inter-run
precision (%)
<0.1 <0.1 <0.1 <0.1 <0.1
Table 4. Intra-Assay Performance Data for Paroxetine
in Human DPS Samples on Indicating Paper (n ) 6 for
Each Concentration Level in Each Individual Run)
nominal concentration
(ng/mL) 0.2 0.8 10 160 200
Individual (Intra-Run) Statistics
run 1 mean concentration
(ng/mL)
0.179 0.882 9.60 162 200
SD 0.011 0.052 0.63 9.1 11
precision (% CV) 6.4 5.9 6.5 5.6 5.6
accuracy (% bias) -10.7 10.2 -4.0 1.1 -0.2
Table 5. Influence of the Volume of Human Plasma
Spotted on 226 Paper on the Precision and Accuracy
of the Assay at Two Concentration Levels (n ) 6
Replicates)a
nominal concentration 0.8 ng/mL 160 ng/mL
volume of human
plasma spotted
onto 226 paper 15 µL 20 µL 25 µL 15 µL 20 µL 25 µL
mean concentration
(ng/mL)
0.756 0.832 0.760 167 173 168
SD 0.061 0.076 0.042 6.4 7.8 13
precision (% CV) 8.130 9.127 5.586 3.8 4.5 7.8
accuracy (% bias) -5.5 4.0 -5.0 4.4 8.0 4.8
difference from 20
µL spot (%)
-9.2 -8.7 -3.4 -3.0
a Concentrations were measured against a calibration line prepared
with 20 µL human plasma.
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Application of the DPS and Plasma Assay to the Analysis of
Samples from a Clinical Study. The pooled plasma and DPS profile
samples prepared as previously outlined were extracted according
to their respective extraction methods and analyzed, resulting in
a PK profile for each sample type shown in Figure 4. The profiles
were interpreted with WinNonLin using a linear/log trapezoidal
model, and the parameters generated are shown in Table 6.
The total exposure shown by calculating the area under curve
(AUC) for the DPS profile fell within 8.3% of the fresh plasma
profile, the Cmax (maximum calculated concentration) for DPS
was within 6.4% of plasma, and the Tmax (time point at Cmax)
was identical at 12 h for both profiles.
CONCLUSIONS
A simple and rapid assay (less than 4 min combined extraction
and run time) has been developed and validated for the determi-
nation of paroxetine in human DPS samples by HPLC-MS/MS,
comfortably being able to reach an LLQ of 0.2 ng/mL using a 6
mm punch size from a 20 µL spot. The validated method was
demonstrated to be accurate, precise, and robust and complied
with the most recent regulatory guidelines.22,23 In addition to the
factors normally tested under these guidelines, a number of other
parameters associated exclusively with the utility of dried matrix
samples on a paper substrate were also validated, leading to
greater confidence in the robustness and utility of the technique.
Data demonstrating that there is no quantitative difference
between the size of the spot obtained allows greater flexibility in
sample processing and spotting procedures between different
study centers. The stability of paroxetine in DPS samples stored
desiccated at room temperature for 35 days demonstrates that
samples in this form can be stored for moderately long periods
of time before analysis, without the need for refrigeration, thus
reducing costs and increasing flexibility in selection of study
centers and bioanalytical laboratories. The comparison of DPS to
fresh plasma extraction through analysis of a pooled PK profile
has shown for this work that interconversion of these techniques
is possible. This is initially evident from the visual tight fit of the
various time points and reinforced through the calculation of PK
parameters, which all fall within 10%. The use of indicating FTA
DMPK paper has been assessed for DPS extraction and it offers
the benefit of an easily recognizable dried spot, so allowing
spotting errors to be easily flagged. It makes the sample simple
to track during manual processing and lends itself well to
automated processing due to the contrast in coloration from the
spot to the surrounding paper. For this particular work, no
experimental issues were identified with the use of the indicating
FTA DMPK paper. The excellent comparison of DPS and
conventional plasma analysis demonstrates the simple transition
between DPS and plasma and opens up many of the benefits of
card sampling to late stage clinical, drug discovery groups using
plasma and direct elution techniques and compounds that are not
applicable to DBS.
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Figure 4. PK profiles of paroxetine obtained from extraction of human DPS and plasma pooled samples, consisting of five individual samples
per time point after a single oral administration of 37.5 mg of paroxetine.
Table 6. PK Parameters Obtained from the Analysis of
Extracted Plasma and DPS Pooled Profiles Using a
Linear/log Trapezoidal Model with WinNonLin
type of sample
fresh plasma dried plasma spot
AUC (ng h/mL) 83.52 76.56
Cmax (ng/mL) 3.51 3.75
Tmax (h) 12 12
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Dried blood spot sampling has been used since 
the 1960s for newborn screening [1]. Dried blood 
spots (DBS) offers a number of advantages 
over conventional blood sampling, such as the 
use of a simplified and less invasive sampling 
method (heel or finger prick), simpler sample 
handling, shipment and storage (no centrifuges 
and freezers are required) and a reduction in 
sample volume (typically 10–20 µl per spot) 
[2]. Over the past few years, the technology has 
been applied by more and more companies as 
a tool for microsampling in drug research and 
development in support of TK and PK studies. 
As a result, the pharmaceutical industry is 
gaining a better insight into the strengths but 
also into potential weaknesses and hurdles in 
application of the technique. Hurdles such as 
changes in the size of the blood spot as a function 
of hematocrit, inhomogeneous distribution of 
analytes across the blood spot and hematocrit-
dependent extraction recovery, as detailed below, 
are unique to DBS and not applicable to more 
traditional wet matrices, such as plasma and 
serum.
The recent recommendation on DBS from 
the European Bioana lysis Forum (EBF) states 
that “Hematocrit is currently identified as the 
single most important parameter influencing 
the spread of blood on DBS cards, which could 
impact the validity of the results generated by DBS 
methods” [3]. The hematocrit of a blood sample 
influences the spread of blood on dried blood 
spot cards due to the fact that the viscosity of 
blood increases with increased hematocrit [4]. As 
a result, in general a linear inverse relationship 
between spot area and blood hematocrit is 
observed [5,6]. Thus, when a fixed blood spot 
punch is taken, the punch contains more blood 
for a high-hematocrit sample than for a low-
hematocrit sample. Also, it has been reported 
that the analyte does not distribute evenly across 
the spot, as demonstrated by center/perimeter 
(C/P) concentration ratios not being equal to 
one. The C/P ratio can also vary depending on 
the hematocrit [6,7]. Finally, hematocrit can have 
an influence on the extraction recovery [8,101].
In 2011, the EBF initiated the composition of 
several teams to design and execute experiments 
to further document the scientific relevance of 
the (real or perceived) issue with respect to the 
acceptability of DBS in regulated bioana lysis 
[9–11,102]. The experiments conducted by the 
hematocrit team are described in the current 
article, together with results, observations and 
conclusions. The results from other teams on 
spot homogeneity [12] and IS addition [13] were 
also published, and the results from all teams 
has also resulted in an update of the EBF 
recommendation for the use of DBS in regulated 
bioana lysis [14].
Building on data on the subject that was 
already available in the peer-reviewed literature, 
we designed and executed an experimental plan 
to try to provide an answer to a number of key 
questions around hematocrit and DBS as listed 
below:
The effect of hematocrit on bioana lysis of 
DBS: results from the EBF DBS-microsampling 
consortium
Background: The European Bioanalysis Forum dried blood spots (DBS)/microsampling consortium is reporting 
back from the experiments they performed on further documenting the potential hurdles of the DBS technology. 
This paper is focused on the impact of hematocrit changes on DBS analyses. Results: The hematocrit can have an 
effect on the size of the blood spot, on spot homogeneity and on extraction recovery in a compound-dependent 
manner. The extraction recovery can change upon aging in an hematocrit-dependent way. Different card materials 
can give different outcomes. Conclusions: The results from the conducted experiments show that the issues of 
DBS in regulated bioanalysis are real and that the technology will need improvements to be ready for use as a 
general tool for regulated bioanalysis.
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n	What is the relationship between hematocrit 
and response (peak area ratio)?
n	What is the relationship between hematocrit 
and spot homogeneity?
n	What is the relationship between hematocrit 
and the actual spot size?
n	What is the relationship between hematocrit 
and extraction recovery?
n	Does the age of the wet blood used have an 
impact on the results?
n	Does the age of the blood spot used have an 
impact on the results?
n	What is the influence of different card types 
(treated, nontreated, cellulose-based or 
noncellulose based) on the results obtained at 
different hematocrit?
n	Which parameters are compound dependent?
Details of the experiments and results are 
provided in the next sections.
Experimental
	n Analytes
Twelve compounds were selected covering a wide 
chemical space with a variety of log P and pKa 
values. The compounds that were included in 
the tests are listed in Table 1, together with some 
of their physicochemical parameters. 
	n Blood samples
A standardized way of preparing blood with 
varying hematocrit values was used by all 
participating companies. A fresh blood sample 
was taken, mixed and the hematocrit was 
measured in duplicate. Then the volume of 
plasma to be added or removed to obtain each 
of the target hematocrit values (see below) 
was calculated. Subsequently, the required 
plasma volume was added to blood samples for 
which the hematocrit needed to be decreased. 
The blood that required plasma removal to 
increase the hematocrit was spun for 10 min 
at 1300 g and the required plasma volume was 
removed. The blood samples prepared in this 
way were gently roller-mixed for 30 min. The 
hematocrit of each of the samples was finally 
measured in duplicate to confirm that the target 
hematocrit was obtained. The blood samples at 
each hematocrit value were spiked with one or 
multiple analytes at the concentrations as shown 
in Table 2.
	n Card materials
The Ahlstrohm 226™ (ID Biologicals, SC, 
USA), BondElut DMS™ (Agilent, CA, USA), 
GE DMPK-A™ (formally FTA, Whatman, GE 
Healthcare, UK) and GE DMPK-B (formally 
FTA-Elute, Whatman, GE Healthcare) were 
selected as card types for the experiments. The 
DMPK-A and DMPK-B cards are treated cards 
and according to the vendor, contain proprietary 
chemical mixtures that lyse cells and denature 
degrading enzymes. The other two card types 
are untreated. All cards are cellulose-based, 
except for the BondElut DMS. Of note, virtually 
all studies conducted and published in literature 
on effect of hematocrit are from filter paper 
(cellulose-based) dried blood spot cards.
	n Spotting
For the regular analyses, 25 µl of spiked blood 
was spotted onto the cards using a volumetric 
pipette. For recovery determination, a smaller 
volume of 5 µl was spotted. All cards were 
dried for at least 2 h at ambient temperature 
and subsequently transferred to plastic bags 
containing desiccant. The spotted cards were 
analyzed as soon as practical (within 1 week for 
most compounds; see Table 3) and additional 
spots were put aside (stored at room temperature) 
for ana lysis at a later time point (after 2 months 
for one compound, after 6–6.5 months for 
most compounds; see Table 3). In this way, the 
influence of the age of the blood spot itself on 
the results could be assessed. 
	n Analysis
All experiments were conducted at one analyte 
concentration. Analyte concentrations for each 
analyte are detailed in Table 2. As QC, one 
appropriate test sample was injected in triplicate 
at the beginning, middle and end of the run. The 
coefficient of variation over the nine values had 
to be ≤15%, and the mean of the last injections 
versus the mean of the first injections had to 
differ by no more than 15%. 
The experimental details are summarized 
in Table 2. The table contains details on the 
extraction solvents and volumes, the IS and the 
equipment used. For all of the assays an IS was 
used. For eight assays this was a stable-isotope-
labelled IS, and for four assays a structural analog 
was used. All results presented in this paper are 
based on peak area ratios, so these data include 
correction by the IS. The age of the blood spots 
at the initial ana lysis and at ana lysis after aging 
is listed in Table 3.
Key Term
Hematocrit: Percentage of a 
blood sample that consists of 
red blood cells, measured after 
the blood has been centrifuged 
and the cells compacted.
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	n Spot size & response dependence on 
hematocrit
For the investigations on spot size and analyte 
response dependence on hematocrit, spiked 
fresh blood was tested at eight different 
hematocrit values (Hct = 20, 30, 35, 40, 45, 
50, 60 and 70%) on the Ahlstrohm 226 card. 
Both fresh and stored spiked blood were tested 
at three hematocrit values (Hct = 20, 45 and 
70%) on all four card types. It was decided to 
test over a hematocrit range from 20 to 70% 
to be sure that the clinically relevant range of 
hematocrits was covered, including the higher 
hematocrit values that are in particular relevant 
in dried blood spot applications for neonate 
blood samples [5,15,16].
The spotted blood volume was 25 µl and 
the punch size was 3–3.3 mm to ref lect 
common practice used in bioanalytical 
laboratories for dried blood spot analyses. 
Spot size measurements were in mm2 and were 
determined using Image J software [103]. The 
same software was used across all test sites for 
consistency in the spot size measurements. 
Analyte response was expressed as peak area 
ratio. For all analytes an IS (structural analog 
or stable-isotope-labeled) was used. Analyses 
were measured in singleton on three individual 
blood spots per hematocrit per card type, both 
for fresh and for stored blood.
	n Recovery dependence on hematocrit
For the investigations on recovery dependence 
on hematocrit, spiked fresh blood was tested at 
three hematocrit values (Hct = 20, 45 and 70%) 
on all four card types. Stored blood was spiked 
and tested at one hematocrit value (Hct = 45%) 
on all four card types. For these experiments, 
duplicate 6-mm punches were taken from 5-µl 
blood spots, which means that the whole spot 
was punched. Duplicate blank spots were also 
included; these were punched, extracted and 
thereafter spiked so that the recovery could be 
calculated. Recovery was calculated as:
Response of blood spot spiked before spotting 
of the blood/response of blank blood spot where 
analyte was spiked to the extraction solvent 
post-extraction × 100%
equaTion 1
For the endogenous compounds in the 
test set, recovery was determined using stable 
isotope-labeled or structural analogs and 
calculated as: T
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Response of blood spot spiked with 
stable isotope or structural analog before 
spotting/response of blank blood spot spiked 
with stable isotope or structural analog 
post-extraction × 100%
equaTion 2
	n Spot homogeneity dependence on 
hematocrit
For the investigations on spot homogeneity 
dependence on hematocrit, spiked fresh blood 
was tested at three hematocrit values (Hct = 
20, 45 and 70%) on all four card types. Stored 
blood was spiked and tested at one hematocrit 
value (Hct = 45%) on all four card types. For 
these experiments, two 1-mm punches were 
taken from the same 25-µl blood spot, one from 
the center and one near the perimeter of the 
spot. This experiment was carried out on three 
individual blood spots per hematocrit per card 
type, both for fresh and for stored blood.
Results & discussion
From published hematocrit ranges in human 
blood, it is apparent that these can vary over a 
wide range. Hematocrit values across different 
patient populations as reported from a 1-year 
data set from Ghent University Hospital 
(Ghent, Belgium) range from 19 to 63% [15], 
and published typical human hematocrit 
levels for different age groups range from 28 
Table 2. Extraction conditions and equipment used for the different assays.
Compound 
ID
Extraction method IS Instrument Concentration
1 Methanol containing IS – 500 µl (recovery experiments) 
or 200 µl (all other experiments)
Stable isotope HPLC–MS/MS 
(API5500 Triple Quad™)
100 ng/ml blood
2 20/80 methanol/(10 mM ammonium formate/methanol 
[95/5] v/v) + 0.1% formic acid (v/v) 
450 µl (recovery experiments) or 300 µl (all other 
experiments)
Structural analog HPLC–MS/MS 
(API5000 Triple Quad™)
200 ng/ml blood
3 20/80 methanol/(10 mM ammonium formate/methanol 
[95/5] v/v) + 0.1% formic acid (v/v) 
450 µl (recovery experiments) or 300 µl (all other 
experiments)
Structural analog HPLC–MS/MS 
(API5000 Triple Quad)
200 ng/ml blood
4 200 µl methanol, including IS
After extraction dilute with 200 µl water
Stable isotope HPLC–MS/MS  
(API3000 Triple Quad™)
6.25 µg/ml blood
5 200 µl water; 25 µl IS solution in methanol; 
1 ml TBME; evaporate and redissolve
Structural analog HPLC–MS/MS  
(API3000 Triple Quad)
250 ng/ml blood
6 200 µl of a mixture of methanol and water (80/20, v/v), 
containing the IS. Vortex mixed for 2 h
Stable isotope HPLC–MS/MS  
(Thermo Vantage™)
15 ng/ml blood
7 20/80 water/methanol (v/v) – 500 µl (recovery 
experiments) or 200 µl (all other experiments)
Stable isotope HPLC–MS/MS  
(API4000 Triple Quad™)
200 ng/ml blood
8 20/80 water/methanol (v/v) – 500 µl (recovery 
experiments) or 200 µl (all other experiments)
Stable isotope HPLC–MS/MS  
(API4000 Triple Quad)
200 ng/ml blood
9 20/80 water/methanol (v/v) – 500 µl (recovery 
experiments) or 200 µl (all other experiments)
Stable isotope HPLC–MS/MS  
(API4000 Triple Quad)
200 ng/ml blood
10 Extract 1: 20 µl water, after 5 min 80 µl methanol
Extract 2: 100 µl isopropanol – combine extract 1 and 2
Stable isotope HPLC–HRMS  
(Orbitrap™)
Native (~75 µmol/l 
range)
11 Extract 1: 20 µl water, after 5 min 80 µl methanol
Extract 2: 100 µl isopropanol – combine extract 1 and 2
Structural analog HPLC–HRMS  
(Orbitrap)
Native (~10 µmol/l 
range)
12 Extract 1: 20 µl water, after 5 min 80 µl methanol
Extract 2: 100 µl isopropanol – combine extract 1 and 2
Stable isotope HPLC–HRMS  
(Orbitrap)
Native (~20 µmol/l 
range)
Table 3. Age of the blood spots at initial ana lysis and after aging.
Compound ID Age of blood spots at 
initial ana lysis (weeks)
Age of blood spot at 
re-ana lysis after aging 
(months)
1 0–1 2 
2 0–1 6
3 0–1 6
4 0–1 Not analyzed
5 0–1 Not analyzed
6 0–1 5
7 0–1 6.5
8 0–1 6.5
9 0–1 6.5
10 7 Not analyzed
11 9 Not analyzed
12 9 Not analyzed
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to 67% [5]. For neonates, the hematocrit can 
vary over a relatively broad range (i.e., 42–64% 
at birth and 31–67% when less than 1-month 
old) [16], whereas for healthy adults the range of 
hematocrits is much smaller (i.e., 36–44% for 
adult females and 41–50% for adult males). It 
was decided to focus on human blood only, and 
to test over a hematocrit range from 20 to 70% 
to be sure that the clinically relevant range of 
hematocrits was covered, including the higher 
hematocrit values that are in particular relevant 
in dried blood spot applications for neonate 
blood samples.
For practical reasons, it is very useful if 
human blood can be used for a prolonged period 
of time for preparation of calibration curves 
and QC samples. Therefore, both fresh human 
blood (≤1-day old) and stored human blood 
(14-day old, blood stored refrigerated until use) 
were included in the tests to determine whether 
14-day-old control (wet) blood could still be 
used reliably for preparing calibration standards 
and QC samples.
	n Spot size dependence on hematocrit
The results of the spot size measurements as 
obtained by Image J are shown in Tables 4 & 5. For 
the three cellulose-based cards (226, DMPK-A 
and DMPK-B), the spot size decreases with 
increased hematocrit. This can be explained by 
the fact that the viscosity of the blood increases 
at higher hematocrit, thus reducing the radial 
travelling speed of the blood on the card and 
resulting in a smaller spot. Comparable findings 
were reported in various other papers [5,17]. The 
results obtained at the different laboratories 
from the team members were similar, although 
not always completely identical. There was 
some variation across laboratories despite the 
fact that the same cards and the same spot size 
measurement technique were used. This implies 
that spotting of the same blood volume at the 
same hematocrit on the same card type does 
not always result in exactly the same size of the 
resulting DBS. For 226 and DMPK-A cards, 
the %CV of the spot size measurements over 
the different laboratories was between 6 and 
10%, for DMPK-B and BondElut the %CV 
was higher. 
For the BondElut cards, the spot size is much 
smaller than on the other card types, and the 
spot size increases with increased hematocrit. 
This is probably related to the material used 
for the cards. The exact composition of the 
material used was not disclosed by the vendor, 
but is mentioned to be noncellulose based. The 
Table 4. Results of spot size measurements (in mm2) as obtained using Image J.
HCT 1 2, 3 4 5 6 7, 8, 9 10, 11, 12 Average %CV
226 
20 62 65 75 78 70 73 74 70.9 7.8
30 56 64 63 66 70 66 68 64.9 7.2
35 54 61 67 68 67 64 68 64.1 8.2
40 54 64 64 61 65 63 66 62.5 6.4
45 54 60 62 63 64 65 65 61.8 6.4
50 50 59 62 58 63 61 63 59.4 7.6
60 49 55 64 59 64 59 61 58.8 8.7
70 47 52 52 51 58 57 58 53.5 7.9
DMPK-A 
20 54 63 69 75 65 71 71 66.8 10.4
45 52 57 69 64 58 62 63 60.6 8.7
70 49 51 58 49 52 58 58 53.5 7.8
DMPK-B 
20 66 62 76 71 69 139 102 83.7 33.0
45 58 58 74 66 65 136 129 83.8 40.3
70 56 52 60 55 57 118 95 70.5 36.0
BondElut 
20 22 29 38 35 14 32 38 29.5 30.2
45 30 39 48 41 19 37 40 36.4 25.4
70 34 41 47 43 25 40 42 38.8 19.2
HCT: Hematocrit. 
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spot size measurements for the DMPK-B cards 
was more difficult to conduct, as for these cards 
a notable halo is present around the blood spot 
as shown in Figure 1. The halo was included in 
the spot size measurements for this card type. 
The size of the halo was quite large for two of 
the participating companies, leading to partial 
blending of the adjacent spots via the halos. This 
explains the much higher spot areas found for 
these two participating companies. The reason 
why the size of the halo varied remains unclear.
The spot sizes found when 14-day-old blood 
was spotted were within 90–110% of the spot 
sizes found when fresh blood was spotted, for 
all tested card types and hematocrits for the 
majority of the measurements. Apparently, 
the spot size is not significantly affected by the 
changes that may occur in whole blood when 
stored for up to 14 days at 4°C.
Results of the spot size measurements can be 
seen in Table 4. Spot sizes are expressed as mm2. 
Some compounds were co-spiked in one spot, 
therefore only one set of spot size measurements 
was available for compounds 2/3, 7/8/9 and 
10/11/12. Spot sizes were obtained as a mean of 
one (compound 1), two (compound 2) or four 
(compound 4, 5, 6, 7/8/9, 10/11/12) singleton 
measurements on individual blood spots.
	n Response dependence on hematocrit
The response (peak area ratio) was expressed 
relative to the response obtained at Hct 45%. 
The results are shown in Table 6. For the majority 
of the compounds, an increase in response is seen 
with increased hematocrit on all card types. 
This correlates with the decreased spot size 
(and thus larger blood volume punched) with 
increasing hematocrit as observed for the 226, 
DMPK-A and DMPK-B cards. However, the 
BondElut card shows an increase in spot size 
with increasing hematocrit, so the increase in 
response cannot be explained by a decrease in 
spot size for this card type.
A large variation in results between different 
compounds was observed. For instance, on 
the 226 cards, the relative response at Hct 
20% varied between 51 and 95%, and the 
relative response at Hct 70% varied between 
81 and 145% of that at Hct 45%. Some of the 
compounds (2/3, 7/8/9 and 10/11/12) were 
Table 5. Comparison of spot sizes obtained by spotting fresh blood and by spotting 14-day-old wet blood†.
HCT 1 2, 3 4 5 6 7, 8, 9 10, 11, 12 Average %CV
226
20 97.9 95.2 97.3 92.9 ND 97.5 ND 96.2 2.2
45 109.5 97.0 104.5 96.8 ND 95.8 ND 100.7 6.0
70 96.4 95.6 55.2 103.6 ND 99.6 ND 90.1 22.0
DMPK-A
20 95.8 105.1 104.3 NR ND 98.9 ND 101.0 4.4
45 103.0 98.9 100.0 NR ND 99.4 ND 100.3 1.8
70 103.0 94.1 94.7 NR ND 99.6 ND 97.9 4.3
DMPK-B
20 117.2 99.8 109.6 112.4 ND 100.5 ND 107.9 7.0
45 116.9 96.2 96.1 105.6 ND 88.5 ND 100.7 10.9
70 118.0 98.2 95.7 99.2 ND 83.1 ND 98.9 12.6
BondElut
20 96.6 102.6 98.6 94.8 ND 72.2 ND 93.0 12.9
45 92.1 85.5 86.4 96.7 ND 92.8 ND 90.7 5.2
70 105.3 86.7 105.2 102.6 ND 91.4 ND 98.2 8.8
†Spot sizes in the table are expressed as (spot size of spotted 14-day-old wet blood/spot size of spotted fresh blood x 100%). 
Spot sizes were obtained as a mean of one (compound 1), two (compound 2) or four (compound 4, 5, 6, 7/8/9, 10/11/12) singleton measurements on individual 
blood spots. 
HCT: Hematocrit; ND: Not determined; NR: No result.
Figure 1. Variation in shape of the halo on DMPK-B cards obtained in two 
different laboratories.
  
ReseaRch aRticle |  de Vries, Barfield, van de Merbel et al.
Bioanalysis (2013) 5(17)2152 future science group
co-spiked into the same blood spot, but even 
then for some compounds a variation in results 
was observed. For instance, when compound 7 
and 8 are compared on the 226 card, the results 
differ significantly. Thus, it can be concluded 
that different compounds behave differently 
on the cards. Therefore, the change in response 
as a function of hematocrit cannot solely be 
attributed to a change in spot size.
The consequence of these findings for the 
use of DBS in regulated bioana lysis is that the 
accuracy and precision at different hematocrits 
in QC samples needs to be assessed over the 
range of hematocrits for which the dried blood 
spot assay is validated. In these experiments, 
the hematocrit of the blood used for the 
calibration curve should be held constant. The 
range of hematocrits within which the normal 
QC acceptance criteria can be met will vary 
depending on the intrinsic accuracy and 
precision the assay already has when run at 
equal hematocrit for curve and QCs combined 
with the hematocrit/response relationship on the 
chosen card type for the compound for which 
the assay is validated [18,104].
	n Response dependence on age of the 
wet blood
The results of the influence of the age of the 
wet blood used on the results are shown in 
Table 7. For most analytes, no large differences 
in response were observed when spiked to fresh 
(<1-day old) or spiked to stored (14-day old) 
wet blood. However, for individual compounds 
there are differences, indicating that for some 
compounds the use of 14-day-old wet blood for 
preparation of calibration and QC samples would 
not be acceptable. For instance, for compound 
4 at Hct 45 the result in fresh and 14-day-old 
wet blood is the same, whereas at Hct 20 and 70 
the response in 14-day-old wet blood is much 
lower than in fresh blood. It has been reported 
that clots were seen in blood after 5–8 days of 
refrigerated storage [12], indicating that the wet 
blood samples are physically changing over this 
storage period. 
The consequence of these findings for the use 
of DBS in regulated bioana lysis is that if stored 
wet blood is used for preparation of calibration 
curves or QC samples in DBS, it should be 
demonstrated that the results obtained in aged 
wet blood over the hematocrit range used are 
comparable with the results obtained when 
fresh wet blood is used. It is advised that the 
wet blood is used before it starts to change T
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significantly physically, and at least before clots 
start appearing, which could be within 5 days 
after collection [12].
	n Recovery dependence on hematocrit
There are some indications in the literature that 
the extraction recovery can vary as a function 
of hematocrit. For verapamil, for example, 
extraction recoveries at Hct 70 and Hct 30% 
were 68 and 92%, respectively, and the recovery 
at Hct 70% further decreased to 58% upon 
aging of the blood spot [101]. In a company 
perspective paper, it was mentioned that for some 
compounds the recovery from high hematocrit 
blood is reduced relative to lower hematocrit 
levels [19]. In a paper about perforated DBS [8], 
a decrease in extraction recovery was observed 
for lansoprazole with increasing hematocrit. 
After further optimization of the extraction 
conditions, this effect was no longer observed.
The individual results of the experiments 
conducted in our team are shown in Table 8. 
The recovery as a function of hematocrit varied 
considerably between different compounds and 
also between different card types. For some 
compounds, the recovery remained more or less 
constant across the range of tested hematocrit 
values (e.g., for compounds 7 and 9 on all card 
types). For other compounds, the recovery 
either increased or decreased with increasing 
hematocrit. For one and the same compound, 
the behavior on different card types can be 
different. For instance, for compound 1 on 226 
cards the recovery at Hct 70% was only 49%, 
whereas the recovery at Hct 20% was 105%. 
For the same compound, on DMPK-B cards, 
the recovery at Hct 70% was 59%, whereas 
the recovery at Hct 20% was 39%. Thus, for 
this compound on 226 cards, the recovery 
decreases with increasing hematocrit, whereas on 
DMPK-B, the recovery increases with increasing 
hematocrit. For compound 5, on 226 cards the 
recovery was more or less constant at different 
hematocrits, whereas on DMPK-B cards, the 
recovery at Hct 70% was approximately one 
third of the recovery at Hct 20%.
It is possible that the matrix effect can also 
vary as a function of hematocrit. For methods in 
which a stable-isotope-labeled IS is used, such as 
the assay for compound 1 in the above example, 
it may be assumed that the IS will compensate 
for differences in matrix effect at the different 
hematocrit values. However, for compounds 
where a structural analog was used as IS, such as 
the assay for compound 5 in the above example, T
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the observed variation in absolute recovery as 
a function of hematocrit may be (partially) 
attributed to a difference in matrix effect as a 
function of hematocrit or may be attributed to a 
combination of both matrix effect and recovery.
No relationship was found between the 
absolute recovery and the difference in recovery 
as a function of hematocrit. Thus, a low absolute 
recovery at Hct 45% does not necessarily result 
in a large variation in recovery as a function of 
hematocrit and vice versa. 
For most compounds, the absolute recovery 
in fresh and 14-day-old wet blood was 
approximately the same.
The consequence of these findings for the use 
of DBS is that the absolute recovery needs to be 
assessed and optimized to be more or less constant 
across the range of hematocrits for which the 
assay is validated, both for freshly spiked blood 
spots and for aged blood spots (see next section). 
In wet matrix assays, such as plasma or serum, 
the IS is typically added to the wet matrix prior to 
extraction. In this way, it is able to compensate for 
variations in extraction recovery across different 
samples. For dried blood spot ana lysis however, 
the IS does not compensate for variations in 
extraction recovery when added to the punched 
spot together with the extraction solvent. For 
this reason, it is much more important to have 
a constant extraction recovery for DBS than for 
wet matrix assays. It is likely to achieve this for 
most assays, but it does require additional method 
development efforts, since recovery needs to be 
assessed at multiple hematocrits both in fresh and 
aged blood spots [13]. 
	n Recovery in aged blood spots at different 
hematocrits
DBS will usually not be analyzed immediately 
after the samples have been taken. There could 
be weeks, months or sometimes maybe even a 
year between sampling and the actual ana lysis, 
depending on the type of study. Therefore, it is 
important to demonstrate that the aging of the 
spots does not impact the ana lysis result. During 
storage, analytes can theoretically degrade on the 
card and the extraction recovery could change 
upon storage. 
The experiments on aged blood spots were 
conducted for compounds 2, 3, 6, 7, 8 and 9. 
In Table 9, the relative recovery (expressed as 
the ratio of recovery in aged spots/fresh spots 
× 100%) is shown at the different hematocrits. 
For compound 8, the absolute recovery dropped 
significantly on all card types, the 226 card being T
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the most extreme. For the 226 card, the recovery 
for 6.5-month-old blood spots was only 31–43% 
of the recovery in fresh spots. In human plasma, 
compound 8 was found to be stable for at least 
723 days in the freezer at -20°C and for at least 
72 h at room temperature. Therefore, it is likely 
that the decrease found is due to a lower recovery 
rather than due to instability on the card.
A hematocrit-dependent decrease in recovery 
was also observed. For instance, for compound 
3 on DMPK-A, the recovery at Hct 20% was 
74% of the recovery in fresh spots, whereas at 
Hct 70% the recovery was 104% of the recovery 
in fresh spots.
	n Spot homogeneity dependence on 
hematocrit
When blood is spotted on a dried blood spot 
card, the analyte can show a chromatographic 
or distribution effect on the card material due 
to interaction of the blood and/or the analyte 
with the dried blood spot card. This may result 
in a nonhomogeneous distribution of the analyte 
across the blood spot. A way to investigate spot 
homogeneity is to take two small punches from 
one blood spot, one at the center and one at the 
perimeter, so near the edge of the spot. The 
C/P concentration ratio will then demonstrate 
the homogeneity of the spot. A C/P ratio of 1 
is expected for a homogeneous spot, whereas 
a C/P ratio <1 would be an indication for a 
preferential distribution of the analyte to the 
perimeter of the spot rather than to the center. 
Significant differences in measured analyte 
concentrations between central and peripheral 
areas within a blood spot have been reported 
[6,7,17,20]. The C/P ratio can differ depending 
on the compound, card type and hematocrit, 
with a more homogeneous blood spot at higher 
hematocrit reported in literature [7].
For the evaluation of the results on spot 
homogeneity, the C/P response ratio was 
determined at different hematocrit values, as 
shown in Table 10. For the comparison of the 
results obtained in fresh blood versus stored 
14-day-old wet blood, response ratios were 
calculated and presented in Table 11.
The C/P response ratio was <1 for most of 
the compounds and hematocrits on the 226, 
DMPK-A and BondElut cards, demonstrating 
that for these card types most (but not all) 
compounds have a preference to migrate 
towards the perimeter of the spot. Thus, these 
data confirm the ‘volcano effect’ that has been 
described previously [20]. A C/P ratio of <1 was T
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also reported by O’Mara et al. for 226, DMPK-A 
and DMPK-C cards [7], thus our results are in 
line with their findings. The DMPK-A card 
showed the smallest variation in C/P response 
ratio across compounds and hematocrits.
For the 226 and BondElut cards, the variation 
in C/P response ratio across different compounds 
was smallest at Hct 70%, but these card types 
showed quite a large variation in C/P response 
ratio across different compounds at hematocrits 
Hct 45 and 20%.
On DMPK-B cards, the C/P response ratio was 
>1 for most of the compounds and hematocrits, 
with a few compounds having a rather extreme 
value for the C/P response ratio, thus showing a 
large preference of the compounds not to migrate 
to the perimeter. Also these findings are in line 
with O’Mara et al ’s findings [7] who also reported 
C/P ratios >1 for DMPK-B cards. In contrast 
with the other card types, DMPK-B cards form a 
halo around the main blood spot. For compounds 
1–6, the perimeter punch was done close to 
the edge of the main blood spot, whereas for 
compounds 7–12, the perimeter punch was done 
in the halo surrounding the spot. Most of the 
compounds punched from the halo showed a very 
high C/P ratio, indicating that not much of the 
compound is migrating into the halo. However, 
compound 10 was an exception with a C/P ratio 
of 1.2–1.5, thus showing significant migration 
into the halo. This result is not surprising, as 
compound 10 is the most water soluble of all 
compounds tested and does not significantly bind 
to plasma proteins. It is expected that compounds 
with these characteristics follow the migration of 
water in the blood spot.
For some compounds and card types, there 
is a noticeable difference between the C/P 
response ratios when stored 14-day-old wet 
blood is used instead of freshly obtained blood. 
For some compounds a decrease is observed, 
but more common is an increase in the C/P 
response ratio, which implies that the compound 
has a decreased tendency to move towards the 
perimeter of the spot obtained from 14-day-old 
wet blood as compared with fresh wet blood.
The consequence of these findings for the 
use of DBS in regulated bioana lysis is that spot 
nonhomogeneity increases the variability of 
a dried blood spot assay. In order to limit the 
variability of the assay as much as possible, 
investigation of spot homogeneity on different 
card types over a range of hematocrit levels 
during the development of a DBS assay can be 
considered. The card type showing a C/P ratio 
closest to 1 and with the most consistent C/P 
ratio across different hematocrits could be chosen. 
Also, it is advised to use a punch size that is large 
enough and punches the majority of the spot. A 
way to completely eliminate the influence of spot 
nonhomogeneity on the assay would be to punch 
the complete spot [6], but this approach would 
require sufficient control over the accuracy of the 
spotted blood volume. This is a risk, particularly 
for large multisite clinical studies.
Conclusion
Our experiments confirm literature data that the 
hematocrit changes affect the absolute response 
found for the spiked compounds when a partial 
punched spot is presented for bioana lysis. The 
sample viscosity is higher at higher hematocrit, 
thus influencing both the spot size and the 
actual blood volume punched. The hematocrit 
can also influence extraction recovery and spot 
homogeneity, and is compound-dependent. The 
extraction recovery can decrease with aging of 
spots, sometimes in a hematocrit-dependent way. 
As a result, an increased variability in the assay 
performance is observed, sometimes beyond 
the current applicable acceptance criteria for 
validated assays in regulated bioana lysis [18,104]. 
The largest impact is expected for assays that 
need to cover a large range of hematocrits, such 
as for blood spots obtained from neonates where 
hematocrit values can vary over a broad range 
(31–67%) [16]. However, many of the observed 
fluctuations still remain significant, and are thus 
also relevant for hematocrit values from 36–50% 
that are more typical for a healthy adult female 
and male population. 
It has to be noted that the experiments did 
not account for inter-patient variation of the 
components in blood that could possibly also 
influence spot size to some degree (e.g., due 
to variation in total protein content and white 
blood cell count). Also, it has to be noted that 
the general use of DBS, such as in newborn 
screening, is complicated further by the fact 
that sometimes not single spots but multiple, 
nonconcentric drop spots are submitted. This 
is a further complication to the use of DBS in 
clinical trials.
The hematocrit could also have an effect 
on measured analyte concentrations in wet 
matrices such as plasma and serum, in particular 
for compounds with a blood/plasma ratio 
significantly different from 1. The hematocrit 
effect in plasma assays is not a bioanalytical issue 
though, as the accuracy of the plasma assay as 
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such is not dependent on the hematocrit. Still, 
this effect is important and PK and TK scientists 
should be aware of this effect. On the other 
hand, for dried blood spot assays the hematocrit 
does affect the accuracy of the assay.
During development of a dried blood spot assay, 
sample extraction conditions can be optimized 
to obtain a consistent recovery at different 
hematocrits, both on freshly prepared blood 
spots and on aged blood spots. Various card types 
can be tested for spot homogeneity, extraction 
recovery and accuracy and precision at different 
hematocrits, and the card type that shows most 
consistent results across the range of hematocrits 
required for the assay could be selected.
In order to eliminate the influence of the 
hematocrit on the amount of blood analyzed 
if only part of the spot is punched, a constant 
accurately pipetted amount of blood could be 
spotted for each sample and the whole blood spot 
could subsequently be punched [6]. However, this 
would require sufficient control over the accuracy 
of the blood volume spotted. While this may be 
achievable for the majority of preclinical studies, it 
will be difficult to assure in most clinical studies, 
especially in case of multicenter patient trials or 
in case of therapeutic drug monitoring. In case 
of punching the entire blood it still needs to be 
assured that the absolute recovery is the same at 
different hematocrits in both fresh and aged DBS. 
We recommend that in the validation of dried 
blood spot assays, multiple additional parameters 
are evaluated beyond what is required for the 
validation of an assay of a liquid sample. It is 
advisable to test the accuracy and precision of the 
method at different hematocrit values over the 
range of hematocrit values for which the assay 
is intended to be used. This experiment will 
show the combined influence of spot size, spot 
homogeneity and absolute recovery at different 
hematocrits on accuracy and precision. Also, it is 
advised to assess long-term stability at different 
hematocrits as absolute recovery can decrease in 
aged DBS in a hematocrit-dependent way.
Finally, we look forward to the development 
of easy-to-use tools that could guarantee the 
accuracy of spotted blood volumes in areas where 
sampling of accurate volumes is less obvious, 
such as multicenter patient trials. In addition, 
further innovations in the card technology that 
would decrease or even eliminate the hematocrit 
issue on DBS would be very welcome. These, and 
potentially other innovations and improvements, 
will be needed to allow DBS to develop towards 
a routine technology for regulated bioana lysis. 
Future perspective 
The effect of hematocrit is a significant hurdle 
for the use of DBS for regulated bioana lysis. 
During development of a dried blood spot assay, 
sample extraction conditions can be optimized 
to obtain a consistent extraction recovery at 
different hematocrits, both on freshly prepared 
and on aged blood spots. Still, the hematocrit 
has an effect on the size of the blood spot that 
affects the response, unless the whole blood spot 
is punched. Whole blood spot punching requires 
the spotting of an accurate blood volume. For 
the moment, the use of DBS methods may be 
limited until manufacturers are able to develop 
easy-to-use tools that can guarantee the accuracy 
of spotted blood volumes, which would allow 
punching of the whole blood spot. Nevertheless, 
also in the latter case, additional consideration is 
needed on the compound dependent effects of 
hematocrit and aging of the spots on extraction 
recovery variability. Going forward, the EBF 
considers DBS as a developing technology, and 
awaits further innovations and improvements to 
better balance the advantages of the technique 
versus its current limitations.
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Executive summary
	n The relationship between hematocrit and response, spot homogeneity, spot size, extraction recovery and card type was investigated for 
12 different compounds.
	n The relationship between hematocrit and the age of the wet blood, as well as the age of the dried blood spot itself, was also 
investigated.
	n Hematocrit changes affect spot size, and as a consequence also the absolute response (in case of partial spot punching).
	n Hematocrit can also influence extraction recovery and spot homogeneity in a compound-dependent way. 
	n The extraction recovery can decrease with aging of spots, and the decrease can be hematocrit-dependent.
	n As a result, increased variability in assay performance of dried blood spot assays is observed in comparison with wet matrix (plasma) 
assays, sometimes beyond the current applicable acceptance criteria for validated assays in regulated bioana lysis.
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In-depth study of homogeneity in DBS using 
two different techniques: results from the EBF 
DBS-microsampling consortium
Background: At the start of their work, the European Bioanalysis Forum dried blood spots microsampling consortium 
did not form a dedicated team to investigate the spot homogeneity. However, two teams performed experiments 
that produced results relating to sample homogeneity. Results: The data, which were produced via two different 
approaches (a radiolabeled and a nonradiolabeled approach), are highly complementary and demonstrate clear effects 
on sample inhomogeneity due to the substrate type, compound and hematocrit levels. Conclusion: The results 
demonstrate that sample inhomogeneity is a significant hurdle to the use of dried blood spots for regulated bioanalysis 
that should be investigated further in the method establishment phase if the whole spot is not sampled.
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The European Bioana lysis Forum (EBF) dried 
blood spots (DBS) microsampling consortium 
was formed in June 2011 with the aim of pooling 
the resources of pharmaceutical companies 
and contract research organizations interested 
in the development and understanding of 
DBS technologies. Specifically, the aim of 
the consortium was to enable research into 
the four major hurdles, identified in the EBF 
recommendation paper published in August 
2011 [1] to be barriers to the implementation and 
use of DBS in regulated quantitative bioana lysis. 
The four major hurdles identified were: effect of 
hematocrit; addition of IS; stability of blood and 
cards; and mechanisms for dilution of samples. 
For each, a cross-company team was formed 
to design and conduct experiments that would 
enable a deeper understanding of each of these 
hurdles and hopefully lead to recommendations 
for overcoming them. The consortium 
recognized sample homogeneity as an additional 
hurdle, but as the experiments conducted in 
relation to two of the aforementioned hurdles 
would also unveil spot inhomogeneity, a 
dedicated team was not established to investigate 
this. Both the hematocrit and the stability team 
designed experiments that encompassed an 
element of investigation into the homogeneity 
of a dried blood sample. It is these data that will 
be discussed in this article.
For any quantitative bioanalytical technique 
to be considered accurate, it is important that 
the portion of sample removed for ana lysis is 
representative of the entire sample. For standard 
liquid biological samples this involves careful 
mixing and removal of an accurate volume 
of sample with a pipette. One of the major 
perceived benefits of DBS is the simplicity of the 
sample collection compared with plasma. The 
simplicity of this technique relies on the DBS 
sample being homogeneous in terms of both the 
spotted blood and the analyte contained within 
it, as well as that the blood spot area is directly 
proportional to the volume of blood spotted 
on the card with no change in the density of 
the blood or analyte per unit area. This enables 
the spotting of an approximate volume of 
blood onto a card followed by punching out a 
portion of the sample for ana lysis. This process 
is highly advantageous over the alternative, 
which includes spotting an accurate volume 
and extracting the entire spot. Spotting accurate 
volumes probably requires significant training 
and risk, particularly for a multisite clinical 
study. However, to achieve this subsampling 
approach, it is important that the DBS sample 
is homogeneous. 
It has been observed during the formation of 
a DBS sample that the wet blood that is spotted 
onto the substrate and the analytes contained 
within it may undergo a chromatographic effect 
as the blood adsorbs or spreads onto the substrate. 
This can lead to a nonhomogeneous sample and 
it has been documented in the literature on a 
number of occasions [2–5] that the measured 
analyte concentrations can, in some cases, be 
significantly different between the central and 
peripheral areas of a DBS sample. 
The homogeneity experiments reported in 
this manuscript were conducted by the two 
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multisite teams. The two experiments were 
designed with different objectives in mind, and 
as a result different methods of measuring the 
homogeneity were used. However, the data are 
highly complementary and provide a greater 
understanding of the effect of hematocrit, the 
age of control whole blood and homogeneity 
of DBS samples across a range of different 
substrates (card types) with a range of analytes 
with varying physiochemical properties.
The aim of the hematocrit team was to 
determine whether the hematocrit levels in a 
blood sample affected the distribution of a drug 
within the DBS sample. To do this, the team 
used well-established, validated or qualified 
conventional LC–MS/MS methods to measure 
nonradioactive compounds, referred to in 
this article as the nonradiolabelled approach. 
Homogeneity was assessed by comparing the 
measured concentrations of analyte in punches 
taken from the central and peripheral areas of the 
DBS sample [6]. This assessment was performed 
over a wide chemical space; molecular weights 
varying from 181 to 854 Da; a pKa ranging from 
1 to >20; blood:plasma ratios ranging from 0.61 
to 1.0; and Log P values ranging from -0.4 to 
approximately 20.
The stability team set out to establish a 
range of recommendations for storage, drying 
and age of the control (wet) blood to enable 
users to differentiate what might be genuine 
stability issues from sample handling issues. 
As a result, they determined how long control 
(wet) blood could be stored for and still used 
reliably for preparing calibration standards 
and QC samples (the data for which will be 
included in a later publication). As part of this 
investigation, they performed an experiment to 
assess the homogeneity of DBS samples with 
increased age of control (wet) blood. The team 
used a nonconventional approach, referred to in 
this paper as the radiolabelled approach, where 
radiolabelled compounds were spiked into 
control blood, spotted and the distribution of 
radioactivity measured across each spot.
The data obtained from both of these 
experiments are presented and discussed in this 
article.
Materials & methods
 Analytes
For the nonradiolabelled approach, 12 small-
molecule compounds were selected covering a 
wide chemical space with a variety of log P and 
pKa values. The compounds that are included in T
ab
le
 1
. P
h
ys
ic
o
ch
em
ic
al
 p
ar
am
et
er
s 
o
f 
co
m
p
o
u
n
d
s 
in
cl
u
d
ed
 in
 t
h
e 
n
o
n
ra
d
io
la
b
el
le
d
 a
ss
es
sm
en
t.
Pr
o
p
er
ty
C
o
m
p
o
u
n
d
 n
u
m
b
er
1
2
3
4
5
6
7
8
9
10
11
12
cL
og
D
 (p
H
 7
.4
)
4.
4
2.
1
2
0.
4
3.
5
>
4.
4
5.
4
4.
7
2.
1
-0
.4
~2
0
6.
9
pK
a
4.
4†
; 8
.1
‡
2.
4
; 8
.5
9.
2
5.
2†
12
‡
2.
5;
 5
.2
5.
6‡
1‡
; 9
‡
3.
1‡
; 8
.2
‡
2.
2 
(C
O
O
H
),
 9
.1
 (
N
H
2)
, 
10
.1
 (
O
H
)
>
20
4.
5†
Bl
oo
d
/p
la
sm
a 
di
st
rib
ut
io
n
0.
61
0.
7
0.
8
0.
67
1.
0
U
nk
no
w
n
0.
68
0.
7
0.
72
U
nk
no
w
n
U
nk
no
w
n
U
nk
no
w
n
PP
B
98
U
nk
no
w
n
U
nk
no
w
n
97
89
–9
8
U
nk
no
w
n
99
.7
U
nk
no
w
n
9
0
U
nk
no
w
n
U
nk
no
w
n
U
nk
no
w
n
M
W
4
42
47
0
45
0
27
0
85
4
75
0
36
6
55
5
41
0
18
1
88
4
30
4
† A
ci
di
c 
gr
ou
p.
‡ B
as
ic
 g
ro
up
.  
PP
B:
 P
la
sm
a 
pr
ot
ei
n 
bi
nd
in
g.
 
ReseaRch aRticle |  Cobb, de Vries, Spooner et al.
Bioanalysis (2013) 5(17)2162 future science group
the tests are listed in Table 1, together with some 
of their physicochemical parameters. 
For the radiolabelled approach, two 
radiolabelled compounds, 14C-lacosamide 
and 14C-deoxy-d-glucose, were selected. Both 
compounds have a blood plasma ratio close 
to one. The structures and physicochemical 
parameters are represented in Figure 1 and 
Table 2, respectively.
 Matrix
Control blood was obtained by each site 
according to local rules on ethics and informed 
consent.
 Substrates
Both teams used the following DBS cards: 
Ahlstrohm 226 (Perkin Elmer, MA, USA); 
Bond Elut DMS (Agilent, CA, USA); FTA 
DMPK-A (formally FTA, GE Healthcare, 
UK); and FTA DMPK-B (formally FTA-Elute, 
GE Healthcare). In addition, the radiolabelled 
approach was also tested on the FTA DMPK-C 
substrate (GE Healthcare). The DMPK-A 
and DMPK-B cards are treated substrates and 
according to the vendor contain proprietary 
chemical mixtures that lyse cells and denature 
degradative enzymes. The other three card types 
are untreated substrates.
 Nonradiolabelled approach
A standardized way of preparing control blood 
with varying hematocrit values was used by 
all participating companies. A fresh blood 
sample was taken, mixed and the hematocrit 
was measured in duplicate. Following this, the 
volume of plasma to be added or removed to 
obtain each of the target hematocrit values (20, 
45 and 75%) was calculated. Subsequently, the 
required plasma volume was added to blood 
samples for which the hematocrit had to be 
decreased. The blood that required plasma 
removal to increase the hematocrit was spun for 
10 min at 1300 g and the required plasma volume 
was removed. The blood samples prepared in 
this way were gently roller-mixed for 30 min. 
The hematocrit of each of the samples was finally 
measured in duplicate to confirm that the target 
hematocrit was obtained. The blood samples at 
each hematocrit value were spiked with one or 
multiple analytes [6].
To prepare the samples, human whole blood 
at 20, 45 and 70% hematocrit was spiked with 
one or more of the 12 compounds. The amount 
of solvent added to the blood during spiking 
consisted of <2% of the blood volume. Spiked 
blood (25 µl) was spotted onto DMPK-A, 
DMPK-B, Ahlstrom 226 and Bond Elut cards, 
and a 1-mm diameter punch was taken from 
the center and the perimeter of the spot. The 
spots were then extracted and analyzed by 
LC–MS/MS and the concentration, peak area 
or peak area ratio data are used as appropriate.
The experiments were performed at six 
different sites with each site producing data for 
at least one or more compounds. All experiments 
were conducted at a single concentration with 
n = 3 spots analyzed per card type for each 
compound [6]. As a QC, one appropriate test 
sample was injected in triplicate at the beginning, 
Table 2. Physiochemical parameters of compounds included in the radiolabelled 
assessment.
Compound name Molecular properties
cLogD (pH 7.4) pKa Blood/plasma 
distribution
PPB Molecular 
weight
Lacosamide 0.91 ~14 ~1 Unknown 250
Deoxy-d-glucose 0.73 ~15 ~1 <15% 164
PPB: Plasma protein binding.
Figure 1. Compounds included in the 
radiolabelled assessment.
Lacosamide
Doeoxy-D-glucose
OH
OH
HO
HO
O
O
O
O
N
H
H
N
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middle and end of the run. The coefficient of 
variation over the nine values was required to be 
≤15%, and the mean of the last injections versus 
the mean of the first injections were required to 
differ by no more than 15%. 
Radiolabelled approach
A radioactive compound (14C-lacosamide or 
14C-deoxy-d-glucose) was added to the control 
(wet) blood at 2200 and 1400 ng/ml (prepared 
by adding 10 µl of radiolabelled solution to 
2 ml of blood), respectively, on the day of blood 
collection. Lacosamide was added to mouse 
blood, while a second site added deoxyglucose 
to human and rat blood. Both sites compared 
heparin and EDTA anticoagulants. Then, 
four replicates of 15 or 30 µl of blood was 
spotted onto DMPK-A, DMPK-B, DMPK-C, 
Ahlstrom 226 and Bond Elut cards, on day 1. 
The spiked mouse blood was also spotted 
(n = 4 per card type) on day 2, 3, 4, 5, 8, 10 
and 15. Once dry (2 h at room temperature) the 
radioactivity across the spots was measured. The 
measurement of 14C-lacosamide was performed 
every 0.425 mm across the diameter of the spot 
using a Fuji BAS-5000 with a Fuji SR 2025 
phosphorus screen (Japan). 14C-deoxy-d-glucose 
was measured on a GE Healthcare Typhoon 
FLA7000 scanner at 50-µm resolution following 
exposure to phosphor screens (BAS-SR, Fuji 
Photo Film, Japan) for approximately 24 h. The 
hematocrit levels were not measured for any of 
the control matrices, however the human blood 
was obtained from a healthy volunteer and the 
rat and mouse hematocrit levels are expected 
to be typical for hematocrit concentrations in 
healthy laboratory rats and mice. 
Results & discussion
 Nonradiolabelled approach
The data obtained via the nonradiolabelled 
approach, was carried out across six different 
sites, using a total 12 different compounds from 
a variety of chemical classes, with at least one or 
more compounds assessed at each site.
The homogeneity between the center and the 
perimeter of each spot has been plotted against 
the blood hematocrit level for each individual 
compound, on each card type (Table 3). 
Homogeneity was calculated from the analyte 
response (peak area ratio of the analyte to its 
corresponding IS) of the center punch, divided 
by the analyte response of the perimeter punch 
(C/P ratio). Values below one indicate that the 
analyte was observed at a higher concentration T
ab
le
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in the perimeter punch. Values greater than one 
indicate that the analyte was observed at a higher 
concentration in the center punch. 
For most compounds at all three levels of 
hematocrit, the C/P ratio on DMPK-A, 226 and 
Bond Elut cards is less the one. This indicates 
that in the majority of cases these cards types 
result in analyte concentrations that are higher 
in the peripheral punch, than the central punch. 
Of these three card types, DMPK-A shows the 
smallest variation in the data obtained from the 
12 different compounds and between the three 
different hematocrit levels, indicating that the 
hematocrit and compound type have less effect 
on the homogeneity of the sample than the 
card itself. Both the 226 and Bond Elut cards 
show extensive variation (>50%) between the 
12 different compounds demonstrating that, 
for these cards both the card type and the 
compound itself have a notable effect on the 
homogeneity of the DBS sample. The level of 
hematocrit also affects the homogeneity for these 
card types with an observed improvement in 
homogeneity being seen on both cards for nearly 
all compounds when there is 70% hematocrit, 
which is supported in the literature [2].
The homogeneity data obtained for DMPK-B 
has C/P ratios notably greater than one. There 
is also extensive variation in homogeneity 
between the different compounds investigated. 
Values greater than one indicate that analyte 
concentrations are higher in the central punch 
than the peripheral punch. For some compounds 
Figure 2. Photographs showing the 
location of the 1-mm-diameter punches 
taken from dried blood spot samples of 
25 µl of human blood on FTA DMPK-B 
substrate. (A) Peripheral punch taken from the 
halo; and (B) peripheral punch taken from the 
main body of the spot.
 
A
B
Figure 3. Average measure of radioactivity from four dried blood spot samples for 
14C-lacosamide, in 15-µl dried blood spot samples derived from mouse blood. (A) DMPK-A 
substrate; (B) 226 substrate; (C) Bond Elut substrate; and (D) DMPK-C substrate.
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and hematocrit levels there is a large difference 
in analyte response between the central and 
peripheral punch locations, such that in one 
case, a peripheral punch, yields a tenfold less 
concentrated sample than the center punch. 
The formation of a halo (a paler area around 
the outside edge of the DBS sample) is the 
most notable difference between spots obtained 
on DMPK-B cards and spots obtained on all 
other cards. Of the six sites conducting these 
experiments, two sites sampled the peripheral 
punch from the halo (Figure 2a; Table 1; 1–6) 
while four sites sampled the peripheral punch 
from the outer edge of the main body of the 
spot (Figure 2b; Table 1; 7–12). By sorting 
the compounds based on the location of the 
peripheral punch, it can be noted that those 
compounds, for which the peripheral punch 
was taken from within the main body of the 
spot, have a reasonably consistent homogeneity 
between the different hematocrit levels. The 
exception to this is compound 4, which has a 
tendency towards a slightly higher concentration 
of analyte in the central punch. For those 
compounds where the peripheral punch was 
taken from the halo, the results are the most 
variable, clearly demonstrating that in general 
(with one exception) compounds do not 
distribute homogeneously between the main 
body of the spot and the halo. Compound 10, 
a small and highly polar compound, is the 
exception to this observation. This result is not 
surprising as this compound is the most water 
soluble of all compounds tested and does not 
significantly bind to plasma proteins. It is possible 
that compounds with these characteristics follow 
the migration of water in the blood spot into 
the halo.
It is also interesting that three of the four 
compounds that do not distribute homogeneously 
into the halo, have increased homogeneity when 
the hematocrit level is 20%.
The nonradiolabelled assessment was 
performed over a wide chemical space, as detailed 
in Table 1. However, the data are too variable 
on the majority of cards to be able to link the 
observed homogeneity to the physicochemical 
properties of the compounds used. It is clear 
from these data that the distribution of the 
spiked compound across the blood spot is not 
homogeneous and that the card substrate, 
compound and hematocrit level can greatly 
affect the extent of the homogeneity. This 
confirms sample homogeneity in DBS as a major 
hurdle for which methods of overcoming must 
be examined in greater detail.
 Radiolabelled approach
A typical example of the data obtained from 
the radiolabelled assessment is represented in 
Figure 3a. The plot shows average data from four 
blood spots, prepared by spiking fresh control wet 
mouse blood with 14C-lacosamide and spotting 
15 µl onto a DMPK-A card. The enclosing lines 
represent the standard deviation seen within 
the four sets of data. It can be clearly observed 
from this profile that a ‘volcano’-shaped graph is 
obtained, with lower amounts of radioactivity 
measured in the center than the edge of the 
spot. Therefore, 14C-lacosamide concentrations 
are lower in the center of the spot than the 
periphery. These data confirm the finding 
from the nonradiolabelled approach and that 
reported in the literature [2,4]. Both the 226 and 
Bond Elut cards show similar trends with a higher 
concentration at the perimeter of the spot than 
the center (Figure 3b & C). However, the dip in 
the center of the volcano is more pronounced on 
these two substrates, which may be the cause of 
the extensive variation seen between the different 
Table 4. Average measure of intensity of radioactivity across the 
diameter of four dried blood spot samples on each substrate.
Distance 
across 
spot (mm)
DMPK-A DMPK-C 226 Bond Elut DMPK-B
0.425 0.0 0.0 0.0 0.0 7.8
0.85 0.0 0.0 78.2 0.0 30.5
1.275 88.6 36.2 196.4 9.4 66.2
1.7 175.8 173.9 185.5 47.0 77.2
2.125 170.3 212.5 170.5 167.2 92.0
2.55 162.3 200.0 164.4 244.4 100.7
2.975 160.6 190.3 161.3 250.4 107.6
3.4 157.6 190.8 163.2 238.2 111.6
3.825 160.8 186.9 166.5 224.4 115.4
4.25 161.1 191.9 164.1 220.9 117.7
4.675 165.6 190.6 163.6 221.4 119.3
5.1 159.5 187.6 164.5 221.1 118.9
5.525 162.7 184.9 159.9 228.0 119.7
5.95 164.8 182.8 166.0 229.5 121.6
6.375 167.7 194.8 165.6 239.0 117.9
6.8 165.4 193.1 168.3 250.1 116.8
7.225 170.3 188.2 173.8 289.5 113.1
7.65 172.8 188.1 173.4 310.1 106.3
8.075 176.2 200.0 177.3 141.6 96.8
8.5 176.5 185.3 193.6 32.1 83.1
8.925 118.2 55.0 117.1 7.6 69.2
9.35 91.3 0.0 15.8 0.0 35.0
9.775 0.0 0.0 0.0 0.0 10.0
10.2 0.0 0.0 0.0 0.0 4.3
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molecules on these cards in the nonradiolabelled 
assessment. DMPK-C was also seen to produce a 
volcano effect using the radiolabelled assessment. 
The numerical data used to prepare the graphs in 
Figure 3 are presented in Table 4, along with the 
data for the DMPK-B cards. 
A similar pattern of distribution was observed 
for DMPK-A, DMPK-C, 226 and Bond Elut 
substrates when 14C-deoxy-d-glucose was 
added to freshly obtained rat and human wet 
blood, with 15 or 30 µl spotted onto the cards. 
With this analyte there did appear to be some 
slight changes in homogeneity for different 
species, blood spot volume or anticoagulant on 
DMPK-A, DMPK-C and 226 cards. There was 
also a much more pronounced volcano effect for 
rat blood than human blood (Figure 4) on the 
Bond Elut cards, demonstrating that in some 
cases the species of control matrix, in addition to 
the substrate and analyte, can have a significant 
effect on the homogeneity.
The distribution of 14C-lacosamide across the 
DMPK-B cards is notably different to those of 
the other card types, with analyte distribution 
being almost Gaussian across the spot diameter 
(Figure 5). Higher concentrations of this analyte 
were observed at the center of the spot than the 
perimeter, potentially due to a strong interaction 
with the substrate, which prevents the analyte 
from spreading. This also supports the data 
from the nonradioactive approach and from 
O’Mara et al. [3]. A photograph of the spots used 
to obtain this data is presented in Figure 6. The 
data outside the two vertical lines in Figure 5 
are representative of the halo, while anything 
within the lines can be considered as the main 
body of the spot. In this case approximately five- 
to six-fold more 14C-lacosamide is measured in 
the center of the spot than the in halo. In view 
of these data, it is possible that compound-to-
compound differences seen in the nonradioactive 
data could be as much due to the location of the 
peripheral punch as the compound itself.
A similar pattern of distribution was observed 
for the DMPK-B substrate, when 14C-deoxy-d-
glucose was added to freshly obtained rat and 
human wet blood and 15 or 30 µl spotted onto 
the cards. It was possible to observe small changes 
in the ratio of the radioactivity measured at the 
center and periphery of the spots, for different 
anticoagulants in human DBS samples (Figure 7).
For the 14C-lacosamide data no difference in 
homogeneity was observed, when spotting 15 or 
30 µl, or when using heparin or EDTA as the 
anticoagulant, for any of the substrates types.
Figure 4. Measure of radioactivity across four 15-µl dried blood spot 
samples on a Bond Elut substrate, using 14C-deoxy-d-glucose as the 
analyte spiked in blood. (A) Human heparin blood; and (B) rat heparin blood.
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Figure 5. Average measure of radioactivity 
from four dried blood spot samples for 
14C-lacosamide, in 15-µl dried blood spot 
samples derived from mouse blood on 
DMPK-B substrate.
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As for the nonradiolabelled approach, it is clear 
that the distribution of the spiked compound 
across the blood spots is not homogeneous and 
that the card substrate in particular affects the 
extent of the homogeneity; again confirming 
sample homogeneity in DBS as a major hurdle.
Conclusion
In conclusion, radiolabelled and nonradiolabelled 
approaches to measuring the homogeneity 
of DBS samples have produced highly 
complementary data, which also supports the 
results reported in the literature. A volcano effect 
in distribution of the analyte (lower analyte 
concentrations in the center of the spot than at 
the edge) was observed for DMPK-A, DMPK-C, 
226 and Bond Elut cards using the radiolabelled 
approach. A similar effect was observed for 
DMPK-A, 226 and Bond Elut cards using the 
nonradiolabelled approach. Both methods also 
illustrated that DMPK-B cards exhibit higher 
analyte concentrations at the center of the spot.
It can be concluded from these data that the 
degree of nonhomogeneity across a DBS sample 
is affected by a number of factors, including, but 
not limited to: card substrate type, compound 
and hematocrit levels; in control blood. 
DMPK-A card types appear to be less affected by 
compound and hematocrit levels than the other 
cards, there is still a degree of nonhomogeneity 
observed across this card type that will need 
to be managed appropriately during method 
establishment, to allow the method to provide 
reliable and reproducible concentration values.
It is also worth noting that these assessments 
of homogeneity have been performed in 
analytical laboratories where it is possible to 
generate perfect spots due to the pipetting of 
control blood directly onto the card substrate. In 
a clinical setting it may not be possible to prepare 
these ‘perfect’ spots, which may also have an 
additional impact on the sample homogeneity.
In light of the fact that DBS samples 
are generally nonhomogeneous, for use in 
regulatory bioana lysis going forward, it will be 
necessary to investigate the homogeneity for 
any particular analyte, perhaps using a range of 
hematocrit levels, during method development, 
to ensure that these issues do not exist. Where 
nonhomogeneity exists, there is an expectation 
that the inaccuracy due to homogeneity, in 
addition to the other sources of inaccuracy in 
the method, should not add to the imprecision of 
the method beyond what is accepted as standard 
bioanalytical acceptance criteria. Approaches that 
may limit the effect of nonhomogeneity include 
punching the whole spot and taking it through 
the extraction procedure, although it is important 
to note that this has severe implications for the 
sample collection procedure that will require 
significant training and is a risk, particularly for 
large multisite clinical studies, as the sampling 
Figure 7. Measure of radioactivity across four 15-µl DBS samples on a 
Bond Elut substrate, using 14C-deoxy-d-glucose as the analyte spiked in 
blood. (A) Human heparin blood; and (B) human EDTA blood.
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Figure 6. Photograph of corresponding 
DMPK-B dried blood spots for Figure 4.
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must be accurate. Another approach is to take one 
punch per spot; punching from the same location 
in every sample. However this leads to a question 
of how the bioanalyst could ensure and prove that 
the punch is being taken from the same location 
in every sample. Another possibility might be 
to take a larger diameter punch, which may 
be a compromise between the two alternatives 
without the need for accurate spotting of the 
sample in a clinical setting. 
Finally, our data demonstrate that spot 
non homogeneity can significantly affect the 
performance of a DBS method, particularly if the 
whole spot is not taken through the extraction. 
As such, the effect of any nonhomogeneity should 
be assessed during the method establishment. 
Future perspective 
DBS sample homogeneity may be a significant 
hurdle for the use of DBS for regulated bioana-
lysis and it should be investigated during the 
method establishment to ensure that the affect 
is overcome or compensated for where DBS 
methods that do not use the whole spot are 
employed. Going forward, EBF considers DBS 
as a developing technology and awaits further 
innovations and improvements to better balance 
the advantages of the technique versus its 
current limitations. In order to realize the full 
benefits of DBS, we require manufacturers to 
develop substrates that enable the formation of a 
homogeneous DBS.
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Executive summary
 Dried blood spot sample homogeneity was investigated using two different techniques that provided highly complementary data.
 Sample homogeneity was demonstrated to be primarily affected by the compound, card substrate and hematocrit levels.
 Sample homogeneity was also affected (to a lesser extent) by species and anticoagulant.
 Sample inhomogeneity is confirmed as a hurdle to the use of dried blood spots for regulated bioana lysis, which may be overcome or 
limited by taking the whole spot through the extraction procedure.
 As spot inhomogeneity could potentially affect the performance of a dried blood spot method, the sampling approach taken for 
ana lysis of dried blood spot samples should be assessed to ensure it compensates for any inhomogeneity observed, or the whole spot 
should be analyzed.
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Aim: The quality of quantitative analytical measurements is dependent on the quality 
of the sample collected, and dried blood spots (DBS) are no exception. As the use of 
DBS has matured into late-stage clinical drug-development studies, it has become 
apparent that a simple and straightforward approach in a controlled single-site, first-
time-into-human clinic, does not always translate into multicenter clinical studies. 
Using synthetic blood, a method of training and assessing clinical laboratory staff 
has been developed to ensure the quality of sampling.Methods: A test kit comprising 
of synthetic blood, a pipetting aid, blank blood spot card, drying rack and training 
manual was sent to each clinical site for each technician to assess and approve prior 
to spotting PK samples. Results: The development of a DBS training kit along with a 
step-by-step guide has been successfully implemented. Conclusion: The training kit 
has been 100% successful across three large multisite clinical studies.
First draft submitted: 14 July 2016; Accepted for publication: 19 October 2016; 
Published online: 14 December 2016
Keywords:clinical bioanalysis • data quality • dried blood spot samples • training
The use of the dried blood spot (DBS) sam-
pling technique in the drug development 
process has been highlighted in recent years 
as an alternative to plasma [1,2], the preferred 
matrix for toxicokinetic and pharmacoki-
netic (PK) studies. The evolution from its 
initial use in neonatal screening [3,4] of DBS 
has been a combined effort of many scien-
tists across the pharmaceutical industry, 
all focusing on a common goal and using 
their expertise to overcome the challenges 
faced, leading to a better understanding 
of its application in the drug development 
process [5]. This technology offers mul-
tiple advantages; preclinically, the most 
recognized advantage is ethical and relates 
to the 3Rs (replacement, reduction and 
refinement) in animal use, while clinically 
the reduction in sample volumes allows for 
pediatric PK assessments, simplified blood 
sampling, enrollment of critically ill patients 
and facilitates the collection of samples in 
remote locations and at home. Logistically, 
the use of DBS sampling delivers cost sav-
ings through ambient sample shipment and 
storage, particularly for multisite clinical 
trials. DBS does have many advantages, but 
also there are limitations especially with 
changing hematocrit for certain compounds 
and patient populations [6].
One of the issues we have observed dur-
ing the performance of clinical studies using 
DBS sampling is the quality of the spotting 
(regardless of sampling technique i.e., heel 
prick, finger prick or venous cannula) 
particularly for late-phase multisite stud-
ies. Historically, DBS multisite studies were 
provided training materials in the form of a 
digital video disk (DVD) and an illustrated 
textual guide (Figure 1) [7]. In the first study 
supported by our laboratories where DBS 
samples were collected at multiple sites and 
across different continents, training materials 
were provided in the form of a DVD and an 
Ensuring the collection of high-quality 
dried blood spot samples across multisite 
clinical studies
Tina Panchal*,1, Neil Spooner1,2 
& Matthew Barfield1
1Bioanalysis, Immunogenicity & 
Biomarkers, GlaxoSmithKline Research & 
Development, Ware, UK 
2School of Life & Medical Sciences, 
Department of Pharmacy, University of 
Hertfordshire, Hatfield, UK, and Spooner 
Bioanalytical Solutions Ltd, Hertford, UK 
*Author for correspondence: 
Tina.2.Panchal@gsk.com
For reprint orders, please contact: reprints@futuremedicine.com
210 Bioanalysis (2017) 9(2)
Figure 1.  Valid DBS sample – correct spotting 
technique used.
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i llustrated textual guide. In that study, approximately 
2150 DBS samples were supplied for analysis. However, 
due to the incorrect spotting technique (i.e., incorrect 
volume spotted, irregular spots outside the specified 
area and puncturing of the filter paper during spotting) 
used by the site technicians, approximately 700 of the 
samples could not be analyzed, equating to >30% of 
the study samples (Figure 2).
This study highlighted that even the simple 
instructions provided could be readily misinterpreted 
and that the current training procedure was inade-
quate. In many cases, the first attempt to spot blood 
by a healthcare provider was with the actual study 
sample, which is a major study risk. Sending analysts 
to train hospital staff all across the world is not a via-
ble solution, so an alternative approach was sought 
to ensure higher quality samples were obtained in a 
reliable manner. It was identified that in addition to a 
guide on blood spotting, the clinical sites also needed 
to be able to practice their spotting technique and 
that an approval process was required for each tech-
nician, prior to spotting real samples to ensure that 
high-quality spots were received. Further, as control 
blood is not readily available to perform this practice, 
we developed a suitable surrogate blood matrix. This 
manuscript highlights that process.
Materials & methods/experimental
Falcon tubes (20 ml) were supplied by Corning Sci-
ence (Mexico, SA). Condensed milk powder and red 
dye were supplied by Sigma Aldrich (Dorset, UK). 
Synthetic blood was spotted using 15 μl EDTA capil-
lary tubes, supplied by Bibate limited (Daventry, UK) 
utilizing a microcap dispensing device (referred to as 
a pipette aid), supplied by Drummond Scientific Co 
(PA, USA). Blank blood spot cards (type dependent on 
validated method). Those illustrated were provided by 
Whatman (GE Healthcare, Maidstone, UK; FTA™ 
DMPK-A) and Perkin Elmer (MA, USA; 226). Dry-
ing racks were supplied by Whatman (GE Healthcare).
The DBS training kit
The kit is illustrated in Figure 3 and comprised a 20 ml 
falcon tube containing 1 g condensed milk pow-
der and 0.5 g red dye (to make the synthetic blood), 
250 × 15 μl EDTA capillary tubes, 1 microcap dis-
pensing device (referred to as a pipette aid), three 
blank blood spot cards (filter paper type dependent 
on validated method), one drying rack and PK blood 
spotting instructions incorporated into the Biopacket/
sample procedure manual. The training manual sent 
to  clinical sites is included in Supplementary material.
Results & discussion
In developing the synthetic blood test solution, water 
and milk were initially tested. However, the consis-
tency of the solution did not adequately mimic blood 
when spotted. It was found that using condensed milk 
powder with the addition of water provided the best 
match for blood and had the most similar character-
istics. Red dye was also added to the milk powder to 
ensure the synthetic blood solution once spotted was 
visible. This DBS training kit was tested and validated 
internally by two colleagues who had never performed 
DBS sampling, to see if the kit was adequate and would 
provide sufficient instructions to a ‘new’ DBS user. 
Both users found the instructions easy to follow and 
were able to produce four acceptable spots per card. 
This demonstrated and gave confidence that this tool 
was a successful method to train and confirm blood 
spotting technique of new users.
The kits were subsequently used for multisite clini-
cal trials where the sampling procedure was identical to 
that used previously. The initial pilot study consisted 
of 15 sites, spanning across the USA and Germany 
and involved multiple technicians. Blood sampling in 
all cases was by venous cannula of 250 μl into a 1-ml 
EDTA vacutainer tube and 4 × 15 μl aliquots accu-
rately spotted utilizing glass capillaries onto the card. 
All sites received the DBS training kits prior to study’s 
start and each technician was assessed and approved 
prior to spotting PK samples. All samples received 
from this study (2158 samples) were of good enough 
quality for analysis. Subsequently, the technique has 
been used for two further studies each with one site, 
which have also demonstrated high-quality spots (1890 
samples). Notably, no technicians failed the evaluation 
across all three studies across 17 sites. Further, success-
ful incurred sample reproducibility was obtained for 
the assay from these samples (Figure 5) [7]. This experi-
ment is required by regulators for quantitative drug 
bioanalytical data and involves the repeat analysis 
of a proportion of samples and demonstration of the 
concordance of the repeated samples with that of the 
original. The results of this experiment clearly demon-
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Figure 2.  Invalid DBS samples. (A) Spot too small, likely incorrect volume spotted. Only one spot supplied, four 
spots are required per sample time point. (B) Spots too large hence overlapping and merged with the next spot. 
(C) Irregular spots and additional spot outside the marked area. (D) Irregular spots made up of multiple spots.  
(E) Spots placed in incorrect area (F) Card punctured during spotting and spots too small.
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strate c onsistency between the replicate spots for the 
same sample on the same card. The use of a test kit has 
shown that technicians in different geographical loca-
tions can all receive the same training to ensure that 
high-quality PK blood spots are obtained when sup-
porting large clinical multisite studies. Without this 
procedure in place, the use of DBS for late-stage clini-
cal development would not be a viable option. Figure 4.
There is a possibility that DBS and other dried blood 
sampling approaches may facilitate the collection of 
blood samples in the home setting, rather than a cen-
tral clinical facility, either by the patient themselves, 
or a healthcare provider. This would offer increased 
patient convenience and potential cost savings. Fur-
ther, it may enable the collection of samples from 
patients in remote locations, or at times not c urrently 
possible with centralized testing. However, there is a 
risk that the quality of such samples may not be suf-
ficient. Therefore, if this approach is to be used, it is 
imperative that the patient and/or healthcare provider 
receive/s high-quality training and if possible demon-
strate their competence in the collection of high-qual-
ity samples using approaches similar to that outlined 
in this manuscript.
Conclusion
The use of DBS to produce high-quality concentra-
tion data for toxicokinetic and PK studies in drug 
development is highly dependent on the quality of the 
DBS provided for analysis. Previous experience with 
single-center studies had not highlighted the training 
of staff responsible for spotting the samples as one of 
212 Bioanalysis (2017) 9(2)
Figure 4.  Scanned test card from site technician.
Figure 5.  Incurred sample reproducibility in dried spots of human blood study samples.
Figure 3.  DBS training kit.
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the challenges to using DBS sampling. However, our 
experience with an initial multicenter study demon-
strated considerable issues with sample quality. We 
therefore developed a blood spot training kit using 
synthetic blood and a peer review process to assess and 
approve the quality of the spots produced. To date, the 
implementation of a synthetic blood spot training kit 
in three large multisite clinical trials has demonstrated 
that the test-site technician’s blood spotting technique 
can be assessed prior to handling PK blood samples, 
ensuring the PK sample is of adequate quality. Since, 
successfully deploying this strategy for all new DBS 
studies within GSK, it has been demonstrated that 
technicians across different geographical locations who 
have followed the training kit have produced high-
quality DBS samples, with no spots which were unable 
to be analyzed. The implementation of this procedure 
now allows the confident use of DBS for large multisite 
clinical studies and the benefits that are associated with 
this technique to be realized.
Future perspective
The shipment of condensed milk powder across dif-
ferent continents is not as straightforward as initially 
perceived, due to import laws. Currently, investigation 
work is being performed to find a suitable alternative 
which can be shipped at room temperature to vari-
ous continents. One possibility is a red quality control 
glucose solution for StatStrip glucose monitors, which 
does not need to be shipped refrigerated. In addition, 
an ‘off the shelf ’ DBS kit would be the ideal solution 
moving forward, which could be supplied and con-
trolled by the healthcare groups which help pharma-
ceutical companies run their clinical trials. For studies 
which run for a long duration, a monitoring process 
www.future-science.com 213future science group
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is required to ensure all new technicians continue to 
receive adequate training, prior to handling PK blood 
spot samples.
Supplementary data
To view the supplementary data that accompany this paper 
please visit the journal website at: www.future-science.com/
doi/full/10.4155/bio.2016.0189
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Executive summary
•	 The quantification of drugs in dried blood spot samples is dependent on the quality of the initial sample 
collected.
•	 Without sufficient training to the test site technicians, poor-quality spots can lead to samples that cannot be 
analyzed, which is not acceptable.
•	 The use of a dried blood spot training kit has been demonstrated as a valid approach to assess and approve 
the test site technicians, prior to handling pharmacokinetic blood samples.
•	 Implementation of the training kit has shown to be successful in three large clinical multisite studies.
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